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THE ROLE OF MYELOID-DERIVED SUPPRESSOR CELLS IN THE 
IMMUNOTHERAPY OF BREAST CARCINOMAS 
 
By Johanna Keeler Morales, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2009 
 
Major Director:  Masoud H. Manjili 
Assistant Professor, Department of Microbiology and Immunology 
 
 
 
 
 
Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immature 
cells at various stages of differentiation. These cells are broadly characterized by the 
simultaneous expression of the surface markers CD11b and Gr1 and have been found to 
accumulate in large numbers in response to many different tumors in both mice and 
humans, including HER2/neu+ breast cancers. The adoptive immunotherapy of cancers 
has been a promising field, yet the clinical efficacy of adoptive immunotherapies targeted 
   
 xxiii 
against human breast cancers and many other cancers has been extremely limited. Given 
the influx of MDSC in tumor-bearing individuals, we hypothesized that these cells were 
the reason for the failure of adoptively transferred T cells to effectively reject primary 
tumors. Using either monoclonal antibodies or the chemotherapeutic drug, gemcitabine, 
we aimed to eliminate MDSC cells in vivo to determine if adoptively transferred T cells 
would be more effective in the absence of these cells. We further aimed to characterize 
the mechanism of T cell suppression by MDSC and the tumor-derived soluble factor(s) 
responsible for their accumulation. We have found that the elimination of MDSC in vivo 
does result in significant tumor inhibition when adoptively transferred T cells are 
administered. Furthermore, the use of gemcitabine in conjunction with adoptively 
transferred T cells resulted in complete tumor rejection in 100% of mice and was 
accompanied by large antibody titers against HER2/neu as well as strong recall responses 
characterized by IFN-γ  release and subsequent rejection of further tumor challenges. We 
report herein that suppression by MDSC is contact dependent and affects the proliferation 
of both CD4+ and CD8+ T cells. The accumulation of MDSC in tumor-bearing mice can 
be entirely attributed to tumor-derived soluble factors, with GM-CSF specifically causing 
the generation and maintenance of these cells. Our findings suggest that the adoptive 
immunotherapy of breast carcinomas in a clinical setting should be combined with the 
use of gemcitabine, and that the use of GM-CSF as an adjuvant in cancer vaccines should 
be carefully re-evaluated as this cytokine may result in increased MDSC accumulation in 
vivo.  
  1 
   
 
 
 
Introduction 
 
I. The ErbB Family of Receptor Tyrosine Kinases 
A. Structure and Function: Breast cancer is the most frequently occurring cancer 
in women in the United States, with an overall risk of developing breast cancer of 1 in 6, 
and a risk of developing invasive breast cancer of 1 in 8 (1, 2). Of these cancers, 
approximately 30% are positive for the overexpression of the HER2/neu oncogene (3), 
which has been associated with a more aggressive phenotype and poor clinical prognosis 
(4). HER2/neu, or its 89% homologous rat counterpart, neu (5), is a member of the 
epidermal growth factor receptor family, or the ErbB family, of tyrosine kinase receptors. 
The epidermal growth factor receptor (EGFR) was discovered in 1975 as a specific target 
for epidermal growth factor, previously shown to stimulate the proliferation of epithelial 
cells (6, 7). In 1978, Stanley Cohen’s group observed that the addition of EGF to 
epidermoid carcinoma cells increased the incorporation of 
32
P in vitro (8). Hence the idea 
that signals could be transmitted through the phosphorylation of receptors was initiated. In 
1984, the peptide sequence of EGFR was discovered to share a high level of similarity 
with a known avian oncogene, v-erbB (9). Thus, the first connection was made between a 
known human receptor tyrosine kinase and a sequence exhibiting oncogenic function. In 
1985, the discovery of a second member of the EGFR family was published, having been 
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discovered by Coussens et al using v-erbB as a screening probe (10). This 138,000-dalton 
polypeptide, encoded by 4.8-kb of mRNA originating from the q21 region of chromosome 
17 in humans was found to be widely expressed in many normal tissues including the 
kidney, liver and colon (10). Furthermore, this paper noted that this newly coined “HER2” 
gene shared its chromosomal location with that of the previously mapped neu proto-
oncogene isolated from a rat neuroblastoma (10). The EGFR family is now comprised of 4 
members: ErbB1 (the epidermal growth factor receptor, or EGFR), ErbB2 (or HER2/neu in 
humans), ErbB3 (HER3), and ErbB4 (HER4) (11). Members of the ErbB family exhibit 
structural similarity, with an extracellular region composed of four domains, a 
transmembrane and juxtamembrane region, an intracellular tyrosine kinase domain, and an 
C-terminal regulatory region (11-13). The extracellular region of the ErbB tyrosine kinases 
is made up of four sub-domains. Domain I, which is the most distally located from the cell 
membrane, along with domain III, are homologous members of the leucine rich repeat 
family, and it is these domains that take part in binding to extracellular ligands (11-15). 
Domains II and IV, on the other hand, are cysteine-rich domains and do not participate in 
ligand binding. Rather, domain II acts as a dimerization arm, which, in the presence of 
ligand, is exposed and contacts the domain II dimerization arm of a second ErbB molecule 
(Fig. 1A, right) (11-13). In the absence of ligand, however, the ErbB molecule assumes its 
“tethered” orientation, in which domain II interacts with domain IV in such a way as to 
block the dimerization interface of domain II (Fig. 1A, center)(11-13). ErbB2, however, is 
unique in that its domain II dimerization arm is constitutively exposed, thus making it 
available to heterodimerize with any of the other ErbB family members (Fig. 1A, left) (16). 
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Unlike the other ErbB receptors, ErbB2 also has no known ligand, which may explain the 
need for exposure of domain II, since ligand binding to domains I and III in other ErbB 
molecules results in a conformational change that exposes domain II, resulting in a unique 
dimerization that is entirely receptor-mediated (14, 15). Since ErbB2 is the only of the 
ErbB molecules that has no ligand, overexpression of this molecule alone, with no further 
stimulating factors leads to increased dimerization, both with other ErbB molecules and 
with ErbB2 itself, and results in increased proliferation and survival (Fig. 1B) (12, 17). 
While normal cells express 2-10 copies of the ErbB2 gene, amplification of ErbB2 in 
breast cancer patients has resulted in as many as 200 copies, correlating with surface 
expression of up to 2 million ErbB2 molecules, as compared to 20,000-50,000 molecules 
on the surface of normal breast cells (18-20)Accordingly, experiments have shown ErbB2 
to be the preferred dimerization partner for the other 3 ErbB molecules, with tyrosine 
phosphorylation levels of ErbB molecules 1,3 and 4 in response to ligand being greatly 
reduced in the absence of ErbB2 (17). In fact, it has been found that ErbB2 actually 
enhances tyrosine phosphorylation of ErbB1 in response to its ligand, epidermal growth 
factor as well as of ErbB3, the only ErbB molecule with no intrinsic kinase activity, and 
ErbB4 in response to one of their ligands, neu differentiation factor in certain tumor cell 
lines (21-23).  The lack on ligand for ErbB2 can be explained by its crystal structure, 
which reveals that domains I and III of the extracellular domain are in direct contact, 
therefore eliminating the need for these two domains to be bridged by a ligand, as they are 
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other ErbB receptors (16) This explains the constitutively active form of ErbB2 
independent of a ligand, and justifies the observation that ErbB2 overexpression can lead 
to cell transformation in the absence of ligand (11, 24).   
The FVBN202 mouse model of spontaneously arising mammary carcinomas 
provides a clinically relevant model for investigating the immunotherapy of neu positive 
mammary tumors. These mice develop mammary carcinomas within 4-12 months of age as 
a result of the overexpression of the inactivated form of rat neu oncogene, which lacks the 
activating mutation that is present in the transmembrane domain of the activated form of 
the oncogene, in their mammary glands under the regulation of the mouse mammary tumor 
virus (MMTV) promoter (25). Spontaneously arising mammary carcinomas were then 
harvested for the development of a neu overexpressing mouse mammary carcinoma cell 
line, referred to as MMC. The persistent overexpression of the neu oncogene in FVBN202 
mice results in mice that are immunologically tolerant to the neu oncoproteins, therefore 
creating an ideal and clinically relevant model in which to investigate tumors arising from 
“self” tissues to which immune responses are not robust. In contrast, parental FVB mice do 
not express the rat neu oncogene and therefore are able to generate a robust immune 
response against challenge with neu-expressing MMC. These mice subsequently reject 
MMC, thus generating a pool of T cells with proven effectiveness against these tumors.  
B. Signaling Pathways: RTK’s have extensive downstream signaling capabilities, 
and signaling events stemming from ligation of the epidermal growth factor receptor have 
been extensively studied. Specifically, activation of the ErbB family of RTK’s has been 
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shown to result in cellular proliferation and pro-survival effects that are mediated through 
one of three main pathways: the phosphatidylinositol 3-kinase (PI3K) pathway, the Ras-
MAPK pathway, or the JAK-STAT pathway. (12, 26). Since ErbB2 does not have a ligand 
of its own, but has a constitutively active dimerization arm, it frequently functions to 
augment signaling by the other ErbB molecules, particularly ErbB1 and ErbB3, through 
heterodimerization. In particular, overexpression of ErbB2 in breast cancers leads to 
increased activation or constitutively active signaling through the PI3K and the MAPK 
pathways (27). For example, binding of EGF to ErbB1 and subsequent dimerization results 
in autophosphorylation of critical tyrosine residues on ErbB1 by its intrinsic kinase 
function. Subsequently, the Src-homology 2 (SH2) domain of the p85 subunit of PI3K is 
recruited to the phosphorylated tyrosines ErbB1 (28, 29). Heterodimerization of ErbB2 
with ErbB3 also initiates this pathway, as activation of ErbB3 results in six 
phosphotyrosine docking sites for the PI3K p85 subunit (27). The p110 subunit of PI3K 
then generates phosphatidylinositol-3,4,5-triphosphate (PIP3) from phosphatidylinositol-
4,5-bisphosphate (PIP2). Phosphoinositide-dependent kinase 1 and Phosphoinositide-
dependent kinase 2 then phosphorylate and subsequently activate AKT, all of which were 
recruited to PIP3 via their plekstrin homology (PH) domains (29). AKT is a serine-
threonine kinase that exerts vast effects on cell cycle and survival. Importantly, AKT 
prevents the translocation of the p21 and p27 cell cycle inhibitors into the nucleus through 
the phosphorylation of both of these molecules (30, 31). Furthermore, AKT phosphorylates 
and thereby inhibits the pro-apoptotic BAD molecule as well as activates NFкB, which 
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activates genes to inhibit apoptosis as well as induce progression through the cell cycle and 
cellular proliferation (29, 32-36).  
A second important means of signaling used by the ErbB family of receptor 
tyrosine kinases is the mitogen-activated protein kinases, or MAPK, cascade (27). 
Increased MAPK signaling resulting from ErbB2 overexpression first goes through the 
small GTPase Ras, which in turn activates Raf, MEK, and ERK, a cascade that has been 
shown to be indispensable for Ras-meidated oncogenesis (27, 37-39). Hyperactivation of 
Ras may result from mutation of Ras itself which occurs in 30% of all human cancers (40). 
Mutated Ras molecules are insensitive to the GTPase-activating proteins which are 
required to hydrolyze the GTP bound to the active form of Ras to GDP, thus resulting in 
the restoration of the inactive form of Ras (37, 40). Conversely, hyperactivation of Ras 
may result from overexpressed or mutationally active ErbB1 or ErB2 molecules. Of the 
30% of breast cancers that overexpress ErbB2, it has been found that 20% of these result 
from amplification of the ErbB2 gene at the DNA level (41), and mutations in the kinase 
domain of ErbB1 or ErbB2 can lead to constitutively active signaling (42)(43). 
Compounding this problem of increased signaling from constitutively active ErbB 
molecules is the fact that Ras activation and the subsequent MAPK cascade causes results 
in the transcription of ErbB1 ligands such as TGFα, heparin-binding EGF, and 
amphiregullin, which then feed back further stimulate ErbB receptor signaling (44, 45). 
Furthermore, signaling through ErbB1 was reported to be responsible for over half of the 
total transcriptional effects mediated through the Raf protein (45). Signaling through the 
MAPK pathway, primarily through the induction of Ras and Raf, is therefore a major 
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means of signal transduction through the ErbB receptors, with alternations in this pathway 
linked to a significant number of cancers.  
Adding to the diversity of signal transduction through ErbB receptors, Yamauchi et 
al reported that, although ErbB receptors possess intrinsic kinase ability, that treatment of 
mice with growth hormone resulted in the phosphorylation of not only the growth hormone 
receptor (GHR), but also of ErbB1. Further experiments proved that ErbB1 complexes 
with activated GHR and that ErbB1 was directly phosphorylated by JAK2 which resulted 
in the association of the adaptor molecule Grb2 to the phosphorylated ErbB1. Importantly, 
it was shown that the expression of mutant ErbB1 molecules that lacked all intrinsic 
receptor tyrosine kinase activity had no effect on the phosphorylation levels of ErbB1 in 
response to growth hormone (46). As the downstream target of JAK molecules is the group 
of transcription factors designated as signal transducers and activators of transcription 
(STAT’s), it was also determined that binding of EGF to ErbB1 results in the 
phosphorylation and translocation of both STAT1 (47) and STAT3 (48). Importantly, 
STAT3 activation has been shown to maintain the proliferation of cancer cells and is 
aberrantly activated in 50-90% of human cancers (49-51). Constitutively active STAT3C 
can cause transformation in normal cells, whereas dominant negative STAT3 can block the 
oncogenic transformation of cells in vitro (52-54). STAT3 mediates these effects through 
the activation of genes that promote cellular proliferation such as c-myc and cylicn D1 and 
suppress apoptosis such as MCl-1 and survivan (55-58). Additionally, vascular endothelial 
growth factor, which aids in angiogenesis, and matrix metalloprotease-9, which degrades 
components of the extracellular matrix to allow for invasion, are also activated by STAT3 
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(59, 60). Furthermore increased levels of phosphorylated JAK2 and STAT3 have been 
observed ovarian cancer cells and the levels of increased expression were positively 
correlated with tumor grade and migratory phenotype (61, 62). Additionally, treatment of 
ovarian cells with EGF was shown to significantly increase IL-6 production and secretion 
in ovarian cancer cells lines. Since IL-6 is known to signal through STAT3 and is a 
proinflammatory cytokine associated with chronic disease and promotion of cancer, the 
upregulation of IL-6 by ErbB1 signaling and resultant increase in STAT3 activity 
constitutes another mechanism of tumor promotion by ErbB1 (62).   
II. Cancer Therapeutics 
 A. Chemotherapies: Many chemotherapeutic drugs have been developed to target 
and treat rapidly dividing cancer cells. One of these, 5-fluorouracil (5-FU), is a uracil 
analog that substitutes a fluorine at the C-5 position of uracil where a hydrogen atom 
usually resides (63). This treatment was originally devised following the observation that 
rat hepatomas incorporated the pyrimidine uracil into their RNA at a faster rate than 
normal tissues. In addition to its disruption of RNA synthesis, 5-FU also inhibits the 
synthesis of thymidylate, necessary for DNA replication, by blocking the binding site of 
the thymidylate precursor on the thymidylate synthase enzyme. Despite these effects, 5-FU 
treatment alone has had a relatively low response rate (10-15%) in patients with advanced 
colorectal cancer, where it has been found to be most effective (63). Cyclophosphamide, an 
alkylating agent showing particular potency against lymphocytes, is often used for the 
treatment of lymphomas and autoimmune diseases (64, 65). Furthermore, the use of 
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Cyclophosphamide in conjunction with adoptive immunotherapy results in increased 
efficacy of adoptively transferred cells because of the elimination of endogenous 
lymphocytes, and is able to drive the expansion of a predominantly Th1-skewed response 
(66, 67). Cyclophosphamide exists in an inactive form that must be converted to its active 
form by oxidase enzymes in the liver. The presence of the enzyme aldehyde 
dehydrogenase  results in the eventual formation of carboxyphosphamide, whereas low 
levels of aldehyde dehydrogenase results in the formation of phosphoramide mustard, 
which forms DNA cross-links and leads to cell death (64). Another class of potent, yet 
highly toxic anti-cancer drugs are the platinum-based drugs cisplatin, carboplatin, and 
oxaliplatin. The platinum molecule at the center of these drugs binds covalently to the N
7
 
position on purines, resulting in DNA cross-linking and cell death (68). These drugs are 
often administered in combination with 5-FU. Also administered in combination with 
platinum drugs, Gemcitabine has offered several novel mechanisms of anti-cancer action. 
Gemcitabine is a deoxycytidine analog that must be converted to its active form by 
phosphorylation, which yields successive mono, di, and tri-phosphate forms of the 
molecule. The first round of phosphorylation is mediated by deoxycytidine kinase, which 
is the rate limiting step of these reactions (69). Once in its diphosphate form, Gemcitabine 
can inhibit the ribonucleoside reductase molecule, which is needed for the synthesis of 
deoxyribonucleoside diphosphates to be converted to deoxyribonucleoside triphosphates 
that will be used in DNA synthesis. Additionally, in its triphosphate form, Gemcitabine is 
able to incorporate into DNA and inhibit replication (69). A unique attribute of 
Gemcitabine was found in its ability to decrease numbers of myeloid-derived suppressor 
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cells (MDSC) in the spleens of tumor-bearing mice. These results were confirmed in vitro, 
with the addition of Gemcitabine to splenocyte cultures causing a significant reduction in 
MDSC while having no effect on CD4+ or CD8+ T cells or B220+ B cells (70). 
Importantly, Gemcitabine has been shown to exert effects through the immune system, 
given that the anti-tumor effects of Gemcitabine seen in immunocompetant mice were 
completely lost in nude mice in some tumor models. Supporting the role of Gemcitabine 
on the immune system were the findings that mice given immunogenic tumors resistant to 
Gemcitabine in vitro still had significantly reduced tumor volumes after Gemcitabine 
treatment in vivo, as opposed to mice given non-immunogenic, Gemcitabine-resistant 
tumors, on which Gemcitabine had no effect. Therefore, it is plausible that at least some of 
the anti-tumor effects of Gemcitabine are mediated through the immune system and that 
this drug may be an ideal candidate to use in conjunction with immunotherapies such as 
adoptively transferred T cells (71).   
B. Monoclonal Antibodies: The use of monoclonal antibodies for the treatment of 
ErbB overexpressing tumors is common clinical practice and has shown positive results. 
Monoclonal antibodies function by disrupting the structure, ligand binding, or dimerization 
of the ErbB receptors and have the added benefit of recruiting immune effector cells that 
express Fc receptors. The first monoclonal antibody to be approved by the FDA for use in 
patients with HER2 overexpressing metastatic breast cancer was Trastuzumab, a 
humanized antibody directed against domain IV of HER2 which is capable of inhibiting 
MAPK and PI3K signaling through HER2 (72). Preclinical in vitro studies using 
trastuzumab indicated its ability to inhibit cell growth, downregulate HER2, reduce VEGF 
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production, and elicit antibody-dependent cell-mediated cytotoxicity (73). Clinical trials 
have shown objective responses in 15% and 26% of patients with metastatic breast 
carcinoma, with clinical benefit being closely correlated with higher expression of HER2 
(74, 75). A second monoclonal antibody, pertuzumab, is directed against the domain II 
dimerization arm of HER2, thus blocking dimerization of HER2 with any of the other 
ErbB molecules. Although promising in theory, a phase II clinical trial using pertuzumab 
for the treatment of metastatic breast cancer showed limited benefit, however it must be 
noted that patients had low expression of HER2 (37). Additionally phase II trials for both 
hormone refractory prostate cancer and non-small cell lung cancer (NSCLC) have shown 
no response to pertuzumab (37, 76), although results seem promising against ovarian 
cancer (37). Cetuximab, which was approved in 2004 for the treatment of refractory 
metastatic colorectal cancer (77) specifically targets domain III of the EGFR with a higher 
affinity than its EGF or TNF-α ligands, and therefore blocks their binding (78, 79). A 2004 
study using cetuximab monotherapy to treat EGFR positive colorectal cancer resulted in 
partial responses in 8.8% of patients and 36.8% had stable disease (80). Another phase II 
study carried out using a combination of cetuximab and the topoisomerase I inhibitor, 
irinitecan found a significant reduction in the time to disease progression in patients 
receiving both cetuximab and irinitecan as compared to patients receiving cetuximab alone, 
although this did not correlate with a significantly increased survival time (78). Since 
certuximab is a chimeric IgG1 antibody, anaphylactic reactions in patients prompted the 
development of humanized and fully human monoclonal antibodies. In 2006, 
panitumumab, a 100% human antibody, was approved for use in patients with progressive 
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metastatic colorectal cancer (37). Although this antibody, which also targets the EGFR, is 
an IgG2 antibody which does not cause antibody-dependent cell-mediated cytotoxicity, a 
phase III trial showed an 8% response rate in patients with metastatic colorectal 
cancer.(81), although phase II trials for panitumumab have not shown promise for patients 
with NSCLC (82). Matuzumab, currently in phase II clinical trials, is a humanized IgG1 
antibody that binds to domain III of EGFR and instead of blocking ligand directly, 
sterically inhibits domain rearrangement of EGFR required for receptor dimerization (83). 
Although matuzumab monotherapy in women with ovarian or primary peritoneal cancers 
previously treated with chemotherapeutic agents showed not advantage (84), phase I 
monotherapy trials have shown responses in esophageal squamous cell carcinoma and 
colorectal cancer. A 23% response rate was seen in a phase I trail combining matuzumab 
with paclitaxel for the treatment of NSCLC (82). Resistance to monoclonal antibody 
treatment can arise given the fact that signaling through alternate ErbB receptors can 
compensate for a loss of signaling in the target molecule. Resistance to trastuzumab has 
been particularly well documented, showing that the vast majority of patients become 
resistant to this therapy within one year, with 66%-88% of patients exhibiting resistance to 
single agent trastuzumab treatment (72, 85). Several factors could influence resistance to 
trastuzumab and other monoclonal antibody therapies. First, since trastuzumab binds to 
domain IV of HER2, it is inefficient in blocking the heterodimerization of HER2 in the 
presence of other ErbB ligands (12, 86). Second, since anti-neu antibody administered in 
the FVBN202 mouse model has lead to downregulation of neu expression and the 
emergence of ANV tumors, it is possible that HER2 negative tumor cell clones, selected 
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under immunological pressure, may also lead to relapse in humans (87). Another prevalent 
mechanism of trastuzumab resistance is loss of the phosphatase PTEN, which antagonizes 
the phosphorylation of the PI3K-AKT pathway and has been shown to have increased 
activity after trastuzumab treatment (72, 85) Patients with HER2 overexpressing breast 
tumors that are deficient in PTEN show a poor clinical response to trastuzumab. For these 
patients, treatment with tyrosine kinase inhibitors, which are not dependent upon surface 
expression of HER2 and can ameliorate signaling directly stemming from ErbB receptors, 
are an attractive alternative (85). 
C. Tyrosine Kinase Inhibitors: The existence of over 58 currently known receptor 
tyrosine kinases (RTK’s), and the observation that overexpression or mutation of over half 
of these molecules is associated with hyperproliferative disorders and has been observed in 
a variety of cancers including gastrointestinal, prostate, ovarian, NSCLC, and breast 
cancers causes these molecules to be natural targets for cancer therapeutics (12, 26). More 
specifically, the epidermal growth factor receptor is overexpressed in a substantial 
percentage of colorectal, pancreatic, lung, and NSCLC and had been found to be mutated 
in NSCLC as well as in glioblastomas (37) One class of drugs used against the ErbB 
receptors are tyrosine kinase inhibitors (TKI’s), which can counteract the cascade of events 
triggered by RTK signaling. One TKI, gefitinib (ZD1839), was approved by the FDA in 
2003 for the treatment of NSCLC based on results obtained from phase II trials (26, 88). 
Although phase I and II trials had indicated that treatment with gefitinib reduced EGFR 
phosphorylation and exhibited some antitumor activity, later phase II trials failed to 
achieve statistically significant differences between groups receiving gefitinib and groups 
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receiving a placebo (88). Therefore, in 2005, the FDA limited use of gefitinib to patients 
currently receiving the drug or patients enrolling in clinical trials for gefitinib at the time 
(88). Gefitinib is a quinazoline, a class of inhibitors which works by competing with ATP 
for its binding site on the EGFR (89).  Abolishing the ATP binding site consensus 
sequence on the EGFR was shown in 1987 to be critical for the kinase function of EGFR 
as well as leading to be eventual down-regulation of this receptor from the cell surface 
(90). Another quinazoline, erlotinib, was approved by the FDA in 2004 for the treatment of 
NSCLC and pancreatic cancer, based on increased survival times shown in phase III 
clinical trials (37). This drug has also shown responses in phase I/II trials for the treatment 
of metastatic squamous-cell carcinoma of the head and neck and hepatocellular carcinoma 
when combined with the anti-VEGF antibody, bevacizumab (91, 92), but failed to exhibit 
advantageous effects as a single agent administered against recurrent glioblastoma, or in 
combination with bevacizumab against ovarian, peritoneal, or fallopian tube cancers (93, 
94). Given the incomplete effectiveness of TKI’s targeting EGFR, TKI’s reactive against 
several RTK’s are now in clinical trials. One of these, Lapatinib, is a quinazoline with dual 
specificity for EGFR and HER2 and has reached phase III clinical trials for the treatment 
of breast cancer, renal cell carcinoma, and head and neck cancer (37). Phase II trials have 
previously shown lapatinib to be effective in reducing HER2+ metastatic lesions in the 
brain and have shown clinical benefit against advanced metastatic breast cancers 
previously treated with Trastuzumab (95, 96). Interestingly, recent in vitro studies have 
indicated a possible synergy between lapatinib and Trastuzumab, with lapatinib treatment 
of HER2-overexpressing cells causing an accumulation of inactive HER2 molecules, 
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thereby rendering these cells more susceptible to the effects of Trastuzumab (97).  A major 
drawback to TKI’s targeted to one or several RTK’s is the development of resistance, 
which has been observed in the vast majority of patients treated with these drugs (98-100). 
The development of cells that are resistant to TKI’s could result from any of several factors 
including the induction of other growth factors such as hepatocyte growth factor (99), 
through the activation of other RTK’s such as the insulin like growth factor-1 receptor 
(101) or the fibroblast growth factor receptor (102), through mutations in the RTK that 
may alter the binding site of the drug (98), or through increased activation and 
heterodimerization of alternate ErbB molecules, mediated by increased release of ligands 
such as heregulin and betacellulin which cause heterodimerization of alternate ErbB 
receptors (103). Of further concern are the in vitro findings that indicate that TKI resistant 
head and neck squamous cell carcinoma cells displayed a dramatically more aggressive 
phenotype characterized by increased levels of phosphorylated EGFR, increased 
proliferation, reduced apoptosis, enhanced angiogenic capacity, and acquired resistance to 
ionizing radiation (104). Thus, while promising at the onset, the use of TKI’s currently has 
limited effectiveness combined with a high probability of generating a drug resistant, and 
possibly more aggressive, phenotype.   
D. Vaccines: The prospect of creating vaccines for tumors by immunizing patients 
with either whole tumor cells, peptides from specific tumor-associated antigens, DNA, or 
dendritic cells loaded with antigen, has been a promising concept, however in most cases 
has failed to produce substantial clinical results. The exploitation of the immune system to 
treat cancer has several advantages over the administration of chemotherapies and other 
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anti-cancer therapeutics, including increased specificity, an accompanying decrease in 
toxicity, and the possible development of long term immunological memory to prevent 
recurrence. The idea of using the immune system against cancer stemmed from the finding 
that human T cells could be reactive to specific antigens expressed or overexpressed on 
tumor cells that are not widely expressed otherwise; these are referred to as tumor-
associated antigens (TAA) (105-107). Many TAA’s have been tested experimentally as 
vaccines, including the immunodominant HLA-A2-binding epitope of HER2 designated as 
E75, which is comprised of amino acids 369-377 (107). Vaccination for the prevention of 
breast cancer in the FVBN202 mouse model has been done using heat shock protein 110 as 
an immunoadjuvant coupled to the intracellular domain (ICD) of neu. This study showed 
the induction of both an IFN-γ response and the secretion of IL-4, indicative of a Th2 
response, as well as a strong antibody response, specifically against ICD in immunized 
animals. Importantly, vaccination of tumor free FVBN202 animals in the initial phases of 
mammary hyperplasia resulted in a significant delay of the onset of spontaneous mammary 
tumors (108). In humans, vaccination in an early stage setting has been done is patients 
with HER2/neu overexpressing ductal carcinoma in situ (DCIS), a preinvasive form of 
malignancy (109). This study used dendritic cells activated with IFN-γ and bacterial 
lipopolysaccharide in order to create cells that not only secrete high levels of IL-12, but 
may also facilitate the breaking of self-tolerance. Although this study design was 
successful in generating HER2/neu reactive, IFN-γ-secreting CD4+ and CD8+ T cells that 
were shown to infiltrate breast and caused a reduction in residual DCIS, HER2/neu 
expression was also decreased in a majority of patients after vaccination. This indicates 
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that IFN-γ-mediated immune pressure can lead to the selection of HER2/neu negative 
variants, which have a less aggressive phenotype than their HER2/neu positive 
counterparts, but may also cause a relapsed phenotype resistant to HER2/neu targeted 
therapies (109). Another vaccination strategy in humans which uses the E75 peptide in 
conjunction with GM-CSF has also shown promise in lowering recurrences rates. Breast 
cancer recurrence rates were significantly reduced in disease-free patients receiving 
vaccination as compared to disease-free individuals who were not vaccinated, a difference 
that was lost after 20 months (110). Mittendorf et al have also used the E75 peptide along 
with GM-CSF to vaccinate disease-free women with node-positive breast cancer 
previously treated by standard surgical and chemotherapeutic techniques at high risk of 
recurrence. Induction of immune responses was confirmed in treated patients and after 22 
months, 85.7% of patients receiving vaccination were disease free, as compared to 59.8% 
disease free patients in the control group, a substantial, albeit not significant, difference 
(107). Extrapolating this data to include vaccination of disease-free node-negative breast 
cancer patients yielded an overall 26 month recurrence rate of 8.3% in the vaccinated 
group versus 14.8% in the control group with mortality rates in the relapsed patients being 
significantly lower in the vaccinated group as compared to the control group (107). Despite 
promising results for breast cancer relapse prevention, vaccination of tumor bearing 
individuals with E75 along with Freund’s Incomplete Adjuvant or with GM-CSF 
succeeded in inducing CTL responses, but provided no clinical benefit (111, 112). It is 
thought that the main reason for the failure of vaccination against established tumors is the 
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low frequency of tumor specific T cells in vivo (113), although it seems that vaccination 
may hold some promise in the area of preventative treatment. 
As an alternative to peptide vaccination, the use of matured dendritic cells in 
vaccines may have substantial clinical benefit given that DC’s in cancer patients are often 
immature and tolerogenic (114, 115). Dendritic cell based vaccines have therefore been 
investigated in several ways. Dendritic cells can be pulsed with one or several peptides or 
with whole cell lysate prior to injection for efficient antigen presentation, they can be 
transduced with full length cDNA clones or mRNA from known immunogenic peptides, 
thus resulting in presentation of multiple epitopes of that peptide, or they can be used to 
generate fusion cells (116). Vaccination with E75 has been evaluated by loading the 
peptide onto dendritic cells prior to vaccination. While results from these trials showed 
induction of immune responses and infiltration of CD4+ and CD8+ T cells, there has been 
an extremely limited or complete absence of any clinical response (117, 118, 118, 119). On 
the other hand, vaccination in mice using DC transduced with a truncated HER2 caused 
significant tumor inhibition against challenge with HER2-expressing tumors and caused 
the development of both cellular and humoral immune responses. Injection of HER2-
transduced DC also extended tumor-free periods and reduced the numbers of spontaneous 
primary tumors and lung metastasis in FVBN202 animals, while DC pulsed with lysate 
from highly HER2-positive tumor cells had no such effect (120). Various other dendritic 
cell based vaccines have been developed using multiple antigens, for example, the human 
telomerase reverse transcriptase, or hTERT, peptide, which is recognized by CTL and 
expressed on over 85% of all human cancers, has also been used in conjunction with DC’s 
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(121). A key study in 2000 demonstrated that transfecting DC’s with RNA encoding 
telomerase and subsequent immunization with these DC’s was able to inhibit the growth of 
several different tumors in mice. Tumor inhibition was most likely CTL-mediated as in 
vitro assays showed that T cells from immunized mice lysed TERT+ targets as well as 
TERT+ tumor cells. Importantly, these results were recapitulated with the use of human 
cell in vitro (122). Several of these methods have produced promising early results. For 
example, phase I and II trials loading DC’s with a novel fusion protein consisting of the 
antigen prostatic acid phosphatase fused to GM-CSF resulted in measurable T cell 
responses in vitro as well as a significant increase in the median time to disease 
progression in patients exhibiting immune responses versus exhibiting no response (123). 
A phase I trial investigating the use of autologous DC’s fused with autologous tumor cells 
found that these cells were able to stimulate T cell proliferation in vitro and 8 out of 23 
total patients vaccinated with fusion cells showed stabilization or regression of disease 
(124). In addition to dendritic cell based vaccines, DNA vaccines may also have some 
therapeutic potential. A recent study by Cho et al has shown that immunization of Balb/c 
mice with a plasmid encoding for one of the dominant epitopes of the rat neu protein along 
with the TLR 9 agonist CpG generated CD8+ T cell responses in vitro, and caused the 
regression of established neu+ tumors in vivo. Additionally, vaccination of Balb-neuT 
mice, which are transgenic for and tolerant to the activated rat neu oncogene, caused 
substantial delay of onset of spontaneously arising neu+ tumors (125).  
E. Adoptive Immunotherapy: Unlike vaccination techniques, the use of 
adoptively transferred T cells to treat established disease has been an attractive method, 
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mainly because it allows for very high numbers of effector T cells to be infused into the 
patient. This method has exhibited some success, particularly in the case of melanoma and 
in the treatment of patients with cancers expressing viral antigens, such as the Epstein-Barr 
virus (126). In breast cancer, since one of the predominant sites of metastasis is the bone 
marrow, it has been shown that the adoptive transfer of reactivated T cells isolated from 
the bone marrow of patients with pre-existing immune responses resulted in 50% of 
patients generating tumor-specific IFN-γ response. Patients that did not generate an anti-
tumor response were those that were given lower numbers of transferred T cells and were 
shown to have higher numbers of regulatory T cells in the bone marrow and higher levels 
of IL-4 and IL-10 in response to tumor antigen (127). These drawbacks highlight the many  
obstacles of adoptive immunotherapy (AIT) that must be addressed, including the fact that 
transferred T cells may not properly expand once in vivo, T cells from tumor-bearing 
individuals are usually of low avidity and occur at a low frequency, and 
immunosuppressive environments in vivo may inhibit adoptively transferred T cells. 
A lack of expansion by transferred T cells in vivo is caused by endogenous T cells 
acting as “cytokine sinks” (128, 129). Consequently, it has been found that 
lymphodepletion of the host immune cells results in greater efficacy of the adoptively 
transferred cells because the newly transferred T cells have greater access to cytokines 
such as IL-7 and IL-15 that are important for homeostatic proliferation (128, 130, 131). 
Most AIT regimens therefore use a chemotherapeutic agent such as CYP, which has been 
shown to create a lymphopenic environment in tumor bearing hosts, prior to transfer (132). 
Dudley et al have shown that adoptive transfer of expanded autologous tumor infiltrating 
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lymphocytes (TILs) from melanoma patients pre-treated with CYP and fludarabine for 
lymphodepletion caused the regression of bulky metastasis at multiple sites in a majority of 
patients when administered concurrently with the T cell growth factor IL-2 (133). Patients 
with metastatic breast cancer that was refractory to other treatments received CYP and 
fludarabine prior to allogeneic hematopoietic stem-cell transplants that had been T cell 
depleted. Subsequent injections of the isolated T cells 42, 70, and 98 days after stem-cell 
transplantation resulted in objective tumor regression in 6 out of 16 patients and was 
associated with donor T cell engraftment (134). Additionally, a single dose of CYP prior to 
AIT using TILs from ovarian tumors expanded in IL-2 resulted in 1 case of complete 
regression and 4 cases of regression exceeding 50% of the tumor were reported out of a 
total of only 7 patients (135). The fact that the latter 2 trials did not use IL-2 injections in 
vivo indicates that the use of CYP for the creation of lymphopenia may be the most 
important factor in achieving expansion of transferred T cells. However, homeostatic 
proliferation within a lymphopenic host may still be ineffective if the expanded T cells are 
specific for only one antigen. One mechanism of immune escape by tumor cells is antigen 
loss. Therefore, it is important to adoptively transfer T cells that have specificities for 
multiple tumor antigens and antigenic epitopes (136). T cells derived from parental FVB 
mice are therefore ideal candidates for evaluating the efficacy of protocols for expanding 
the neu-specific T cells in the absence of the nominal antigen, ex vivo since these mice are 
exposed to whole tumor cells in vivo, generating an immune response effective enough to 
completely reject MMC cells. Bryostatin-1, a protein kinase C activator, and ionomycin, 
which increases intracellular calcium levels, are able to cause vast expansion of tumor-
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specific T cells, while not expanding naïve, non-sensitized T cells,  without the addition of 
specific tumor antigen by mimicking the signals that result from TCR stimulation (137). T 
cells expanded in this manner were able to cause regression of MCA-105 pulmonary 
metastasis in vivo, as well as of established 4T07 and 4T1 mammary tumors (138, 139). 
 In addition to the activation of donor T cells by bryostatin-1 and ionomycin, the 
means of T cell expansion by gamma chain cytokines may also have an important effect on 
T cell generation. The growth factor interleukin-2 has been used to mediate high levels of 
ex vivo expansion of tumor specific T cells. However, there is evidence that IL-2 expansion 
may also lead to the induction and maintenance of regulatory T cells, and IL-2 is known to 
cause activation-induced cell death and the upregulation of Fas/FasL molecules on the 
surface of T cells (140-143). In particular, the expansion of TILs from breast cancer 
patients in IL-2 has resulted in predominantly CD4+ cells and low levels of lysis in vitro 
(113, 144) Alternatively, the cytokine IL-7 is needed for newly arising memory T cells 
(145). IL-15 has also been known to be important in the generation and maintenance of 
effector and memory CD8+ T cells. IL-15 can protect effector CD8+ T cells from 
apoptosis, as well as augmenting the cytotoxic effects of effector CD8+ T cells through the 
induction of molecules such as IFN-γ, perforin, and granzyme B (146-148). Therefore a 
better understanding of how these cytokines may work in concert and an optimized 
expansion protocol are needed to allow for the generation of the most effective pool of 
anti-tumor T cells to be generated ex vivo.  
 A need for the generation of high avidity T cells for transfer into tumor-bearing 
individuals has led to the development of T cells with genetically engineered T cell 
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receptors (TCRs). The first successful demonstration of this was done by transfecting 
Jurkat T cells with cDNA clones encoding the α and β chains of the TCR from a line of T 
cells recognizing the MART-1 TAA of melanoma. The transfected Jurkat T cells were then 
able to recognize MART-1 targets, demonstrating the feasibility of transferring the 
specificity of a reactive T cell clone to other T cells (149). This transfer was subsequently 
accomplished in primary human peripheral blood T lymphocytes, resulting in CD8+ T cell 
clones that could recognize and lyse melanoma cells in vitro (150).The first clinical trial 
using TCR gene therapy was completed in 2006. In this study, T cells from melanoma 
patients that were unresponsive to standard therapies were retrovirally transduced with 
MART-1 specific TCRs and were adoptively transferred back into patients following 
lymphodepletion. Out of 17 total patients, 15 showed persistence of transferred T cells for 
at least 90 days and 2 patients showed complete tumor regression (151). The potential 
efficacy of this for breast cancer has recently been shown in a mouse model using T cells 
with  chimeric receptors specific for human HER2, which were capable of eliminating 
pulmonary micrometastases of an aggressive breast cancer line expressing human HER2 
(152) However, potential concerns include the mis-pairing of transduced and endogenous 
TCR α/β chains, resulting in novel combinations that may be autoreactive, and aberrant 
integration of retroviral vectors potentially leading to malignant transformation (153).  
III. Suppressor Cells Abrogate Anti-Tumor Immune Responses 
 A. Regulatory T cells: In terms of inhibition of adoptively transferred T cells, the 
potential role of regulatory T cells (Treg) has been investigated. In a murine model of 
breast cancer, it has been shown that the adoptive transfer of Treg-depleted tumor 
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infiltrating lymphocytes was more advantageous against established tumors than transfer 
of total T cell populations and resulted in an increased Th1 response and IFN-γ secretion 
(154). Immunostimulatory treatments in mice bearing 4T1 mammary tumors were capable 
of mediating tumor rejection and survival in 65% of treated mice when combined with the 
attenuation of Treg, an effect mediated by tumor-specific T cell cytotoxicity and increased 
IFN-γ (155). Furthermore, the removal of CD25+ T cells in vivo has resulted in the 
rejection of B16 melanomas transduced with IL-12, and the transfer of CD25-depleted 
cells has resulted in complete regression of leukemia in nude mice (156, 157). Clinically, 
Treg infiltration has been observed in breast cancer patients where they have been linked to 
more aggressive cancerous phenotypes, poor prognosis, higher histological grade, and the 
presence of T cells expressing inhibitory molecule B7-H1 (158-160). Increased numbers of 
CD4+CD25+ T cells were also observed in cases of early-stage NSCLC, late stage ovarian, 
and metastatic melanomas. These cells have been found to secrete the immunosuppressive 
molecule TGF-β and suppress the proliferation and cytokine production by tumor 
infiltrating CD4+ and CD8+ T cells (161, 162). However, several studies contradict the 
role of Treg in cancer therapeutics. It has been found that administration of IL-2 to 
lymphopenic patients along with autologous T cell transfer increases the generation of 
Treg as compared to patients that did not receive IL-2 (143). It was further shown that Treg 
increase in response to IL-2 treatment in patients with renal cancer or melanoma who were 
not lymphopenic (163). These findings do not correlate increased Treg levels with clinical 
outcome and are in direct opposition to previous results showing regression of metastatic 
melanoma after treatment with CYP followed by AIT and IL-2 (133, 164). Therefore, 
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although mechanisms have been developed to deplete Treg from patient samples to be used 
for AIT (165), the role of Treg in AIT currently remains highly ambiguous and this cell 
type may not cause major inhibition in the case of adoptively transferred T cells. The role 
of other cell types, such as myeloid-derived suppressor cells, which have been shown to be 
highly suppressive in many models of mouse and human cancers, should therefore be 
evaluated in the context of AIT (166-169). 
B. Myeloid-Derived Suppressor Cells: Myeloid-derived suppressor cells (MDSC) 
are a heterogeneous population of immature myeloid-derived cells, which may include 
macrophages, dendritic cells, and granulocytes, at various stages of differentiation. These 
cells have thus far been characterized by expression of the surface markers CD11b and 
Gr1. The accumulation of these cells has been noted in many types of cancers, including 
the murine colon carcinoma MCA-26, Lewis lung carcinoma, the highly metastatic breast 
carcinoma 4T-1, the neu+ breast carcinoma MMC and melanoma (B16) (167, 170-173). 
The critical role of MDSC in cancer patients is underscored by the observation that 
patients with renal cell carcinoma, melanoma, head and neck cancer, and breast cancer had 
increased MDSC (174-178). Importantly, increases in the circulating levels of MDSC 
correlate with clinical cancer stage and metastatic burden of breast cancer (178) Increased 
numbers of MDSC are associated with enhanced myelopoiesis resulting from factors 
secreted by the tumor itself, predominantly GM-CSF, which stimulates myelopoiesis, and 
VEGF, which has been shown to block the maturation of hematopoietic progenitor cells 
(168).  This is supported by the finding that resection of solid fibrosarcoma tumors has 
resulted in a decrease in the number of CD11b+ Gr1+ cells and in increased number of 
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CD4+ and CD8+ cells in the spleens of mice (179). In renal cell carcinoma patients, 
removal of the primary tumor also resulted in the spontaneous regression of pulmonary 
metastasis (180). In fact, recent data from patients with renal cell carcinoma have 
demonstrated an increased quantity and intrinsic arginase activity of MDSC. In vitro 
depletion of MDSC from the PBL of these patients restored the tumor-specific IFN-γ 
production and T cell proliferation (174). In BALB-neuT female mice, which also develop 
spontaneous mammary carcinomas, CD11b+Gr1+ cells were observed to increase, not 
only with age, but also with tumor multiplicity. This increase was shown to be mediated by 
increased hematopoiesis within the host, as transfer of wild-type bone marrow cells into 
irradiated BALB-neuT hosts showed increasing numbers of transferred CD11b+Gr1+ cells 
upon reconstitution as the tumor number of the host increased (181). T cell proliferation in 
these mice also decreased with the increasing numbers of tumors and MDSC. Expanded 
MDSC populations have also been shown to have suppressive effects both in vivo and in 
vitro, however, the mechanism by which these cells exert their suppression is still 
controversial.  
 i. Mechanisms of T Cell Suppression by MDSC: Several groups have 
reported contact-dependent suppression by MDSC. In particular, Gabrilovich et al have 
shown antigen specific contact-dependency, reporting that while Gr1+ cells do not affect T 
cell proliferation induced by Concanavalin A, they do have an adverse effect on the 
number of IFN-γ-producing CD8+ T cells in response to specific peptide in what they 
determined to be an MHC class I dependent manner (166). It has also been reported that 
MDSC may work through the down regulation of the TCR zeta chain, an affect that was 
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only seen in the absence of transwell inserts (182). This affect was not shown to be antigen 
specific, however, suppression by MDSC was dependent on their derivation from a 
chronically inflamed environment. This is in agreement with current literature has found 
that MDSC isolated from tumor bearing mice are suppressive, while MDSC from non-
tumor bearing mice have little to no suppressive effect, also supporting the notion that 
MDSC must be activated, presumably by the IFN-γ secreted by effector T cells, in order to 
function (167). Further defects in the T cell receptor have been found to be mediated 
through direct contact between MDSC and T cells resulting in nitration of critical tyrosine 
residues in the TCR-CD8 complex, causing T cells to be unable to recognize MHC-peptide 
complexes, an effect caused by the production of reactive oxygen species and peroxynitrite 
(183).  
The function of activated MDSC has also been argued to be dependent on the 
production of nitric oxide, as well as other soluble factors, by these cells (184). The 
enzyme nitric oxide synthase (NOS) is responsible for the production of nitric oxide, and 
there are three main types of this enzyme: inducible NOS, endothelial NOS, and neuronal 
NOS. Although all three of these have shown some correlation with tumor progression and 
can be produced by the tumor cells themselves, the inducible form of NOS is of primary 
importance in MDSC. Nitric oxide can work in a variety of ways, including by the 
inhibition of JAK1, JAK3, and STAT5 molecules that mediate signaling through the IL-2 
receptor (184, 185). Interestingly, inhibition of T cell proliferation by NO has been shown 
to be potent against T cells stimulated in both antigen-specific and non-specific fashions. 
Significantly, inhibition of iNOS by L-NMMA has been shown to reverse MDSC mediated 
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inhibition of naïve T cell proliferation upon stimulation with anti-CD3 and anti-CD28, as 
well as in T cells stimulated with specific peptide or Concanavalin A (170, 184). In all of 
these cases, IFN-γ was required for the production of NO by MDSC. 
In addition to nitric oxide, indoleamine 2,3-dioxygenase (IDO) has also been 
implicated as one of the effector molecules of MDSC. IDO is an immunomodulatory 
enzyme that can also be secreted by alternatively activated macrophages as well as 
dendritic cells and by a variety of malignant human cancer cells. IDO is the rate limiting 
enzyme of the kynurenine pathway of tryptophan catabolism, metabolites from which 
cause T cell apoptosis. Thus, an excess of IDO facilitates the breakdown and subsequent 
depletion of the essential amino acid tryptophan, resulting in inhibition of T cell activation 
and proliferation. IDO is therefore important in maintaining peripheral tolerance and has 
also been implicated to play a significant role in a mother’s tolerance to her fetus and in the 
suppression of transplant rejection (186). Importantly, much like NO, IDO production in 
APC’s is initiated by IFN-γ, and therefore would be a logical mediator of suppression by 
IFN-γ activated MDSC. In a study using the neu transgenic mouse model, it was shown 
that the IDO inhibitor 1-methyl–tryptophan (1-MT), when combined with a 
chemotherapeutic agent such as cyclophosphamide, resulted in a reduced tumor volume, an 
effect that was shown to be dependent on endogenous T and B cells. The lymphocyte-
dependent effect of 1-MT was not, however, a result of direct effects on T and B cells, as 
proliferation of these cells was unaffected in vitro; thus it was the inhibition of IDO+ DC 
by 1-MT that resulted in the restoration of T cell proliferation (187).  
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A third soluble mechanism of MDSC suppression is the expression of arginase I, 
which depletes L-arginine from the environment and thus causes T cell dysfunction by 
inhibiting expression of the CD3 zeta chain (188). This finding correlates with reports of 
reduced TCR zeta chain expression in clinical studies done on patients with breast cancer, 
melanoma, and gastric cancer (182, 189-191) and the fact that increased levels of arginase 
activity have been found in CD11b+ cells in the peripheral blood of renal cell carcinoma 
patients and was concurrent with a decrease in serum arginine and increased serum 
ornithine, a metabolic breakdown product of arginine (174). It was later shown that the 
production of arginase by MDSC was a result of tumor-derived soluble factors from the 
injected Lewis Lung Carcinomas (3LL). In particular, prostaglandin E2, produced through 
the action of COX-2, which is constitutively expressed along with COX-1 in 3LL tumors, 
was found to induce arginase 1 expression in MDSC via the E-prostanoid 4 receptor. 
Specific inhibition of COX-2, but not COX-1, completely ablated the induction of arginase 
1 in MDSC in this model (173).  
                        ii. MDSC and COX-2: COX-2 has proven to be a key molecule in 
promoting inflammation and tumor induced angiogenesis, and is expressed by 
inflammatory cells after exposure to proinflammatory cytokines. COX-2 overexpression 
can also be found in many human cancers including breast carcinoma and is believed to be 
upregulated in tissues in response to carcinogens such as ultraviolet light, nicotine, and 
Helicobacter pylori.  Expression of this enzyme leads to the production of prostaglandin-
E2 from arachidonic acid, which subsequently upregulates the Th2 response (resulting in 
increased pro-angiogenic factors such as IL-6 and VEGF) while simultaneously 
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downregulating the Th1 response, leading to decreased apoptosis in tumor cells through 
the induction of bcl-2 (192). Indeed, COX-2 expression and activity has been correlated 
with increased aggressiveness in breast cancer. It has been shown that COX-2 protein 
expression and activity were greatly increased in a metastatic breast cancer cell line as 
compared to a nonmetastatic cell line (193). This difference was shown to be mediated by 
increased methylation of the COX-2 promoter region in DNA from the nonmetastatic 
carcinoma. Conversely, the promoter region in metastatic breast carcinoma lines remained 
unmethylated. Treatment of cells with the DNA demethylating agent 5-aza-2’-
deoxycytidine correlated with an increase in COX-2 expression and activity (193). 
              In accordance with the correlation between increased COX-2 expression and the 
development of cancer, it has been observed that the use of nonsteroidal anti-inlfammatory 
drugs (NSAIDs) is linked with a decreased mortality rate from human breast and colon 
cancers (194, 195). Likewise, several studies have indicated that use of COX-2 inhibitors 
slow the progression of tumors. Rozic et al showed that both the non-selective inhibitor 
indomethacin and the selective inhibitor NS-398, resulted in an inhibition of the migration, 
invasion and angiogenesis of a highly metastatic C3L5 mammary tumor, while the 
selective COX-1 inhibitor valeryl salicylate did not have a significant effect (196). Kundu 
and Fulton confirmed the effectiveness of indomehtacin, and another COX-2 inhibitor, 
celecoxib, against tumor volume, incidence, and metastasis in the murine mammary tumor 
cell line 410 but also found the COX-1 selective inhibitor, SC560, to be effective (197). 
Here, the discrepancy of the effectiveness of COX-1 inhibition lies in the fact that the cell 
line used in the first study expressed very low levels of COX-1 whereas the 410 mammary 
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carcinoma of the latter study expressed higher levels of this enzyme and therefore would 
be more susceptible to its inhibition.  
             Also of significance is the finding that administration of celecoxib greatly reduced 
the number of 1,2-dimethylhydrazine induced intestinal tumors and that this decrease in 
tumor burden was correlated with a substantially decreased number of CD11b+ Gr1+ 
splenocytes in the mice that were given celecoxib in addition to 1,2-dimethylhydrazine  
versus mice that were given 1,2-dimethylhydrazine alone. Additionally, this study showed 
greatly decreased mRNA levels of NOS-2, arginase, and COX-2 in the spleens of animals 
given celecoxib treatment versus animals given 1,2-dimethyhydrazine alone (198). These 
findings and others, which have indicated that COX-2 expression in tumors is also linked 
to increased numbers of CD11b+ Gr1+ MDSC and these cells can work through a variety 
of mechanisms, including through the production of arginase 1, which is a direct result of 
prostaglandin E2 production via COX-2 expressing tumors, provides some interesting 
insights into the crosstalk and feedback mechanisms that exist between tumor-derived 
soluble factors and myeloid-derived suppressor cells (173). Interactions between known 
tumor-derived soluble factors, as well as yet-unknown factors, should be thoroughly 
investigated in order to determine the multi-factorial parameters of MDSC activation and 
function within the tumor-bearing host.   
                    iii. Mechanism of MDSC Induction: In addition to its role in tumorogenesis 
through activation by ErbB1, STAT3 is also  believed to downregulate the expression of 
proinflammatory cytokines and can have a profound impact on the immune response to 
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cancer (199). It has been found that blocking STAT3 causes an increase in several 
proinflammatory cytokines in melanoma, colon carcinoma, and breast carcinoma cell lines 
(199). These proinflammatory cytokines proved essential in causing the activation of 
potent dendritic cells in the context of the innate immune response, and transduction of 
tumor cells with a dominant negative form of STAT3, STAT3β, caused increased 
infiltration of immune cells to the tumor site in addition to causing the apoptosis of B16 
melanoma cells. Increased apoptosis induced by blockade of STAT3 is caused by STAT3 
expression upregulating the anti-apoptotic proteins BCL-XL, MCL1 (myeloid cell 
leukemia-1, a member of the Bcl-2 family that controls mitochondrial integrity), myc, and 
survivin. Tumor expression of STAT3 was additionally found to inhibit the maturation of 
dendritic cells, particularly because of the fact that STAT3 expression upregulates 
immunosuppressive molecules such as IL-10 and TGF-β. Binding of IL-10 to its receptor 
on dendritic cells can subsequently activate STAT3 within the dendritic cell, and cause the 
downregulation of critical maturation factors such as MHC Class II molecules, and the co-
stimulatory molecules CD80 and CD86 (199, 200). Thus, the activation of STAT3 in 
tumor cells leads to and maintains the activation of STAT3 in MDSC. This was also shown 
by Nefedova et al who demonstrated that it was Jak2 activation by tumor-derived soluble 
factors, particularly M-CSF and to a lesser extent VEGF and IL-10 secreted by C3 and 
CT26 cell lines, that lead to the hyperactivation of STAT3 in MDSC (201). IL-6, which 
has anti-apoptotic and pro-angiogenic effects and can regulate the differentiation of 
myeloid lineages and dendritic cells, has also been shown to activate STAT3 (202). In fact, 
COX-2 overexpression in a human non-small cell lung carcinoma cell line caused 
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increased STAT3 phosphorylation of both the tyrosine 705 and the serine 727 residues, 
which was at least partly mediated by increased IL-6 expression, in these cells (203). 
Phosphorylation of the tyrosine 705 residue of STAT3 results in its dimerization and 
nuclear translocation, whereas phosphorylation of serine 727 is believed to cause the 
subsequent activation of transcription (199). The effect of tumor-derived soluble factors on 
STAT3 was confirmed in vivo by the fact that STAT3 DNA binding was significantly 
increased in Gr1+ cells from CT-26 tumor bearing mice over that of control mice. One 
mechanism by which STAT3 activation causes increased MDSC is by maintaining a high 
rate of proliferation amongst these cells, however, further studies should be done to 
investigate other potential surface molecules or soluble factors upregulated in these cells as 
a result of STAT3 hyperactivation that may cause a positive feedback loop which initiates 
the accumulation of more MDSC either by contact-dependent mechanisms or by actively 
blocking the maturation of newly recruited hematopoietic cells, in addition to the increased 
proliferation of existing MDSC (201). 
             MDSC can act in a variety of ways to cause suppression of anti-tumor immune 
responses including, but not limited to, the secretion of soluble factors such as nitric oxide 
and arginase I. There are also a variety of mechanisms by which the actions of MDSC may 
be induced, regulated, or altered. Adding to the complexity are the means by which MDSC 
may be induced and regulated. Several groups support the idea of activation of MDSC by 
IFN-γ, which requires STAT1 to exert its effects. Meanwhile, recent data also supports an 
important role for STAT3 in MDSC function. The data are therefore seemingly 
contradictory given that the effects of STAT1 and STAT3 have been shown to contradict 
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one another in terms of cellular proliferation as well as apoptosis (204-206). Suppressive 
activity by these cells may therefore require a balancing act between opposing signals, or 
alternatively, may require that one pathway be able to overcome another in order to 
maintain a suppressive phenotype. The role that individual cytokines and chemokines play 
in inducing and maintaining the suppressive phenotype of MDSC therefore is of critical 
importance and warrants further investigation in varying tumor models, particularly as the 
tumor microenvironment and subsequent cytokine profiles will vary in different tumor 
models.  
          iv. MDSC and Soluble Factors: A correlation between tumor burden and increased 
MDSC suggests that tumor-derived factors may cause accumulation of MDSC in cancer patients. 
Pan et al found that abrogating the secretion of stem-cell factor, or blocking its receptor, ckit, 
reduced MDSC expansion in mice bearing MCS26 colon carcinomas (207). In a transgenic model 
of breast carcinoma which expresses the activated form of the neu oncogene, VEGF serum levels 
were found to correlate with tumor multiplicity and progression, as well as accumulation of 
MDSC (181). Continuous VEGF administration in mice has been shown to result in the inhibition 
of dendritic cell development as well as an increase in Gr1+ cells and blocking VEGF in vitro 
prevents the negative effects of tumor-derived soluble factors on dendritic cells (208). In humans, 
high levels of VEGF in the plasma of patients with head and neck cancer, lung cancer, and breast 
cancer were closely correlated with a decrease in functional dendritic cells in the peripheral blood 
concurrent with an increase in circulating immature myeloid cells (209). GM-CSF has also been 
linked to the accumulation of MDSC, both in murine models through GM-CSF transduced tumor 
cells lines (167), and in humans, where a correlation was made between levels of circulating 
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CD34+ myeloid cells in patients with head and neck carcinoma and the ability of the tumor cells 
to secrete GM-CSF (210). Interestingly, a review compiling the results from multiple clinical trials 
using GM-CSF has found that the dosage of GM-CSF was paramount, with lower doses (40-80µg) 
eliciting an immune response, whereas higher doses showed no advantage (211). For example, 
melanoma patients receiving peptide vaccination along with either 100 or 500µg doses of GM-
CSF for 6 days showed a decrease in the induction of specific T cell responses (212),which was 
associated with increased levels of MDSC (213). In a mouse model of melanoma, increasing the 
concentration of GM-CSF beyond the therapeutic dose of 300ng/10
6
 cells/24 hours resulted in 
decreased survival and increased CD11b+Gr1+ cells in multiple organs (214). However, there is 
no direct evidence identifying the major tumor-derived soluble factors that could induce 
generation of MDSC from bone marrow progenitor cells and/or support MDSC survival 
          v. Subsets of MDSC and the Ly6G Molecule: Given the broad range of 
heterogeneous cells commonly defined as CD11b+Gr1+ MDSC, recent studies have 
explored more specific and extensive phenotyping for these cells. These studies identify 
different epitopes of the Gr1 molecule, namely Ly6G and Ly6C in distinguishing subsets 
of MDSC that may be more prone to expansion and/or suppression in various tumor 
models (171, 215, 216) . The Ly6 family members are cysteine-rich molecules that are 
usually glycosyl phosphatidylinositol (GPI)-anchored to the cell surface and it has recently 
been reported that expression of Ly6G correlates with a granulocytic phenotype, while 
expression of Ly6C correlates with a monocytic phenotype (171, 215). It is important to 
note, however that the subsets have not been identified in FVBN202 mice bearing neu+ 
(MMC) tumors. Given the discrepancies between subset phenotypes, expansion, and 
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suppressive capabilities in various models, we believe it is important to investigate the 
specific subsets of MDSC present in FVBN202 MMC tumor bearing animals. 
Furthermore, given differences in the profiles of soluble factors secreted by various 
tumors, we thought it imperative to identify the specific soluble factor(s) involved in the 
generation and accumulation of MDSC, MDSC subsets, and the function of these subsets 
in mice with neu+ tumors. 
Although MDSC in mice are becoming fairly well-defined, MDSC phenotypes in 
humans are still a topic of debate. MDSC were first broadly defined as being negative for 
lineage markers indicative of mature lymphocytes or myeloid cells including CD3, CD19, 
CD57 and CD14 (178, 209). These cells also consistently express the myeloid marker 
CD33, and in tumor-bearing individuals this is often the predominant marker used for 
MDSC isolation (178, 217, 218). These cells are also frequently identified as being HLA-
DR negative or low (178, 218, 219). However, the presence of other markers has varied 
significantly between different cancers, with MDSC in renal cell carcinoma patients being 
described as CD15+ CD14- while identification of MDSC in patients with hepatocellular 
carcinoma did not use CD15 as a marker, but found MDSC to be CD14+ and HLA-DR 
negative or low(218, 219). MDSC in patients with breast cancer have been defined as 
being lineage negative or low, HLA-DR- CD33+ and CD11b+ (178) The phenotypic 
markers used to identify MDSC not only vary between different types of cancer, but also 
between groups, as Rodriguez have recently identified a subtype of arginase I producing 
MDSC in patients with renal cell carcinoma as expressing high levels of CD66b, CD11b, 
and VEGFR1 while expressing low levels of CD62L and CD16 while Ko et al have 
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recently identified MDSC in renal cell carcinoma patients with the more conventional 
CD33+ HLA-DR- CD15+ CD14- designation (218, 220). Since MDSC can use a variety of 
mechanisms of suppress T cell activation and proliferation, and since MDSC, being 
derived from multi-potent bone marrow cells and existing at various stages of 
differentiation, are inherently heterogeneous, the identification of specific markers of 
MDSC that correlate with specific function would offer the most advantageous means of 
developing treatments to counteract the detrimental effects of these cells.    
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Materials and Methods 
 
Mouse Model:  
Parental FVB (Jackson Laboratories) and FVBN202-transgenic female mice (Charles 
Riveer Laboratories) were used between 6-10 weeks of age throughout these studies. 
FVBN202 mice overexpress an unactivated rat neu transgene under the regulation of the 
MMTV promoter (25). These mice develop pre-malignant mammary hyperplasia similar to 
ductal carcinoma in situ (DCIS) prior to the development of spontaneous carcinoma (221). 
These studies have been reviewed and approved by the Institutional Animal Care and Use 
Committee (IACUC) at Virginia Commonwealth University.  
Tumor cell lines 
The MMC cell line was established from a spontaneous tumor harvested from an 
FVBN202 transgenic mouse as previously described (136). The antigen negative variant 
(ANV) cell line was derived from a relapsed MMC tumor in the FVB strain as previously 
described and is characterized by a loss of neu expression (136). Both cell lines were 
maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). Mice were 
challenged with 3-5X10
6 
MMC cells intradermally (i.d.) where indicated.  
Flow cytometry 
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Flow cytometry analysis was performed as previously described by our group (136). 
Briefly, splenocytes or bone marrow cells were homogenized into a single cell suspension 
and red blood cells were lysed using 1X ACK Lysis buffer for 5 minutes. Cells were 
washed and resuspended in 1XPBS with 2% FBS and 0.0065% sodium azide. Cells were 
counted and 10
6
 cells were aliquoted into each sample tube. Non-specific binding to Fc 
receptors was blocked with anti-CD16/CD32 antibody (Biolegend) for 20 minutes on ice. 
The following primary antibodies were purchased from Biolegend and used to stain the 
surface antigen CD11b (FITC or PE, clone M1/70), Gr1 (PE or PE/Cy5, clone RB6-8C5), 
CD4 (PE or PE/Cy5, clone GK1.5), CD8 (PE or PE/Cy5, clone 53-6.7), CD44 (PE, clone 
IM7), CD62L (FITC, clone MEL-4), CD69 (FITC, clone H1.2F3), CD25 (FITC, clone 
PC61), LFA-1 (FITC, clone 2D7), CD127 (FITC, clone SB/199),CD86 (PE, clone 
YTS156.7.7), PD-L1 (PE, clone 105.9G2),  I-A
q
 (Biotinylated, clone KH116), and CCR7 
(PE/Cy5 clone 4B12). Primary antibodies purchased from BD Pharmingen were against 
the surface antigens CD8a (FITC, clone 53-6.7), PD1 (PE, clone J43), H-2D
q
/H-2L
q
 
(Biotinylated, clone KH117), and Ly6G (FITC, clone IA8). A purified mouse monoclonal 
antibody against rat neu was purchased from Calbiochem (anti-c-ErbB2/c-Neu). All 
primary antibodies were added at the manufacturer’s recommended concentration and 
incubated on ice in the dark for 20 minutes. Cells were washed twice and secondary 
antibody added where applicable (FITC anti-mouse IgG and PE/Cy5 Streptavidin, both 
from e-bioscience) and incubated and washed as before. Cells were fixed with 1% 
paraformaldehyde or were washed again in 1X Annexin V buffer (BD Pharmingen) and 
the Annexin V staining protocol was followed for the addition of Annexin (FITC or PE) 
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and/or propidium iodide (BD Pharmingen). Whole blood was obtained by retro-orbital 
bleed. 50X10
6 
whole blood cells were used per sample and were blocked and stained as 
described above, and subsequent red blood cell lysis with 1X ACK. Samples were run on a 
Beckman Coulter FC 500 and analyzed using Expo 32 or Summit version 4.3 software.  
Cytotoxicity assay 
Neu-specific effector lymphocytes were cultured with MMC at 10:1 and 20:1 E:T ratios in 
complete medium (RPMI 1640 supplemented with 100 U/mL penicillin, 100 µg/mL 
streptomycin, and 10% FBS) and 20 U/mL recombinant IL-2 (Preprotech) in 6 well culture 
dishes. After 24 hours, 3 mL fresh media was added to the existing 3 mL of media. After 
48 hours, cells were harvested and stained for neu (anti-c-ErbB2/c-Neu, Calbiochem), 
Annexin V and PI according to the manufacturer’s protocol (BD Pharmingen). Flow 
cytometry was used to analyze the viability of neu positive cells 
IFN-γ ELISA 
Effector lymphocytes were cultured in complete medium at a 10:1 ratio with irradiated 
MMC cells or ANV cells (15,000 rad) or in medium alone for 24 hours. Supernatants were 
collected and stored at -80
0
C until used. IFN-γ was detected using a Mouse IFN-γ ELISA 
Set (BD Pharmingen) according to the manufacturer’s protocol.  
Expansion of effector T cells from FVB mice 
FVB parental mice were inoculated with 5X10
6
 MMC cells and splenocytes harvested 
after 20-30 days. Splenocytes (10
6
 cells/mL) were stimulated in complete medium 
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containing 15% FBS with bryostatin-1 (5 nM) and ionomycin (1 µM) along with 80 U/mL 
of IL-2 for 16 hours. Cells were washed 3 times and cultured at 10
6
 cells/mL in complete 
medium, Cells expanded in IL-2 alone received 40 U/mL of IL-2, while cells expanded in 
IL-7 and IL-15  received 10ng/mL of each cytokine. Media was changed and fresh 
cytokines added every other day for a total of 7 days. Cells expanded with alternating 
gamma chain cytokines were cultured on day 1 with 10 ng/mL IL-7 and 10 ng/mL IL-15. 
On day 2, 40 U/mL of IL-2 was added. Medium was changed on days 3 and 5, each time 
culturing with 10 ng/mL each of IL-7 and IL-15 and cells were harvested for infusion on 
day 7. All cytokines were from Peprotech. Aliquots of cells were taken at indicated time 
points and samples were stained with combinations of the following antibodies and 
assessed by flow cytometry: FITC-CD25, FITC-CD62L, FITC-CD8, PE-CD44, PE-CD69, 
PE-CD8, PE/Cy5-CD4, PE/Cy5-CD8, PE/Cy5-CD69 from Biolegend and PE-CD25, PE-
CD4 from BD Pharmingen. All antibodies were used at the manufacturer’s recommended 
concentration.   
Adoptive immunotherapy  
For MDSC depletion and CD62L+/- AIT studies: twenty-four hours prior to AIT, 
FVBN202 mice were treated with Cyclophosphamide (CYP, 100 mg/kg) by intraperitoneal 
(i.p.) injection in order to induce lymphopenia. Mice were challenged i.d. with 3-5X10
6 
MMC
 
cells and then received 70X10
6
 T cells by tail vein injection later the same day. For 
AIT with Gemcitabine studies: CYP (100 mg/kg given i.p.) was given 48 hours prior to 
adoptive transfer and 3X10
6 
MMC cells were administered i.d. 24 hours prior to adoptive 
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transfer. AIT was then administered on Day 0 as before. In all cases, tumor growth was 
monitored by digital caliper and tumor volumes were calculated by: V(volume)= 
[L(length) X W(width)
2
]/2. Blood was collected from the orbital sinus periodically to 
determine antibody responses and levels of CD11b+Gr1+ cells by flow cytometry. At the 
termination of the experiment, splenocytes were harvested and stained for activated T cells 
or used in IFN-γ release assays, as indicated. 
Depletion of MDSC in vivo 
For AIT using IL-2 expanded T cells, LEAF purified monoclonal antibody against the 
surface antigen Gr1 (clone RB6-8C5) was ordered from Biolegend and 300µg was 
administered i.p. starting on day 6 after tumor challenge and continuing every 3 days for 
the indicated time period. For AIT using alternating gamma chain cytokine expanded T 
cells, anti-Gr1 antibody was purified from the RB6-8C5 hybridoma by collecting 
supernatant from the CELLine CL 1000 flask (IBS Integra Biosciences) according to the 
user manual. Supernatant was stored at -80
ο
C until IgG purification using a MEP-
Hypercell column. Where indicated, mice were injected i.p. with 250µg of purified anti-
Gr1 antibody for a total of 6 times at 3-day intervals, followed by a final injection of 
200µg on day 25. In all cases, depletion was verified by flow cytometry of the peripheral 
blood for the CD11b and Gr1 surface markers. The dose of anti-Gr1 antibody was proven 
completely effective in mice bearing MMC tumors that were 25mm
3
 or smaller.  
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Gemcitabine Treatment 
Mice receiving CYP and MMC challenge were given 75mg/kg of Gemcitabine i.p. on days 
6, 11, and 16 after MMC challenge. Gemcitabine injections after re-challenge with MMC 
were also 75mg/kg each and administered on the days indicated. Flow cytometry of 
peripheral blood showed complete inhibition of MDSC after 2 injections.  
Recombinant neu protein 
The cDNAs coding for sub-domain II and sub-domain IV of the extracellular domain of rat 
neu (ECDII:187-332 aa and ECDIV: 503-642 aa) were amplified by PCR using the 
following primers: ECDII: 5’- GTGGAATTCACCAATCGTTCCCGGGCC-3’(sense) and 
5’-CTCCTCGAGACAACGCTGTGTTCCGTC-3’(antisense); ECDIV: 5’-
ACGAAGCTTGAGGACTTGTGCGTCTCG-3’ (sense) and 5’-
AGTGGATCCTCGTTCATCCAGATCCAC-3’ (antisense). Restriction sites are 
underlined. The resulting ECDII fragments were cleaved with EcoRI and XhoI restriction 
enzymes and ligated into the EcoRI-XhoI fragment of pRSET B, while fragments from 
ECDIV were cleaved with HindIII and BamHI restriction enzymes and ligated into the 
HindIII-BamHI fragments of pRSET B to generate the constructs. The cDNA for full 
length ECD (23-654 aa) was amplified using the primers 5’-
ATTGGTACCACCCAAGTGTGTACCGGCACA-3’ (sense) and 5’-
TGCAGAATTCGTCACCGGGCTGGCTCT-3’ (antisense) with underlined restriction 
sited cleaved with KpnI and EcoRI. Resulting fragments were ligated into the KpnI-EcoRI 
fragment of pRSET B. The recombinant proteins were expressed in E.coli using IPTG as 
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an inductor of expression. Purification of His-tagged protein was performed under 
denaturing conditions using the Guanidinium Lysis Buffer. After elution, proteins were 
dialyzed in 20 mM Tris, pH 9.0 overnight (4°C). Dialyzed proteins were concentrated 
using 10,000 MW cut-off columns (Viva Spin), filter-sterilized and protein concentration 
was determined using Bradford assay. 
ELISA 
Blood was collected from mice via the retro-orbital sinus, allowed to sit at room 
temperature for 10 minutes, and then spun for 10 minutes at 10,000 rpm. Serum was 
harvested and stored at -80
ο
C until used. For measuring the antibody response against neu, 
96 well plates were coated with 10 µg/mL of full length ECD or 4 µg/mL of subdomain II 
(ECDII) or subdomian IV (ECDIV) of ECD and incubated overnight at 4
ο
C. Plates were 
washed with PBS+0.05% Tween-20 and blocked with 2% skim milk for one hour. After 
washing, 5-fold serial dilutions of the sera were added (100 µl/well) and incubated for 2 
hours at room temperature. Horse-radish-peroxidase (HRP)-conjugated anti-mouse IgG1 
from Caltag was added at a 1:2000 dilution for 1hour. Plates were washed and reactions 
developed by adding 100 µl/well of the TMB Microwell peroxidase substrate (Kierkegaard 
& Perry). The reaction was stopped with 2 M H2SO4, and the O.D. read at 450 nm. Mean 
antibody titers were then calculated where indicated. 
Isolation of MDSC in vitro 
Gr1+ cells were isolated using an EasySep PE Selection kit from StemCell Technologies. 
The protocol from the manufacturer was followed using splenocytes homogenized from 
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MMC tumor-bearing FVBN202 mice labeled with 2 µg/mL of PE-Gr1 or PE-CD11b 
antibody from Biolegend. Purity of Gr1+ cells was confirmed by flow cytometry and was 
>90%.  
In vitro proliferation assays and BrdU labeling  
Splenocytes or sorted CD11b+Gr1+ cells were cultured in 96 well plates. For T cell 
stimulation assays using splenocytes, plates were coated with 10 µg/mL of anti-CD3 (BD 
Pharmingen) and were washed 3 times with PBS after 24 hours to remove any unbound 
antibody. Cells were brought to a concentration of 1X10
6
 cells/mL in complete media and 
2X10
5
 cells were added to each well. Cells were labeled by adding 10 µM BrdU (5-bromo-
2-deoxyuridine, BD Pharmingen) directly to the culture medium. Soluble anti-CD28 
antibody (BD Pharmingen) was also added to wells for T cell stimulations at 1µg/mL. For 
sorted CD11b+Gr1+ proliferation assays, 100ng/mL of GM-CSF (Peprotech) was added. 
Cells were allowed to proliferate for 72 hours at 37
ο
C, 5%CO2. Staining for BrdU was 
done following the protocol from the manufacturer (BD Pharmingen) using the FITC-
conjugated anti-BrdU flow kit. Where indicated, MDSC were depleted from the splenocyte 
populations using the PE Selection protocol above with either PE-Gr1 or PE-CD11b 
antibodies (Biolegend). Isolated MDSC were added to wells where indicated at a 1:2 
MDSC to splenocyte ratio either in the absence of a transwell insert, or in the top chamber 
of a transwell insert with 8.0um pore (Corning Life Sciences). MDSC sorted on the basis 
of Ly6G and Ly6C expression were added to splenocytes at a 1:2 MDSC to splenocytes 
ratio where indicated and labeled with BrdU and stained as above. 
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MMC-derived supernatants 
MMC-derived conditioned medium was generated by culturing 10X10
6 
MMC cells in 
10mL of media for 24 hours in RPMI1640 supplemented with 10% FBS. Supernatant was 
then removed and concentrated to a volume of 600µL using 10,000kDa molecular weight 
cut-off columns (Viva Spin). Concentrated supernatant or control medium was then 
injected i.d. into FVB mice (n=3, 200µL per mouse). Injections were repeated once per 
day on 3 consecutive days; mice were then sacrificed on day 4 and spleens, blood, and 
bone marrow were subjected to flow cytometry analysis of CD11b and Gr1 levels, as 
described above.  
Multiplex cytokine array of MMC supernatants 
MMC cells were cultured at a concentration of 10
6
 cells/mL for 24 hours. Supernatants 
were harvested and sent to Allied Biotech, Inc. for Multiplex array analysis in a blinded 
fashion.  
Cell sorting 
Bone marrow cells were harvested from naïve FVBN202 mice and stained for surface 
expression of CD11b and Gr1 as described. Cells were kept in sterile RPMI1640 with 10% 
FBS throughout. Cells were sorted on a Cytomation MoFlo by gating on the granulocyte 
region and then sorting CD11b+Gr1+ and CD11b-Gr1- cells. MDSC subsets were triple 
sorted from the spleens of tumor-bearing mice by first staining with anti-Ly6G, followed 
by anti-CD11b and anti-Gr1. Cells were gated on CD11b+ cells from within the gated 
granulocyte region, and subsequently sorting this population based on expression of Ly6G 
   
 49 
and Ly6C. After sorting, an aliquot of each population was restained for the CD11b and 
Gr1 surface markers as well as either Annexin V or Ly6G (as previously) and run on the 
Beckman Coulter FC 500. Purity of sorted cells was consistently greater than 96%.  
Culture of sorted or whole bone marrow cells 
Total bone marrow cells from one FVBN202 mouse were cultured in 10mL dishes with 
100ng/mL GM-CSF (Peprotech). Cells were split on day 3 and fresh cytokine added. On 
day 6 all floating and adherent cells were harvested and used for analysis by flow 
cytometry. Sorted bone marrow populations (CD11b+Gr1+ and CD11b-Gr1-) were 
cultured in 6 well plates (1-2X10
5
 cells/well) for a total of 6 days. GM-CSF (100ng/mL), 
VEGF (50ng/mL), or MCP-1 (50ng/mL) were added directly to the culture medium on day 
0 (all cytokines/chemokines from Peprotech) or sorted cells were cultured in the bottom of 
a 6 well dish with a 24mm Transwell insert with a 0.4µm pore on top (Corning Life 
Sciences). To the Transwell insert, 0.1X10
5
 MMC cells were added on day 0. On day 3, 
cells were split and fresh cytokine was added. Transwell inserts were discarded on day 3 
and a fresh insert with 0.1X10
5
 MMC cells was added. On day 6, all cells were harvested 
and aliquoted into tubes for analysis by flow cytometry.  
Isolation of RNA and RT-PCR 
RNA was isolated from magnetically selected or sorted cells via TRIzol reagent and was 
treated with DNase. Total RNA (5µg) was used as a template for reverse transcription 
(20µL total volume). cDNA was used in a PCR master mix containing 1X PCR buffer,, 
1.5mM MgCl2, 2.5U Taq polymerase, and 1µM gene-specific primers: β-actin [5’-
   
 50 
GTGGGCCGCTCTAGGCACCAA-3’ (sense) and 5’-
CTCTTTGATGTCACGCACGATTTC-3’ (anti-sense)];  GAPDH [5’-
ACCACAGTCCATGCCATCAC-3’ (sense) and 5’-TCCACCACCCTGTTGCTGTA-3’ 
(anti-sense)]; TGF-β [5’-AAGACCATCGACATGGAGC-3’ (sense) and 5’-
TGTCACAAGAGCAGTGAGCG-3’ (anti-sense)]; IL-10 [5'-
ATGCAGGACTTTAAGGGTTACTTGGGTT-3' (sense) and 5'-
ATTTCGGAGAGAGGTACAAACGAGGTTT-3' (anti-sense)]; and IDO [5’-
GTACATCACCATGGCGTATG-3’ (sense) and 5’-GCTTTCGTCAAGTCTTCATTG-3’ 
(anti-sense)]. PCR conditions were as follows: TGF-β: 94ºC 5 min, 94ºC 1 min, 58ºC 1 
min, 72ºC 2 min (42 cycles) followed by a 7 min extension at 72ºC; IL-10: 94ºC 5 min,  
94ºC 30 s, 60ºC 30 s, 72ºC 1 min (35 cycles) followed by a 7 min extension at 72ºC; IDO: 
94ºC 3 min, 94ºC 30 s, 60ºC 1 min, 72ºC 2 min (40 cycles) followed by a 5 min extension 
at 72ºC. Amplified fragments were visualized by ethidium bromide staining of the agarose 
gel and photography under UV light in Gel Doc 2000
TM
 (BioRad). β-actin or GAPDH 
were used as internal controls.  
In vivo treatments with GM-CSF, IL-6, VEGF and MCP-1 
Recombinant GM-CSF (500ng), GM-CSF+IL-6 (500ng and 120 units, respectively), 
VEGF (1.5µg), or MCP-1 (2.5µg) or PBS was injected i.d. into FVB mice once per day for 
3 consecutive days. Mice were sacrificed on day 4 and spleens, bone marrow, and blood 
analyzed by flow cytometry for the expression of CD11b and Gr1. GM-CSF (2.5µg) was 
   
 51 
administered i.d. for 2 consecutive days and mice were sacrificed on day 3 for analysis of 
the spleen, bone marrow, and blood, as above.   
Tumor re-challenge studies: 
FVBN202 mice that rejected initial MMC challenge were challenged again with 3-5X10
6
 
MMC cells (as indicated) i.d. on the contralateral side. Subsequent challenges were done 
i.d. on the side contralateral to the first re-challenge.  
Statistical Analyses:  
Analyses were done using the students, one-tailed, unpaired T-Test. Significant values are 
less than or equal to 0.05. 
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Chapter 1 
 
I. Study Rationale 
Our lab has had a long standing interest in developing an effective means of 
treating neu positive mammary tumors with adoptively transferred T cells. The FVBN202 
mouse model is a clinically relevant means by which to investigate adoptive 
immunotherapy (AIT) because of their immunological tolerance to the neu oncoprotein. 
Despite this tolerance, it has previously been shown that FVBN202 mice develop atypical 
hyperplasia of the mammary glands preceding spontaneous tumor development (25) and 
that this increase in mammary epithelium provides a “danger signal” that results in 
antibody responses against the neu ECD as well as IFN-γ secretion in response to the neu 
protein in FVBN202 mice (221). This break in self tolerance, however, was not successful 
in inhibiting subsequent tumor challenges with neu+ MMC cells, since we have shown that 
both a non-self entity and a danger signal are needed to mount effective anti-tumor 
immune responses in these mice (221). Additionally, atypical hyperplasia generated an 
immunosuppressive microenvironment characterized by the increased expression of IL-10 
and the IL-10 receptor, as well as suppressor of cytokine signaling (SOCS)-1 and SOCS-3 
(222), which may lead to increased MDSC. We have observed elevated levels of MDSC in 
FVBN202 mice during the premalignant stage and have correlated this with mammary 
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hyperplasia and the failure of the pre-existing immune response to prevent spontaneous 
tumor development (172, 221).  
Previous attempts in our lab to use adoptively transferred T cells to cure neu+ 
tumors in FVBN202 mice have proven unsuccessful, despite the fact that T cells were 
activated and expanded from FVB mice that had successfully rejected a neu+ tumor 
challenge. Efforts to identify reasons why expanded T cells from FVB mice fail to reject 
tumors in FVBN202 mice lead us to the observation that tumor-bearing FVBN202 mice 
exhibited large increases in their granulocytes. Previous finding in a transgenic mouse 
model similar to ours that expresses the activated rat neu oncogene have revealed that 
increases in spontaneous mammary tumor development coincided with increases in 
CD11b+Gr1+ MDSC (181), which lead us to determine the prevalence of these cells in our 
model and in response to MMC  tumor challenge. The increase in granulocytes previously 
observed was, in fact, because of large increases in CD11b+Gr1+ cells. A subsequent 
finding showed that the transfer of T cells into chronically inflamed environments 
characterized by MDSC resulted in the suppression of those T cells via TCR 
downregulation (182). The increase in MDSC in tumor-bearing FVBN202 mice, combined 
with the fact that these mice also exhibit atypical hyperplasia of the mammary glands and 
elevated MDSC prior to spontaneous mammary development led us to hypothesize that the 
failure of adoptively transferred T cells in FVBN202 mice is a result of the presence of 
elevated levels of MDSC. We further hypothesized that the attenuation of these cells or the 
ability to overcome/circumvent these cells in vivo would allow adoptively transferred T 
cells to mediate tumor regression.  
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II. Results 
FVBN202 Mice Bearing Neu Positive MMC Tumors Accumulate Large 
 
Numbers of CD11b+Gr1+ Cells in their Spleens, Bone Marrow, and Blood 
In the FVBN202 mouse model of spontaneously arising mammary carcinomas, we 
have observed a large increase in cells of the granulocyte region in mice bearing neu-
expressing MMC tumors. This increase in the overall percentage of granulocytes has been 
observed in the spleen, bone marrow, and blood of these mice (Fig. 2). Representative dot 
plots show that the granulocyte region in the spleens of tumor-bearing mice increases four-
fold from 6% to 24%, while also increasing 2.7-fold from 22% to 59% in the bone marrow 
and 4.3-fold from 7% to 30% in the blood (Fig. 2). Analysis of the absolute numbers of 
granulocytes present in the spleen and the bone marrow of the tibias and femurs shows a 
statistically significant increase in granulocytes in MMC tumor-bearing FVBN202 mice 
over tumor-free FVBN202 mice (Fig. 3). In the spleen, tumor-bearing mice showed an 
average of 6.56X10
7
 granulocytes, whereas tumor-free mice had an average of 1.11X10
7
 
granulocytes (P=0.004, Fig. 3A). Similarly, the number of granulocytes present in the  
bone marrow recovered from the tibias and femurs of tumor-bearing animals averaged 
1.95X10
7
 whereas the average number of granulocytes in the bone marrow recovered from 
the tibias and femurs of tumor-free mice was 7.2X10
6
 (P=0.003, Fig. 3B).  There is no 
such influx in cells of the lymphocyte region, as shown in Figure 4, the increased 
granulocytes cause a significant decrease in the overall percentage of cells in the 
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lymphocyte region of the spleen (39.2% in tumor-bearing vs. 59.3% in tumor free, 
P=0.0377), although this is not accompanied by a significant decrease in the absolute  
number of these cells (11.3X10
7 
in tumor-bearing vs. 8.99X10
7
 in tumor-free)
,
 indicating 
that the presence of the granulocytes does not inhibit the persistence of cells in the 
lymphocyte region in the periphery, but rather causes a shift in the lymphocyte to 
granulocyte ratio (Fig. 4A,C). In the bone marrow, however, both the percentage and the 
absolute number of cells in the lymphocyte region recovered from the tibias and femurs are 
significantly decreased, with tumor-bearing mice having only 2.4X10
6
 cells in the 
lymphocyte region whereas tumor free-mice averaged 9.4X10
6
 cells in the lymphocyte 
region (Fig. 4D, P=0.001). Furthermore, the percentage of cells in the lymphocyte region 
decreased by 4.9-fold, from 43.7% in tumor-free bone marrow, to 9% in tumor-bearing 
bone marrow (Fig. 4B,D P=0.001). This indicates that the increased number of 
granulocytes may out-compete cells in the lymphocyte region for available cytokines. 
Further investigation of the granulocyte region in these mice reveals the presence of cells 
staining double positive for the integrin CD11b and the glycosylphosphatidylinositol-
linked myeloid differentiation protein Gr1. We have found in every compartment in vivo, 
that the presence of CD11b+Gr1+ cells increases in MMC tumor-bearing FVBN202 mice 
as compared to naïve FVBN202 mice. We have found these cells to increase both as a 
percentage from within the granulocyte region, as well as a percentage of the overall 
spleen (Fig. 5). In the spleen, the total percentage of CD11b+Gr1+ cells increases from 3% 
to 34% in naïve versus tumor-bearing animals and from 8% to 92% in comparing naïve 
versus tumor-bearing granulocytes, respectively. A similar observation was made in the 
   
 60 
bone marrow, where the total percentage of CD11b+Gr1+ cells increased from 28% in 
naïve mice to 76% in tumor-bearing mice and from 77% of the granulocytes in naïve mice 
to 91% of the granulocytes in tumor-bearing mice (Fig. 5). Likewise, large increases in 
double positive cells are observed in the blood (4% of the total peripheral blood 
leukocytes, or PBL, in tumor-free versus 34% of the total PBL in tumor-bearing). The 
percentage of double positive cells comprising the granulocyte region of the blood 
increases to 84% in tumor-bearing mice from 54% found in tumor-free mice. A somewhat 
smaller population of double positive cells (9%) was also observed at the tumor site itself 
when MMC tumors were excised and subjected to flow cytometry (Fig. 5). 
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Bryostatin-1/Ionomycin (B/I) stimulation followed by IL-2 expansion generates 
 highly activated neu-specific effector T cells 
 
Since parental FVB mice recognize the rat neu protein as a foreign antigen and are 
subsequently able to reject MMC, whereas FVBN202 mice often tolerate neu protein and 
are unable to reject MMC, FVB mice were used as donors for AIT transfers into FVBN202 
recipients in these studies. Since B/I selectively activates effector T cells regardless of their 
antigen specificity (139), we sensitized FVB mice with MMC cells in order to increase the 
pool of neu-specific effector T cells. We first compared the populations of CD4+ and 
CD8+ T cells from these donors immediately after harvest, after activation with B/I, and 
after a 7-day expansion with IL-2. Representative data from duplicate experiments are 
presented in Figure 6. FVB donor splenocytes contained 35% and 9% CD4+ and CD8+ T 
cells, respectively. These populations were similar immediately after B/I activation (27% 
and 12% CD4+ and CD8+, respectively) but were greatly increased after 7 days of culture 
with IL-2 (Fig. 6A, 55% and 32% CD4+ and CD8+, respectively). Furthermore, IL-2 
treatment increased the absolute number of viable T cells by 9.5-fold over the cell number 
that was cultured after B/I expansion (Fig. 6B). The Annexin V+ CD4+ population 
remained nearly constant during ex vivo expansion, starting at 20% on day 0 compared 
with 24% after B/I activation and cytokine treatment (Fig. 6C). The CD8+ T cells, 
however, showed a marked increase in Annexin V+ staining from day 0 to day 7, with the 
fresh splenocytes being only 13% Annexin V+, while the post-B/I and post-cytokine 
values were 23% and 54%, respectively (Fig. 6C).  
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In order to determine T cell phenotypes, flow cytometry was performed for 
memory T cells (CD44+CD62L+) and effector T cells (CD44+CD62L-), as well as for the 
activation marker CD25, and the very early activation marker CD69, in both the CD4+ and 
CD8+ populations. As expected, B/I activation greatly increased the effector phenotype in 
the CD4+ population from 16% to 79% and in the CD8+ population from 5% to 66% 
while naïve (CD44-CD62L+) and memory (CD44+CD62L+) CD4+ and CD8+ T cells 
were greatly decreased (Fig. 6D). After IL-2-induced expansion, both CD4+ and CD8+ T 
cells showed a marked increase in CD44+CD62L+ memory T cells (74% and 58% in the 
CD4+ and CD8+ compartments, respectively), while maintaining increased levels of 
CD44+CD62L- effector T cells compared to pre-B/I treatment (16% vs. 22% and 5% vs. 
38%, respectively). Additionally, the expression of CD25 on CD4+  and CD8+ T cells was 
markedly increased to over 80% in both cases after B/I activation, and increased to over 
90% in both populations after IL-2 expansion (Fig. 6E). The very early activation marker, 
CD69, was greatly increased from about 0.1-0.2% in fresh splenocytes to 87% in CD4+ T 
cells and 93% in CD8+ T cells after B/I activation. This value, however, dropped again 
after a 7-day culture with IL-2, with 0.8% CD69 expression in CD4+ T cells, and, notably, 
3% remaining in the CD8+ T cells. However, most cells retained a late effector phenotype 
(CD44+CD69-) on day 7 (Fig. 6F).     
To confirm anti-tumor efficacy in vitro, T cells derived from MMC sensitized FVB 
mice prior to (Pre-B/I) or after a 7-day ex vivo expansion (Post-Cytokine) were co-cultured 
with MMC target cells (E:T ratio of 10:1) for 48 hours followed by staining with 
antibodies directed towards neu, Annexin V, and PI. Control wells were seeded with MMC 
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in the absence of T cells (No Treatment) (Fig. 7). Gating on neu positive cells and 
analyzing the percentages of Annexin V and PI positive cells allowed for the determination 
of specific killing of neu positive MMC cells by T cells. The viability of MMC in the 
absence of T cells was 86% (Annexin V and PI negative) while it dropped to 44% in the 
presence of the freshly isolated T cells (Pre-B/I). Viability of MMC was further decreased 
to 27% when cultured with B/I-activated, IL-2-expanded T cells (Post-Cytokine) (Fig. 7A)  
Absolute numbers of viable MMC also reflect the increased anti-tumor efficacy of B/I-
activated, IL-2-expanded T cells compared to freshly isolated T cells (P=0.026) (Fig. 7B). 
No killing was detected against the neu negative tumor variant, as determined by trypan 
blue exclusion (data not shown). 
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In vivo Depletion of MDSC is Required for the Efficacy of IL-2 Expanded Adoptively 
Transferred T cells 
 We next wanted to determine if transfer of these IL-2 expanded, highly cytotoxic T 
cells could result in tumor inhibition in FVBN202 mice. To test this, FVB mice were 
inoculated i.d. with 5X10
6
 MMC cells. Spleens were harvested after the mice had fully 
rejected the tumors and cells were activated with B/I and subsequently expanded in the 
presence of IL-2 as before. Twenty-four hours prior to the transfer of expanded T cells,  
FVBN202 mice were treated with 100 mg/kg of cyclophosphamide (CYP) in order to 
create a lymphopenic environment, which has been shown to be beneficial for the 
expansion of transferred T cells (128, 129). After 24 hours, mice were challenged i.d. with 
5X10
6
 MMC cells and 70X10
6
 expanded T cells were transferred into each FVBN202 
mouse that was to receive adoptive transfer via tail vein injection. Since FVBN202 mice 
bearing MMC tumors exhibit a pronounced accumulation of MDSC in vivo, (Fig. 5), we 
hypothesized that adoptively transferred T cells may be prevented from working in such an 
immunosuppressive environment. Therefore, one group of mice that received MMC 
challenge and adoptive transfer of T cells also received i.p. injections of an anti-Gr1 
antibody (300µg per injection starting on day 6 and every three days thereafter for a total 
of 4 injections). Tumor growth measurements in Figure 8 show that the tumor volumes did 
not differ significantly between the control group (CYP +MMC) and the group that also 
received adoptively transferred T cells. Strikingly, there was significant tumor inhibition in 
the group treated with anti-Gr1 antibody compared to the control group at weeks 6 
(P=0.018) and 7 (P=0.032), with the mice receiving Gr1 depletions having an average 
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tumor volume of only 26.9mm
3
 on week 6 as compared to 588.9 mm
3
 in the control group, 
and 32.7 mm
3
 on week 7 as compared to 1121.4 mm
3
 in the control group. Therefore, 
adoptive transfer of anti-neu T cells expanded with IL-2 and highly effective in vitro is not 
effective unless combine with the depletion of endogenous MDSC. To eliminate the 
possibility that the depletion of endogenous MDSC may, on its own, result in tumor 
rejection by these mice by allowing them to break tolerance to MMC tumors, FVBN202 
mice were inoculated with 5X10
6
 MMC cells intradermally (i.d.) and were treated with 
anti-Gr1 antibody starting 6 days after tumor inoculation and continuing every three days 
for a total of 3 injections. As shown in Figure 9, all mice in this group had large tumors by 
week 3, therefore confirming that MDSC depletion alone cannot cause the rejection of 
tumors to which an individual is tolerant.  
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The Efficacy of in vivo MDSC depletions can be directly correlated with the 
effectiveness of the anti-tumor response 
 In order to make sure that the anti-Gr1 antibody injections were effectively 
removing MDSC from MMC-challenged FVBN202 mice in vivo, flow cytometry of the 
peripheral blood was done regularly. High levels of CD11b+Gr1+ cells were observed in 
control mice and mice receiving adoptive transfer without MDSC depletion. As expected, 
these levels were consistent with those seen previously in tumor bearing mice 
(representative plots from tumor bearing mice shown in Fig. 5). However, flow cytometry 
of the peripheral blood from mice receiving anti-Gr1 antibody on day 21 showed that this 
depletion was almost completely effective in 2 out of three mice (Fig. 10A), with the 
granulocyte regions almost completely ablated in both cases (1% remaining in mouse 1 
and 2% remaining in mouse 2). In contrast, mouse 3 was less responsive to treatment with 
anti-Gr1 antibody and maintained 14% granulocytes on day 21 (Fig. 10A). The level of 
surface expression of the Gr1 molecule is depicted in Fig. 10B. The mean fluorescent 
intensity (MFI) of the Gr1 molecule in mouse 3 is 102.6, whereas the MFI of the Gr1 
molecule in mouse 1 and mouse 2 are 1.4 and 1.5, respectively. Interestingly, the efficacy 
of Gr1 depletions seems to correlate positively with tumor rejection, with the tumor 
volumes of mouse 1 and mouse 2 on day 21 being 8.9mm
3
 and 0 mm
3
, respectively, 
whereas the tumor volume of mouse 3 on day 21 was 283.19mm
3
 (Fig. 10B). This trend is 
seen in Figure 11, where mouse 1 and mouse both eventually rejected tumors, while mouse 
3 had a tumor measuring 545.5mm
3
 by the end of week 4. Not only did the depletion of 
MDSC in vivo significantly aid in tumor rejection, but it also resulted in an antibody  
   
 79 
 
   
 80 
 
   
 81 
   
 82 
   
 83 
   
 84 
 
   
 85 
response against the extracellular domain (ECD) of neu. Figure 12 shows that only mice 
receiving adoptive transfer along with MDSC depletion displayed an antibody response, 
whereas control mice and mice receiving adoptive transfer alone showed no antibody 
response, as is typical in this tolerant model. Interestingly, the strength of anti-neu 
antibody responses seems to also correlate with the efficacy of MDSC depletion. As shown 
in Figure 13, mouse 1 and mouse 2, which showed the highest degree of depletion, had 
noticeably stronger antibody responses than mouse 3, which was not efficiently depleted of 
MDSC in vivo.  
 In order to determine if the reason for tumor regression in mice receiving adoptive 
transfer of neu specific T cells with along with MDSC depletion was a greater persistence 
of activated T cells, mice were sacrificed 47-51 days after tumor inoculation and their 
spleens were analyzed by flow cytometry for the presence of activated T cells. Staining for 
CD25 expression on CD4+ and CD8+ T cells showed that in both cases (CD4 and CD8), 
mice receiving adoptive transfer alone had the highest  percentage of activated T cells 
(9.2% CD25+CD4+ T cells and 4.1% CD25+CD8+ T cells). In contrast, control mice and 
mice receiving adoptive transfer along with MDSC depletion had similarly low levels of 
CD25+ T cells (4.6% CD25+CD4+ in control mice and 5.3% CD25+CD4+ in mice 
receiving MDSC depletion; 1.8% CD25+CD8+ in control mice and 1.7% CD25+CD8+ in 
mice receiving MDSC depletion, Fig. 14). Therefore, the presence of activated T cells 
alone is not sufficient for the rejection of MMC tumors, and in the absence of suppressive 
MDSC, mice can remain tumor free even in the absence of high levels of activated T cells.  
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T Cell Expansion Using Alternating Gamma Chain Cytokines Generates More Potent 
Anti-Tumor T cells with Greater Levels of Expansion. 
 In an effort to generate T cells that may be more potent in the face of high levels of 
MDSC, we sought to devise a superior method of T cell expansion. We had previously 
attempted T cell expansion in the presence of IL-7 and IL-15, and noticed that although 
viability was improved over that seen in expansion with IL-2 alone (10% Annexin V+ 
CD4+ T cells after IL-7/15 as compared to 24% Annexin V+ CD4+ T cells after IL-2 
expansion and 13% Annexin V+ CD8+ T cells after IL-7/15 expansion as compared to 
54% Annexin V+ CD8+  T cells after IL-2 expansion), expansion levels were not great 
enough to generate enough T cells for injection on Day 7 (Figs. 6C,15B, 16). Also 
noteworthy is a severe reduction in the levels of activated T cells on day 7 after expansion 
with IL-7/15 (45% CD25+CD4+ and 9% CD25+CD8+, Fig. 15D) as compared to 
expansion with IL-2 (99% CD25+CD4+ and 92% CD25+CD8+, Fig. 6E). In order to 
optimize the benefits of both types of expansion, we decided to use treatment with IL-7/15 
(10ng/ml) on days 1, 3, and 5, with a one time “pulse” of IL-2 (40 U/ml) on day 2. We 
refer to this as “alternating gamma chain cytokine” treatment. This type of expansion 
increased the percentage of CD8+ T cells (47% in Fig. 15A vs. 32% in Fig. 6A) and 
showed an 11-fold expansion in overall viable T cell number as compared to a 9.5-fold 
expansion with IL-2 treatment (Fig. 16). Alternating gamma chain cytokines also greatly 
enhanced the viability of T cells on day 7 of culture when compared to expansion with IL-
2 alone (Fig. 15B shows 13% Annexin V+ CD4+ T cells and 11% Annexin V+ CD8+ T 
cells compared with 24% Annexin V+ CD4+ T cells and 54% Annexin V+ CD8+ T cells 
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in Fig. 6C). Of note, there were more CD44+CD62L- effector T cells in both the CD4+ 
and CD8+ compartments after expansion using alternating gamma chain cytokines as 
compared to expansion with IL-2 alone (33% vs. 22% CD4+ T cells and 48% vs. 38% 
CD8+ T cells, Figs. 15C and 6D). Like expansion in IL-2 alone, expansion with alternating 
gamma chain cytokines generated only CD62L
low
 effector memory T cells whereas 
expansion with IL-7 and IL-15, generated a population of CD62L
high
 central memory T 
cells. It has previously been shown that the adoptive transfer of B/I activated CD62L
low
 
cells was able to mediate complete regression of the 4T07 murine mammary tumor while 
adoptive transfer of the CD62L
high
 fraction resulted in only a 17% regression of tumors 
(137). While the percentage of CD4+CD25+ T cells and CD4+CD69+ T cells remained 
unchanged, CD8+CD25+ T cells decreased from 92% to 69% and CD8+CD69+ T cells 
decreased from 3% to 0.3% in comparing the IL-2-expanded T cells with alternating 
cytokine-expanded T cells, respectively (Figs. 6 E,F and 15 D,E). Although levels of 
CD25+ CD8+ T cells dropped in cells expanded with alternating cytokines as compared to 
cells expanded in IL-2 alone, levels of activated T cells were greatly increased in 
alternating cytokine-expanded cells as compared to IL-7/15 expanded cells (Fig. 15 D). 
Expression of the IL-7Rα (CD127), necessary for IL-7 to exert its effects in maintaining 
pools of memory T cells (223, 224), was measured after each type of cytokine expansion, 
and also on day 3 of alternating gamma chain cytokine expansion.  CD127 is expressed on 
only 9% of CD4+ cells and 15% of CD8+ cells after expansion in IL-2 (Fig 17). However, 
after expansion in IL-7/15, expression of CD127 is negligible (0.08% on CD4+ cells and 
0.03% on CD8+ cells) indicating the inability of these cells to expand is because of the 
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downregulation of at least one of the necessary cytokine receptors. Interestingly, on day 3 
of the alternating gamma chain cytokine expansion regimen, expression of CD127 is 
present on only 2% of CD4+ cells and 3% of CD8+ cells. However, these levels rise and 
are greatly elevated by day 7, with 21% of CD4+ cells and 18% of CD8+ cells expressing 
CD127 (Fig. 17). This is interesting since IL-2 has been shown to promote expression of 
CD127; however IL-2 expanded cells, and alternating cytokine expanded cells after IL-2 
pulse, show low levels of CD127, which increase without additional exogenous IL-2 (223). 
However, it has been shown in humans that CD8+ T cells with low IL-7Rα expression 
have increased levels of the IL-2/IL-15Rβ chain and respond to IL-15 with increased 
proliferation (225). Therefore the low expression of CD127 in Figure 17 could be 
indicative of cells with increased responsiveness to IL-15, which has been shown to be 
important for the maintenance and function of memory CD8+ T cells (148). Since the 
CD127 receptor is necessary for the homeostatic expansion of cells in vivo and for 
maintenance, particularly of CD8+ memory T cells, it is imperative to expand the cells in 
such a way that facilitates the continued expression of this receptor, as opposed to 
expansion methods that may cause receptor downregulation by negative feedback 
mechanisms (226). Another concern in the generation of T cells in vitro has been the 
induction of regulatory T cells, particularly in response to IL-2 expansion. Figure 18 shows 
flow cytometry staining for regulatory T cells both before and after B/I stimulation and 
after each type of cytokine expansion. Plots are gated on CD4+CD25+ cells so as to 
discern the percentage of FoxP3+ cells amongst activated CD4+ cells. Very low expression 
of FoxP3 before stimulation with B/I indicates that 5.1% of CD4+CD25+ T cells also 
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express FoxP3. This number drops to 1.54% after activation (1.54%), but increases 
substantially after IL-2 expansion to 10.03%. Conversely, Tregs constituted only 4.08% of 
activated T cells after expansion in IL-7/15, whereas expansion in alternating gamma chain 
cytokines resulted in 12.0% of CD4+CD25+ cells containing FoxP3. Given the fact that 
Figure 16 shows that T cell expansion in vitro was the greatest using alternating gamma 
chain cytokines (which had the highest percentage of Foxp3+ cells), and that expansion 
using IL-7/15 produced the smallest number of cells despite having the lowest percentage 
of Foxp3+ cells, we have determined that CD4+CD25+FoxP3+ cells do not necessarily 
constitute a regulatory phenotype in our model and are not capable of inhibiting cytokine-
driven expansion of activated T cells. Additionally, transferred CD4+CD25+FoxP3+ T 
cells did not inhibit effective anti-tumor responses in the absence of MDSC (Fig. 8). The 
cytotoxic effect of T cells against MMC, in vitro, was also greater using alternating gamma 
chain cytokines compared to that using IL-2 (14% viable MMC in Fig. 19A vs. 27% viable 
MMC in Fig. 7A). Absolute numbers of viable MMC also reflects a slight increase in anti-
tumor efficacy of B/I-activated, alternating cytokine-expanded T cells compared to IL-2-
expanded T cells (0.4x10
6
 in Fig. 19B vs. 0.5x10
6
 in Fig. 7B). Cells expanded in 
alternating cytokines also exhibited a strong IFN-γ response when stimulated with 
irradiated neu positive MMC (15000 rad), but not with neu-negative ANV cells (P=0.006), 
thus confirming the neu specificity of these cells (Fig. 19C).  
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Adoptive Transfer of T Cell Subsets Expanded with Alternating Gamma Chain 
Cytokines Inhibits Tumor Growth when Combined with In Vivo MDSC Depletion 
 We hypothesized that a more robust and highly viable population of anti-tumor T 
cells expanded in vitro may be able to overcome inhibition by MDSC in tumor-bearing 
FVBN202 mice. To test this hypothesis, FVB mice were inoculated with MMC (5x10
6
 
cells/mouse) and donor splenocytes were prepared 21 days after tumor challenge, when 
animals had rejected MMC. T cells were activated with B/I and were then expanded in the 
presence of alternating gamma chain cytokines as described above (Fig. 15). All FVBN202 
mice were treated with i.p. injection of CYP (100 mg/kg) in order to create lymphopenia. 
Flow cytometry of the peripheral blood before, and 24 hours after, CYP injection, showed 
no effect of this drug on the CD11b+Gr1+ population. FVBN202 mice were challenged 
with MMC (3X10
6
) 24 hours after CYP treatment. MMC-challenged mice then received 
no treatment, the alternating gamma chain cytokine-expanded T cells alone (i.v. injection 
of 70x10
6
 lymphocytes/mouse), or AIT combined with the depletion of MDSC by i.p. 
injection of 250µg of anti-Gr1 antibody starting 6 days after tumor inoculation and 
continuing every 3 days for a total of 6 injections, followed by a final injection of 200µg 
on day 25. Figure 20 shows that AIT alone offered no protection against MMC tumors. 
However, the in vivo depletion of MDSC improved the efficacy of AIT and caused 
significant tumor inhibition (P=0.001 for week 4 and P= 0.0003 for week 5). The efficacy 
of MDSC depletion was above 98% nine days after tumor challenge (data not shown). 
Flow cytometry analysis of blood collected on day 9 from mice receiving MDSC depletion 
showed a complete lack of granulocytes, as compared to blood from the same mice taken  
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on day 35, 10 days after the last injection of anti-Gr1 antibody (Fig. 21A). Quantitative 
analysis of CD11bGr1 levels from each group 24 days after the tumor challenge showed 
that the group receiving Gr1 depletions had a significantly reduced percentage of MDSC 
(P=0.044 as compared to mice receiving no treatment and P=0.023 as compared to mice 
receiving AIT alone, Fig. 21B). However, it is noteworthy that 38% of the granulocytes 
were still CD11b+Gr1+ at this time, a problem that we believe to be caused by slightly 
increased tumor burden in these mice leading to increased recruitment of MDSC (Fig. 20). 
Despite the residual MDSC in these mice, we were not able to increase the frequency of 
antibody injections because of toxicity of the antibody (data not shown).  
Since the ECD-specific antibody response is also involved in the protection against 
neu positive mammary tumors (87, 227-229), we sought to determine whether FVBN202 
mice mounted an antibody responses against ECD following AIT. Serum taken from mice 
receiving adoptive transfer of T cells expanded with alternating gamma chain cytokines 
with and without the in vivo depletion of MDSC, along with control mice, indicated that 
only mice that were depleted of Gr1+ cells were able to mount an antibody response 
against the neu ECD (P=0.006) (Fig. 22).  
In order to determine if the depletion of MDSC resulted in an increased frequency of 
activated or effector T cells, mice were sacrificed 28 days after tumor inoculation and 
splenocytes were analyzed for the expression of CD44, CD62L, CD25, and CD69 on both 
CD4+ and CD8+ T cells. As shown in Figure 23A, the percentage of activated, 
CD4+CD25+ T cells was approximately equal in mice receiving AIT alone versus mice 
receiving AIT with MDSC depletion (10.9% vs 10.0%). Likewise, the percentage of naïve  
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(CD62L+CD44-), effector memory (CD62L
low
CD44+), and effector (CD62L-CD44+) 
CD4+ T cells were similar between the two groups (Fig. 23B). However, in the CD8+ 
population, it is noteworthy that the levels of naïve T cells were actually higher in the 
group receiving MDSC depletion (35.5% in AIT alone mice vs. 42.6% in MDSC depleted 
mice), while levels of effector memory CD8+ T cells were reduced (49.4% central memory 
in the AIT alone group vs. 35.5% in the MDSC depleted group). Levels of CD8+CD44+ T 
cells were similar between the 2 groups (12.1% in the AIT alone group vs. 10.4% in the 
MDSC depleted group, Fig. 23B). We also wanted to look for expression of the early 
activation marker, CD69. As shown in Figure 23C, CD69 expression on CD4+ and on 
CD8+ cells from both groups is similar. To determine if the overall proportion of 
lymphocytes in animals receiving MDSC depletion may be increased, therefore aiding the 
tumor rejection, we analyzed the percentages of CD4+ and CD8+ cells from the total 
spleens of mice from each group, and the percentages of these cells specifically from the 
lymphocyte region. No significant differences were found in the total percentages of CD4+ 
(black bars) or CD8+ (gray bars) cells between the three groups (Fig 24A). Likewise, 
gating on the lymphocyte region and analyzing the percentages of CD4+ and CD8+ T cells 
also provided no significant differences between the groups (Fig. 24B).  
In an effort to devise an AIT treatment that could avoid the use of MDSC-depleting 
antibody in vivo, we next wanted to determine of the migration patterns of adoptively 
transferred T cells would have an impact on their effectiveness. Since we have previously 
observed very high numbers of MDSC in the spleens of tumor bearing mice, while 
observing very few at the tumor site (Fig. 5), we hypothesized that transferring CD62L-  
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effector cells would allow them to go directly to the tumor site without first homing to the 
immunosuppressive environment of the secondary lymphoid organs. In order to test this, 
FVB mice were inoculated with MMC cells as before and were sacrificed 22 days later. 
Spleens were removed and cells were stimulated with B/I and expanded in alternating 
gamma chain cytokines as previously. FVBN202 mice were pre-treated 24 hours in 
advance with CYP as before. On day 7 of the donor cell expansion, FVBN202 recipient 
mice were divided into 3 groups, those receiving no treatment, those receiving the adoptive 
transfer of CD62L+ cells, and those receiving the adoptive transfer of CD62L- cells. All 
recipient mice were challenged with 3X10
6
 MMC. Donor T cells were then stained with a 
PE labeled anti-mouse CD62L antibody and were subjected to positive magnetic bead 
selection of PE-labeled cells. Both the positively selected PE-labeled cells (CD62L+ 
fraction) and the non-PE labeled cells (CD62L- fraction) were collected; 70X10
6
 CD62L+ 
or CD62L- cells were injected i.v. into mice receiving treatment.  Figure 25A shows that 
the three groups of mice, those receiving no treatment (squares), those receiving CD62L+ 
T cells (triangles), and those receiving CD62L- T cells (diamonds) exhibited extremely 
similar rates of tumor growth. Serum was collected from mice on day 21 and tested for 
antibody responses against neu ECD.  Figure 25B shows that, in the absence of any MDSC 
depletion, none of the groups showed an antibody response against neu, regardless of the 
type of T cell transfer. 
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Gemcitabine is an Effective Inhibitor of MDSC in Tumor Bearing FVBN202 and 
Allows for the Complete Rejection of Neu Positive Mammary Tumors.  
Since Gemcitabine has been reported to decrease MDSC in vivo without affecting 
lymphocyte populations (70), we hypothesized that combining Gemcitabine treatment with 
AIT may result in a more clinically relevant means of inhibiting this population in vivo, 
and would therefore result in the success of AIT treatments. T cells were therefore 
harvested from FVB donors and were stimulated and expanded in alternating gamma chain 
cytokines as previously. All FVBN202 recipient mice were treated 48 hour prior to AIT 
transfer with CYP (100mg/kg). Twenty-four hours prior to transfer, recipient FVBN202 
mice were challenged with 3X10
6
 MMC cells. On the day of adoptive transfer, FVBN202 
mice were divided into four groups: mice receiving no treatment (CYP), mice receiving 
AIT only (AIT), mice receiving Gemcitabine only (Gem), and mice receiving AIT transfer 
along with Gemcitabine treatment (Gem+AIT). 70X10
6
 expanded donor T cells were 
transferred i.v. into recipient mice receiving AIT. Gemcitabine treatment was administered 
i.p. at a dose of 75mg/kg per mouse on days 6, 11, and 16. To test the efficacy of 
Gemcitabine in diminishing MDSC in vivo in tumor bearing mice, blood was drawn at 
several time points and analyzed by flow cytometry for the presence of CD11b+Gr1+ cells. 
By day 8 after tumor inoculation, mice not receiving Gemcitabine had increased MDSC 
levels from 0.885% of the total blood on day 0 to 2.55% of the total blood on day 8 (Fig 
26A). In contrast, mice receiving Gemcitabine, either alone or with AIT, showed more 
modest increases of MDSC on day 8. The Gemcitabine alone group increased total levels 
of MDSC from 0.39% on day 0 to 0.87% on day 8 and the Gemcitabine with AIT group  
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increased levels of MDSC from 0.62% on day 0 to 1.23% on day 8, thus showing a stunted 
accumulation on day 8 in mice that had received one injection of Gemcitabine at that time 
(Fig 26A). By day 14, after 2 Gemcitabine injections, there was a significant decrease in 
MDSC in both groups of mice receiving Gemcitabine treatment (Fig 26B). Untreated mice 
had an average of 15.5% MDSC out of their total peripheral blood leukocytes, whereas 
mice treated with Gemcitabine alone had only 2.61% MDSC (P=0.026 compared to 
untreated) and mice given Gemcitabine with AIT had 0.33% MDSC (P=0.017 compared to 
untreated). Mice receiving both Gemcitabine and AIT also showed significantly reduced 
levels of MDSC when compared to mice receiving Gemcitabine alone (P=0.0004, Fig. 
25B), presumably because of the decreased tumor burden that was becoming apparent by 
day 14 in mice treated with Gemcitabine and AIT (Fig 27A).  Figure 27A shows that by 
day 18, mice receiving Gemcitabine injections and AIT exhibited significantly reduced 
tumor volumes (P=0.004 when compared to CYP control mice, P=0.009 when compared to 
AIT mice, and P=0.024 when compared to Gem mice). The differences in tumor volumes 
were also significantly different between the Gem+AIT group and all other groups on days 
21 and 24. Additionally, by day 24, mice receiving Gemcitabine alone also exhibited a 
significant reduction in tumor volume as compared to mice receiving AIT alone (P=0.037). 
By day 28, all five mice treated with Gem+AIT were completely tumor free. In addition to 
tumor volumes, we thought it important to monitor weights, to evaluate if the treatment 
was well tolerated. Figure 27B shows that, by week 4, the weights of mice in the 
Gemcitabine alone group had dropped significantly compared to those in the Gem+AIT 
group (P=0.015). It is also noteworthy that during the fourth week, mice treated with  
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Gemcitabine alone had significantly reduced weights as compared to mice receiving AIT 
as well (P=0.012). Weeks 5 and 6 showed a continued significant reduction in the weights 
of mice treated with Gemcitabine alone as compared to mice receiving Gem+AIT 
(P=0.022 in week 5 and 0.005 in week 6). The survival of all four groups of mice is shown 
is Figure 27C, with the CYP alone control group reaching 0% survival by the end of week 
5, and the Gemcitabine alone and AIT alone groups reaching 0% survival by the end of 
week 6. It is noteworthy that although the use of Gemcitabine alone offered some 
reduction in tumor volume, the significant reductions in weight coupled with a lack of 
increased survival indicates that despite the role of Gemcitabine as an anti-tumor drug, this 
drug alone is not sufficient. However, the combination of Gemcitabine with AIT results in 
potent anti-tumor activity.  
 Since the depletion of MDSC causes a restoration of antibody responses against the 
ECD of neu in tolerant mice, we wanted to determine if MDSC inhibition by Gemcitabine 
had the same effect. Serum was taken from FVBN202 mice that received either no 
treatment (CYP), AIT alone (AIT), Gemcitabine alone (Gem), or Gemcitabine and AIT 
(Gem+AIT). Serum was tested for antibody responses against ECDII and ECDIV of the 
extracellular domain of neu. Optical density readings showed that only the group that 
received both Gemcitabine and AIT generated an antibody response against ECDII (Fig. 
28A). Analysis of antibody responses from individual mice within the Gem+AIT group 
showed a large variation that correlated with the amount of time it took individual mice to 
fully reject MMC tumors. The mouse with the highest antibody response, mouse 1, (O.D. 
of 3.32 at a 1:20 dilution) took 27 days to fully reject the tumor, and therefore still had an  
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active immune response at the time serum was taken. Mouse 3, which had an O.D. of 1.5 
at a 1:20 dilution took 23 days to reject the tumor, whereas mouse 4, with an O.D. of 0.82, 
took 17 days to reject the tumor, and the 2 mice with the lowest antibody responses (mouse 
2 and mouse 5) both took only 8 days to fully reject their MMC tumors. Therefore, the 
immune responses of some of these mice had fully contracted by the time that serum was 
taken, thus accounting for the large amount of variation in antibody responses (Fig. 28 
A,B). Conversely, no substantial antibody response was seen towards ECDIV of the neu 
ECD (Fig 28 C). This correlates with a previous finding in the lab that after challenge with 
MMC tumors, FVB mice mount an antibody response consisting almost entirely of 
antibody against ECDII (Fig. 29). These mice successfully reject MMC tumors without 
responses against ECDIV. Therefore antibody responses against ECDII are protective 
against MMC tumors, while antibody responses against ECDIV are not needed.  
 Since 100% of the mice that were treated with both Gemcitabine and AIT fully 
rejected their MMC tumors, we wanted to determine if these mice could rejected a second 
challenge with MMC without adoptively transferred T cells. Mice were therefore 
challenged on the contralateral side with 3X10
6
 MMC cells 74 days after the initial MMC 
challenge. Mice were treated on days 6 and 11 with 75mg/kg of Gemcitabine. As indicated 
in Figure 30, MMC tumors never reached palpable status and were not able to be 
measured. By day 16 all mice were completely tumor free.  Serum was taken from all 5 
mice 12 days after the re-challenge and tested for antibody responses against ECDII of 
neu. As shown in Figure 31A, mouse 1 and mouse 3 exhibited strong antibody responses 
against ECDII, whereas mouse 2 and mouse 4 had weak antibody responses and mouse 5  
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had a negligible antibody response. Based on these data, the 2 mice with the lowest 
antibody responses (mouse 4 and mouse 5) were sacrificed 18 days after the MMC re-
challenge. Splenocytes from these mice were cultured for 24 hours either alone (-) or in the 
presence of irradiated MMC cells (+) at an E:T ration of 10:1. Supernatants were collected 
and assayed for IFN-γ by ELISA. Figure 31B shows very low or undetectable levels of 
IFN-γ in wells containing media alone, MMC alone, or splenocytes alone that were taken 
from a naïve FVBN202 mouse or from either of the mice that had rejected MMC challenge 
(Re-challenged AIT). While the addition of MMC did not cause a significant increase in 
IFN-γ secretion by naïve splenocytes, a large increase in IFN-γ by splenocytes taken from 
mice that had rejected 2 MMC challenges was observed. The baseline level of IFN-γ 
secretion from the splenocytes of each mouse was subtracted from the level of IFN-γ 
secretion in the presence of MMC. After this normalization, it was determined that IFN-γ 
secretion by splenocytes from both re-challenged AIT mice in the presence of MMC was 
significantly higher (P<0.001) than that seen by splenocytes from the naïve control in the 
presence of MMC (Fig. 31B). To determine if the 3 remaining mice could reject an MMC 
challenge without Gemcitabine, these mice were challenged for a third time with 3X10
6
 
MMC cells 18 days after the second challenge (challenges are indicated by the black 
arrows in Fig. 30). This was now day 0 of the third challenge. On day 7 of the third 
challenge, 2 mice (mouse 1 and mouse 3) were tumor free and one mouse (mouse 2) had a 
tumor size of 21.1mm
3
. By 14 days after the third challenge, this tumor had shrunk to 
10.4mm
3
 and by day 21 was no longer visible (Fig. 30). To determine if these mice could 
mount an antibody response without the aid of Gemcitabine, serum was taken sixteen days  
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after the third MMC challenge. An ELISA against ECDII of neu showed that all three mice 
indeed had an antibody response (Fig. 32). It is interesting to note, however, that the mouse 
with the lowest antibody response (mouse 2 indicated by squares) is the same mouse that 
grew a small tumor after the third challenge (mouse 2 indicated by squares in Fig. 30). 
Therefore, AIT with Gemcitabine treatment not only causes full rejection of initial tumors, 
but also causes the rejection of subsequent MMC challenges, and creates long-lasting 
immunological memory capable of rejecting neu+ tumors even in the absence of 
Gemcitabine.  
 Long term follow-up of the 3 remaining mice treated with Gemcitabine and AIT 
revealed that by day 148 one mouse (mouse 3) had a tumor of 1076mm
3
. Isolation of the 
tumor and staining for neu expression showed this tumor to be of the ANV relapsed 
phenotype (Fig. 33, left panel vs. right panel) with a small amount of residual neu 
expression but dramatic downregulation from the highly neu+ MMC cells (Fig. 33 left vs. 
center).  
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III. Conclusions and Significance 
These studies have found that the adoptive transfer of B/I activated and IL-2 
expanded T cells results in statistically significant tumor inhibition and increase in 
antibody response in FVBN202 mice only when their Gr1+ cells are depleted in vivo. 
Importantly, the depletion of MDSC was not effective in the absence of transferred T cells 
showed no benefit, showing that tumor rejection requires both the presence of highly 
effective anti-tumor T cells and the absence of MDSC. Furthermore, a correlation exists 
between the efficacy of the Gr1+ depletions and the observed anti-tumor response. Efforts 
to generate T cells with greater cytotoxicity towards MMC were successful through the use 
of the gamma chain cytokines IL-7 and IL-15 with a one time pulse of IL-2. We conclude 
that this is a superior method of T cell expansion based on increased viability, cytotoxicity, 
and expansion levels as compared to expansion in IL-2 alone. The pivotal role of MDSC in 
inhibiting the function of adoptively transferred T cells was confirmed after transfer of T 
cells expanded in alternating gamma chain cytokines resulted in tumor inhibition and anti-
neu antibody responses only when these cells were depleted, as previously. Efforts to 
evade the large population of MDSC in the spleen through the transfer of CD62L- T cells 
were unsuccessful and leads us to conclude that adoptively transferred T cells, regardless 
of their expansion method, in vitro cytotoxicity, or migratory patterns, cannot mediate 
effective tumor regression in vivo in the presence of MDSC and that the elimination of 
these cells in vivo results in effective tumor rejection or inhibition in an otherwise tolerant 
mouse model.  
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 The use of Gemcitabine as a clinically relevant means of inhibiting MDSC in vivo 
in conjunction with AIT was found to be superior to treatment with either AIT or 
Gemcitabine alone and was far superior to AIT in conjunction with depleting antibodies. 
100% of mice receiving AIT with Gemcitabine exhibited complete rejection of the primary 
tumor challenge. Of great significance is the fact that two subsequent tumor challenges 
were also rejected by these mice, showing long-lasting immunological memory, which was 
confirmed by the presence of high antibody titers against neu and strong IFN-γ responses 
against MMC.  
 These studies have therefore identified MDSC as the major mediator of suppression 
against adoptively transferred T cells and have developed a clinically achievable means of 
achieving tumor rejection through the use of Gemcitabine as an MDSC inhibitor. These 
findings are of great significance given the fact that adoptive immunotherapy has exhibited 
extremely limited results for primary breast cancers (113), with some difficulty 
encountered in expanding populations of cells with high percentages of CD8+ T cells and 
cytotoxic activity (144). While there has been some success in the treatment of metastatic 
lesions of breast cancer using AIT (230), overall clinical response rates and long-term 
survival rates have been extremely low (231). We therefore propose that AIT in human 
breast cancer patients, who have been observed to have increased levels of circulating 
MDSC, be combined with the use of Gemcitabine for increased tumor rejection and long-
lasting immunity.  
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Chapter 2 
 
I. Study Rationale 
 MDSC have been reported to suppress T cell responses by a wide variety of 
mechanisms, which include soluble factors such as nitric oxide or IDO (187, 232), but 
some have reported contact-dependency between T cells and MDSC (184, 233). Given the 
important role that MDSC play in suppressing AIT, we sought to determine the mechanism 
of suppression by MDSC in our model and to characterize the existence of possible 
effector molecules expressed either on the surface of, or within these cells. Suppression by 
specific subsets of MDSC was also investigated to further pinpoint the cells responsible for 
immune suppression so they may more precisely targeted in a therapeutic setting. Given 
the equal tumor growth seen in mice treated with AIT consisting of CD62L+ and CD62L- 
cells, we hypothesized that MDSC may be exhibiting wide-spread suppression through 
secreted soluble factors instead of relying on contact-dependent mechanisms, since 
CD62L- T cells would not have come into direct contact with as many MDSC as CD62L+ 
T cells. Therefore MDSC were isolated from tumor-bearing animals, RNA extracted and 
reverse transcribed, and tested for the expression of various suppressive soluble molecules. 
These data indicated that the tested soluble factors are most likely not involved in 
suppression my MDSC in our model, which lead us to investigate possible roles of several 
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inhibitory molecules in mediating what we found to be contact-dependent suppression by 
MDSC.  
II. Results 
 MDSC in Tumor-Bearing FVBN202 Mice Suppress anti-CD3/CD28 Mediated 
  
Proliferation of both CD4+ and CD8+ T cells 
   
To determine the mechanisms by which MDSC suppress anti-tumor immune 
responses, splenocytes were isolated from MMC tumor-bearing and tumor-free FVBN202 
mice. Tumor-bearing mice had a large influx of MDSC in their spleens as compared to 
tumor-free mice (Fig. 5). Splenocytes were labeled with the thymidine analog BrdU and 
stimulated with antibodies against CD3 (10µg/mL, plate-bound) and CD28 (1µg/mL, 
soluble), or were left unstimulated to serve as a control. After 3 days, cells were stained 
using anti-CD4 and anti-CD8 antibodies and analyzed for BrdU uptake by flow cytometry. 
We found significantly higher proliferation of CD4+ T cells from tumor-free mice 
compared to those from  tumor-bearing animals (Fig. 34A left panel, 91% vs. 59%, 
P=0.002). The same trend was seen for CD8+ T cells (Fig. 34A right panel, 93% vs. 70%, 
P=0.001). Similar trends were detected when analyzing absolute numbers of CD4+ and 
CD8+ T cells (Fig. 34B left panel). Figure 34B shows that the average number of 
BrdU+CD4+ and BrdU+CD8+ T cells from  tumor-free mice is 3.3-fold higher than that of 
BrdU+CD4+ and BrdU+CD8+ T cells from tumor-bearing mice (P=0.003 for CD4+ and 
P=0.0004 for CD8+ T cells). To confirm that the suppression of T cell proliferation in 
FVBN202 splenocytes was caused by the presence of elevated MDSC, we depleted MDSC  
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in vitro from the splenocytes of tumor-bearing animals. As seen in Figure 34A, the 
depletion of MDSC (Tumor Bearing-MDSC) significantly restored the proliferative 
responses of both CD4+ (87% BrdU+) and CD8+ (92% BrdU+) T cells over those seen in 
total splenocytes from tumor-bearing mice (P=0.028 for CD4+ and P=0.009 for CD8+ T 
cells). Similar trends were found while comparing the absolute numbers of CD4+ and 
CD8+ T cells, showing a 3.1-fold increase in proliferation in the CD4+ population 
(P=0.027) and 2.5-fold increase in the CD8+ population (P=0.012) over total splenocytes 
from tumor-bearing mice (Fig. 34B).  
CD11b+Ly6G-Ly6C+ MDSC are Suppressive, while CD11b+Ly6G+Ly6C+ Cells are 
not 
It has recently been reported that various subsets of MDSC exist and can be distinguished 
based on their differential expression of two epitopes of the Gr1 molecule; Ly6G, 
corresponding to a granulocytic/ neutrophil phenotype, and Ly6C, corresponding to a 
monocytic phenotype (171, 215, 216). We indeed found two different subsets of MDSC in 
MMC tumor-bearing FVBN202 mice. In order to determine if these subsets have different 
functions in our model, splenocytes were isolated from FVBN202 mice bearing neu+ 
MMC tumors and were stained for CD11b, Ly6G, and Ly6C. CD11b+ cells were sorted 
into Ly6G+Ly6C+ and
 
Ly6G-Ly6C+
 
populations. Sorted MDSC were then added at a 1:2 
ratio to FVB naïve splenocytes with anti-CD3/CD28 stimulation for 3 days. As shown in 
Figure 35A-B Ly6G-Ly6C+
 
subsets inhibited T cell proliferation whereas Ly6G+Ly6C+ 
subsets did not display any suppressive activity. Representative flow cytometry staining 
for BrdU incorporation into CD4+ T cells showed 57.5% BrdU+ cells in culture with  
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medium alone, 55.4% when in the presence of sorted CD11b+ Ly6G+Ly6C+ cells, and 
only 13.0% proliferation when cultured with CD11b+Ly6G-Ly6C+ cells (Fig. 35A). 
Repeated experiments confirmed these results, with the Ly6G-Ly6C+
 
fraction causing a 
70% inhibition of CD4+ T cell proliferation when compared to the medium alone control, 
in which proliferation was normalized to 100% (100% BrdU+ in media alone vs. 30.1% 
BrdU+ in cultures containing Ly6G-Ly6C+
 
cells, P=0.008). In contrast, there was no 
significant inhibition in cultures containing Ly6G+Ly6C+ cells (96.9% Brdu+, Fig. 35A). 
Similar results were found in CD8+ T cells, with representative BrdU staining showing 
38.1% and 51.6% proliferation in splenocytes cultured with medium alone or with 
Ly6G+Ly6C+ cells, respectively (Fig. 35B). Strikingly, splenocytes cultured with sorted 
Ly6G-Ly6C+
 
cells showed only 12.2% BrdU+ CD8+ T cells. Normalizing the 
proliferation in control splenocytes alone to 100% shows a 62% inhibition of proliferation 
in CD8+ T cells cultured with Ly6G-Ly6C+
 
cells from splenocytes alone (P=0.008), 
whereas no significant inhibition of proliferation was seen in CD8+ T cells cultured with 
Ly6G+Ly6C+ cells (Fig. 35B).   
Suppressive MDSC Require Direct Cell-to-Cell Contact that is Independent of LFA-
1/ICAM and PD-1/PD-L1 interactions to Inhibit the Proliferation of CD4+ and CD8+ 
T cells 
To further characterize the suppressive function of MDSC, we sought to determine if the 
anti-proliferative effects of MDSC on T cells may be mediated by the release of 
immunosuppressive soluble factors or by contact-dependent mechanisms. MDSC were 
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isolated from tumor-bearing mice by using a magnetic bead selection kit to positively 
select for PE-labeled Gr1+ cells. RNA was extracted and reverse transcribed. Resultant 
cDNA was analyzed via PCR for the expression of the immunomodulating cytokine IL-10 
(234, 235). Expression of mRNA for IL-10 was visible in both samples, but was relatively 
faint (Fig 36). We also wanted to determine if there may be differential expression of 
immunosuppressive molecules between the two subsets of MDSC. RNA was therefore 
extracted from sorted populations of CD11b+Ly6G+Ly6C+ and CD11b+Ly6G-Ly6C+ 
cells from the spleens of tumor-bearing mice and reverse transcribed. The expression of 
indoleamine 2,3-dioxygenase (IDO), an immunosuppressive enzyme that can inhibit T cell 
responses and promote immune tolerance through the breakdown of tryptophan was 
assessed by PCR (186, 187). After normalizing the data to the actin control, we found that 
both the Ly6G+Ly6C+ fraction and the Ly6G-Ly6C+ fraction displayed extremely low 
levels of IDO (Fig 37). In contrast, both fractions expressed TGF-β to a similar level after 
normalization, which may be secreted or surface-bound and is an important modulator of T 
cell tolerance, with mice lacking TGF-β exhibiting T cell hyper activation, even in the 
absence of foreign antigen (236-239)  (Fig 37). Since expression of IDO was almost 
negligible and since TGF-β expression was observed to be similar in both populations, it is 
unlikely that either of these molecules is the primary means of T cell suppression by 
MDSC. We therefore wondered if suppression by MDSC may be achieved through direct 
cell-to-cell contact.  Therefore, CD11b+ cells were depleted from the splenocytes of 
tumor-bearing and tumor free mice and equal numbers of lymphocytes (5X10
5
) were 
stimulated in the lower chamber of a plate containing a Transwell insert. CD11b+ cells  
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enriched from tumor-bearing mice were then added to the lower chamber of the plate, or 
were added to the top chamber of the Transwell insert, where they were separated from the 
lymphocytes by 8.0µm pores. Staining for BrdU incorporation on day 3 showed potent 
inhibition of both CD4+ and CD8+ T cells when CD11b+ cells were added back to the 
cultures, but only in the absence of a Transwell insert (Fig. 38A). Gray bars indicate wells 
to which CD11b+ cells from tumor-bearing mice were added, whereas black bars are 
indicative of the proliferation seen in cultures of CD11b-depleted splenocytes alone. When 
CD11b+ cells were added directly to the splenocytes (no Transwell), the proliferation of 
CD4+ cells decreased from 80.5% to 50% (Fig 38A, P=0.001). On the other hand, the 
addition of CD11b+ cells to the top of a Transwell insert had no effect on proliferation of 
CD4+ cells (90.5% BrdU+ in splenocytes alone vs. 90% BrdU+ with CD11b+ cells). A 
similar trend was seen in CD8+ cells, with the addition of CD11b+ cells directly to the 
culture causing a reduction in BrdU+ staining from 88% to 53% (P=0.01, Fig. 38A). In 
contrast, the addition of CD11b+ cells to the top of a Transwell insert resulted in no 
reduction of proliferation, with CD8+ splenocytes alone staining 94.5% BrdU+ and CD8+ 
splenocytes staining 89% BrdU+ (Fig 38A).  Analysis of the absolute cell numbers 
recapitulated the above results; with the proliferation of CD4+ cells reduced significantly 
only when CD11b+ cells were added directly to the culture (Fig 38B). 
Since it has been reported that MDSC from tumor free animals are not suppressive 
(167), we decided characterized MDSC in tumor free and tumor bearing animals to 
determine if there were important differences that may account for the suppressive 
capability in tumor-bearing mice. We looked at the expression of Annexin V, H-2
q
, Qa1,  
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CD11c, CD86 and CCR7 on MDSC from tumor bearing and tumor free mice. We found 
no significant differences in the expression of any of these molecules with the exception of 
CD86, which was found to be significantly decreased on MDSC from tumor-bearing mice 
(Fig 39).  
We then hypothesized that, since T cells highly express the integrin LFA-1 (Fig 
40A), and since the LFA-1/ICAM interaction between T cells and DC’s is necessary for T 
cell priming (240) expression of LFA-1 on MDSC could allow MDSC to interact with 
DC’s via ICAM-1 and cause DC’s to suppress T cells as well. Using flow cytometry, we 
found that 100% of CD11b+Gr1+ MDSC express LFA-1 (Fig. 40B). However, we also 
found LFA-1 to be highly expressed on CD11b-Gr1- cells of the granulocyte region as 
well (Fig. 40B). Therefore, interaction through the LFA-1/ICAM-1 axis is unlikely given 
the widespread expression of LFA-1 on non-MDSC as well as MDSC.  
Programmed cell death 1 (PD-1), a member of the extended CD28/CTLA4 family, 
is an immunoinhibitory receptor expressed on activated T cells (241). PD-1 had two 
potential binding partners, PD-1 ligand 1 and PD-1 ligand 2 (PD-L1 and PD-L2, 
respectively). Both ligands can be expressed on activated dendritic cells and macrophages, 
and ligation of PD-1 by PD-L’s has been shown to inhibit TCR-induced proliferation, 
induce T cell anergy, or cause apoptosis (241-243). Flow cytometry of splenocytes from 
FVB mice that had rejected MMC cells showed low levels of PD-1 on the surface of CD8+ 
T cells (Fig 41). However, when these splenocytes were restimulated with MMC cells in 
vitro, PD-1 expression increased to 3.94% on CD8+ T cells, a 4.4-fold increase (Fig 41).  
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We therefore hypothesized that MDSC may express PD-L1 and that the PD-1/PD-L1 
interaction may be the contact-dependent mechanism of MDSC suppression. MDSC were 
then tested for the expression of PD-L1. As shown in Fig. 42, neither CD11b+Gr1+ nor 
CD11b-Gr1- cells from the blood of FVBN202 mice showed any expression of PD-L1 or 
PD-1 (Fig 42), suggesting that PD-1/PD-L1 interaction is not the mechanism by which 
MDSC suppress activated T cells.  
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III. Conclusions and Significance 
 From these studies we can conclude that MDSC require contact with T cells in 
order to suppress CD3/CD28-induced proliferation. Furthermore, we have identified a 
specific subset of CD11b+Ly6G-Ly6C+ cells that are responsible for mediating all 
observed suppression. This finding is of significance given the fact that it will enable the 
more direct targeting of MDSC in a therapeutic setting, while leaving the population of 
non-suppressive CD11b+Ly6G+Ly6C+ cells intact, therefore limiting toxic side effects. 
Indeed, we have seen some toxicity associated with the depletion of Gr1+ cells using 
monoclonal antibodies in vivo, probably because most immature progenitor cells in the 
bone marrow express the Gr1 molecule and complete depletion therefore reduces the 
potential production of mature neutrophils and myeloid-dendritic cells. The identification 
of a more specific subset of suppressive MDSC is therefore immensely important 
Although Gemcitabine does not selectively inhibit certain subpopulations of MDSC and 
shows little toxicity, resistance to chemotherapies is a widespread problem. Alternative 
methods of inhibiting specific subpopulations of MDSC should therefore be investigated 
for administration to Gemcitabine-resistant individuals. More extensive phenotyping of the 
CD11b+Ly6G-Ly6C+ population should be done to identify potential surface markers that 
may be unique to this population and therefore targeted with a humanized antibody.. We 
further conclude that suppression of T cell proliferation by these MDSC in independent of 
IL-10, IDO, and TGF-β. Contact between MDSC and T cells is also independent of LFA-
1/ICAM-1 interactions and PD-1/PD-L1 interactions. Other potential sites of contact 
between MDSC and T cells should be investigated.  
   
 171 
 
 
Chapter 3 
 
I. Study Rationale 
We have observed large increases in MDSC in tumor-bearing mice, and therefore 
hypothesized that MMC-derived soluble factors were responsible for the increase in 
MDSC seen in vivo. We aimed to identify the particular cytokines or chemokines secreted 
by MMC that may contribute to this increase. To more specifically elucidate how MMC-
derived cytokines or chemokines mediate the observed increase in MDSC, bone marrow 
cells were sorted into two pure populations: existing CD11b+Gr1+ MDSC and progenitor 
CD11b-Gr1- cells. Culture of these sorted populations as opposed to culture of total bone 
marrow cells would allow us to determine the effects of MMC-derived cytokines or 
chemokines both on the maintenance and proliferation of existing MDSC and on the 
generation of new MDSC from progenitor cells to determine if the observed increase in 
MDSC was a result of prolonged survival and/or proliferation of MDSC or to increased 
generation of MDSC de novo.  Considering our previous finding that only one MDSC 
subset showed suppressive activity, we sought to establish the influence of various MMC-
derived soluble factors on determining the proportions of these subsets. We hypothesized 
that the presence of MMC-derived soluble factors may specifically increase the proportion 
of suppressive MDSC. Lastly, we hypothesized that exposure to MMC-derived soluble 
factors may result in an inhibition of MHC class I and MHC class II molecules, as well as 
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various maturation markers, thus contributing to the inability of these granulocytes to fully 
mature and function properly as antigen presenting cells.   
II. Results 
MMC-Derived Soluble Factors Cause the generation of MDSC 
To determine if soluble factors released by MMC cells are responsible for the 
increase in MDSC, MMC cells (10X10
6
cells/10mL) were cultured for 24 hours in 
RPMI1640 supplemented with 10% FBS. Supernatant was then removed and concentrated 
to a volume of 600µL. FVB mice (n=3) were then injected i.d. with 200µL of the 
concentrated supernatant. FVB control mice (n=3) were injected i.d. with 200µL of control 
medium alone. Mice were injected on three consecutive days, sacrificed on day 4 and their 
blood, spleens, and bone marrow were subjected to flow cytometry analysis. Figure 43A 
shows representative flow cytometry plots illustrating an increase in the overall 
granulocyte region of the spleen from 7% in RPMI-treated animals to 13% in conditioned 
medium (CM)-treated animals. Representative fluorescent staining for CD11b and Gr1 is 
depict ed in Fig. 43B, with control animals having 17% CD11b+Gr1+ MDSC, while CM-
treated animals had 55% MDSC in the granulocyte regions of their spleens. The difference 
in MDSC in the granulocyte region of the spleens is statistically significant (P=0.003), as 
seen in Fig. 43C, with RPMI-treated mice averaging 21% MDSC and CM-treated mice 
averaging 54.7% MDSC. Differences in the percentage of MDSC in the total splenocytes 
were also significant, with MDSC comprising only 1.5% of the total spleens of RPMI-
treated mice, while these cells comprised 7.33% of the total spleens of CM-treated mice  
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(P=0.002, Fig. 43D). Likewise, calculation of the absolute number of MDSC in the spleen 
of each animal confirmed a significant increase in MDSC in CM-treated mice, with RPMI-
treated mice having 1.8X10
6
 total MDSC, while CM-treated mice had 8.6X10
6
 total 
MDSC (P=0.006, Fig. 43E). We also wanted to determine if MDSC were increased in 
other compartments of the body in CM-treated mice. Therefore, blood was also taken and 
stained for CD11b and Gr1. Figure 44A shows an increase in the overall granulocyte 
region from 10% in RPMI-treated mice to 15% in CM-treated mice. Furthermore, 
representative data from within this granulocyte region shows an increase from 24% 
MDSC in RPMI-treated mice to 93% MDSC in CM-treated mice (Fig. 44B). 
Quantification of the above data shows a statistically significant difference between the 
average percentage of MDSC in the granulocyte region of the blood of RPMI-treated mice 
(21.5%) and CM-treated mice (78%, Fig 44C, P=0.00025). The percentage of the overall 
blood comprised of MDSC also showed a significant difference between RPMI-treated 
mice (1.4%) and CM-treated mice (10.1%, Fig. 44C, P=0.0033). Lastly, there was a 
substantial increase in the overall percentage of granulocytes in the bone marrow as well, 
with the bone marrow of RPMI-treated mice having 39% granulocytes and the bone 
marrow of CM-treated mice having 54% granulocytes (Fig. 45A). The composition of the 
granulocyte region was also significantly affected by treatment with CM, as control mice 
had 35% MDSC while CM-treated mice had 48% MDSC (P=0.028, Fig 45B,D). These 
results were also reflected in the overall percentage of MDSC in the bone marrow (29.3% 
in RPMI-treated mice vs. 38.7% in CM-treated mice, P=0.0186, Fig. 45C), as well as the  
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absolute number of MDSC recovered from the tibias and femurs (7X10
6
 MDSC in RPMI-
treated mice vs. 13X10
6
 MDSC in CM-treated mice, P=0.0156, Fig. 45E).  
To determine if injection with MMC-conditioned medium influenced MDSC in any 
other way, flow cytometry staining was done for the expression of the MHC class II 
molecule I-A
q
 and the MHC class I molecule H-2
q
. We found that mice that were treated 
with CM had significantly lower surface expression of I-A
q
 than mice treated with RPMI 
(P=0.026, Fig. 46). We therefore wondered if MMC-derived soluble factors may be 
affecting antigen presentation on mature antigen presenting cells as well. Figure 47 shows 
the expression of I-A
q
 on CD11b+Gr1- cells, revealing that MMC-conditioned media does, 
in fact, significantly reduce the expression of I-A
q
 on the surface of APC in mice treated 
with CM (76.6%) as compared to mice treated with RPMI (93.9%, P=0.0054).  
To determine the most prevalent soluble factors secreted by MMC that may be 
contributing to the observed effects in vivo, a multiplex array detecting IL-1β, IL-2, IL-4, 
IL-5, IL-6, IL-10, IL-12p40, IL-12p70, IL-13, IFN-γ, TNF-α, GM-CSF, MCP-1, and 
VEGF was performed on MMC-conditioned media after a 24 hour culture. We found that 
high levels of GM-CSF, VEGF, IL-6 and MCP-1 were secreted by MMC (Fig. 48). Other 
cytokines were below detectable levels.  
Since GM-CSF, VEGF, IL-6 and MCP-1 were identified to be secreted by MMC 
cells, we wanted to determine if administration any of the above cytokines could cause an 
increase in MDSC in naïve FVB mice. We therefore injected varying mice once daily with 
a dose of either 500ng of GM-CSF, 2500ng of GM-CSF, or 500ng of GM-CSF with 120U 
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 of IL-6. Injections were done i.d. and were administered once per day for 3 consecutive 
days, with the exception of high dose GM-CSF (2500ng), which was administered i.d. for 
2 consecutive days. Twenty-four hours after the last injection, mice were sacrificed and 
their spleens, bone marrow, and blood subjected to flow cytometry analysis for 
CD11b+Gr1+ cells. Figure 49 shows representative data from the spleens of FVB mice 
receiving various treatments. Representative forward scatter vs, side scatter plots show that 
there is no difference in the overall proportion of the spleen that is made up of granulocytes 
when comparing mice treated with PBS, mice treated with 500ng of GM-CSF, 2500ng of 
GM-CSF, or 500ng GM-CSF with 120U IL-6 (Fig. 49A). Although the percentage of 
MDSC in the granulocyte region varies moderately between mice, with the 500ng dose of 
GM-CSF causing a 4% increase over the control and the GM-CSF with IL-6 treatment 
causing a 9% increase over the control, this difference did not constitute a substantial 
fraction of the whole spleen (Fig. 49B,C), nor was it recapitulated in calculating the 
absolute number of MDSC in the spleen (Fig. 49D). Flow cytometry analysis of the bone 
marrow showed that levels of MDSC in the four treatments groups were indeed very 
similar. Figure 50A shows that the granulocyte region of the bone marrow in PBS-treated 
mice comprised 39% of the total bone marrow, whereas the granulocyte regions of mice 
receiving 500ng GM-CSF, 2500ng GM-CSF, or 500ng GM-CSF with 120U IL-6 
comprised 39%, 41%, and 41% of the whole bone marrow, respectively. Furthermore, the 
percentage of MDSC making up the granulocyte region was similar in all cases, with PBS- 
treated mice having the highest percentage of MDSC (88.3%) as compared to 84% in the 
500ng GM-CSF mouse, 79.6% in the 2500ng GM-CSF mouse, and 83.4% in the GM-CSF  
   
 188 
   
 189 
 
   
 190 
with IL-6 mouse (Fig 50B). These observations were similar when observing the 
percentage of MDSC that made up the whole bone marrow (Fig 50C) and was confirmed 
by similar absolute numbers of MDSC recovered from bone marrow in the tibias and 
femurs (Fig 50D). Flow cytometry of the peripheral blood also showed no discernable 
increase in MDSC in the granulocyte regions of mice treated with 500ngof GM-CSF 
(3.1%), 2500ng of GM-CSF (2.9%), or GM-CSF with IL-6 (4.8%) as compared to the 
PBS-treated controls (4.1%, Fig 51A). The same is true for MDSC levels in the 
granulocyte regions of these mice, as well the overall level of MDSC in the total peripheral 
blood (Fig 51B,C). Therefore neither GM-CSF nor GM-CSF in conjunction with IL-6 was 
able to increase MDSC in FVB mice after i.d. injection.  
We next sought to determine of VEGF could be the MMC-derived soluble factor 
responsible for the increase in MDSC seen after injection of MMC-derived supernatant. 
We therefore treated naïve FVB mice with once-daily i.d. injections of 1.5µg of VEGF, or 
with PBS for 3 consecutive days. Mice were sacrificed on the fourth day and their spleens, 
bone marrow, and blood subjected to flow cytometry analysis. Representative data in 
Figure 52A shows that there was not a substantial increase in the granulocyte region of the 
spleen of VEGF-treated animals (4.9%) as compared to PBS-treated animals (4.2%). 
Likewise, there was no appreciable difference in the levels of MDSC within those 
granulocyte regions, with PBS-treated mice having 24.7% MDSC, while VEGF-treated 
mice had 26.4% MDSC (Fig. 52B). The percentage of MDSC in the whole spleen was also 
similar, with PBS-treated animals having 2.1% MDSC in their spleens, while VEGF-
treated animals had 2.3% MDSC in their spleens (Fig. 52C).  
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Calculation of the absolute number of MDSC in the spleens of each animal confirmed that 
there was no significant difference between the number of MDSC in the spleens of PBS-
treated mice and VEGF-treated mice (Fig. 52D). The bone marrow of VEGF-treated mice 
also did not show any increase in MDSC as compared to PBS-treated controls. 
Representative flow cytometry data in Figure 53A shows that the percentages of 
granulocytes in the two groups are nearly equal (35.4% in PBS-treated mice vs. 36.8% in 
VEGF-treated mice). Levels of MDSC within the granulocyte region were also similar, 
with MDSC making up 82.4% of the granulocytes in PBS-treated mice and 77.0% in 
VEGF-treated mice (Fig. 53B). These data were confirmed by the percentage of MDSC 
comprising the whole bone marrow (36.7%% in PBS-treated mice and 33.4% in VEGF-
treated mice, Fig. 53C) and the absolute number of MDSC in the bone marrow recovered 
from the tibias and femurs (7.5X10
6 
MDSC in PBS-treated mice and 4.8X10
6
 MDSC in 
VEGF-treated mice, Fig. 53D). Figure 54 shows representative data from the blood of 
PBS-treated and VEGF-treated mice. There was no difference in the percentage of 
granulocytes in the blood, with the blood of PBS-treated mice composed of 3% 
granulocytes while the blood of VEGF-treated mice was composed of 2% granulocytes 
(Fig. 54A). Although there seemed to be a large increase in the composition of the 
granulocyte region, with the control mice having 44% MDSC while VEGF mice had 66% 
MDSC, this difference was not statistically significant (Fig. 54B and data not shown). The 
percentage of MDSC in the entire population of peripheral blood leukocytes was similarly 
low in both groups (Fig. 54C). 
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Since injections of GM-CSF and VEGF failed to produce significant increases in 
MDSC in vivo, we hypothesized that MCP-1 may play a role in the increase in MDSC 
caused by MMC-derived soluble factors. We therefore injected FVB mice i.d. with 2.5µg 
of MCP-1 or with PBS once per day for 3 consecutive days. Mice were sacrificed on the 
fourth day and their spleens, bone marrow, and blood were subjected to analysis by flow 
cytometry. Representative flow cytometry data in Figure 55A shows that the percentages 
of granulocytes in the spleen are similar between the two groups (5% in PBS-treated mice 
and 7% in MCP-1-reated mice). The percentage of MDSC in the granulocyte regions was 
also similar, with PBS-treated mice having 4% MDSC and MCP-1-treated mice having 7% 
MDSC (Fig 55B). Similar levels of total MDSC were also found in the spleen, with PBS-
treated mice having 0.19% MDSC and MCP-1-treated mice having 0.40% MDSC (Fig. 
55C). Calculation of the absolute numbers of MDSC in the spleens confirmed that there 
was no significant difference in MDSC in the spleens when comparing PBS-treated mice 
and MCP-1-treatd mice (Fig 55D). The bone marrow of FVB mice treated with either PBS 
or MCP-1 also had very similar levels of granulocytes (29% in both groups), and MDSC 
within those granulocytes (78% in control mice and 80% in MCP-1-treated mice, Fig. 
56A,B). The percentage of MDSC in the whole bone marrow was also similar between the 
two groups (22.9% in control mice and 23% in MCP-1-treated mice, Fig. 56C). The 
absolute number of MDSC in the bone marrow recovered from the tibias and femurs 
reflects the above data, with control mice having 7.51X10
6 
MDSC and MCP-1 treated 
mice having 8.151X10
6 
MDSC, a difference that was not statistically significant (Fig.56D). 
Flow cytometry of the blood of PBS-treated and MCP-1- treated mice showed that there 
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was not increase in the granulocyte regions of MCP-1-treated mice (2%) over PBS-treated 
mice (3%, Fig. 57A). There was an increase in MDSC within the granulocyte region, 
however this difference was not found to be statistically significant (Fig 57B and data not 
shown). The percentage of the total peripheral blood leukocytes made up of MDSC was 
again very similar between the groups with no increase seen in mice treated with MCP-1 
(0.75%) as compared to mice treated with PBS (0.9%, Fig. 57C).  
GM-CSF is Responsible for the Generation and Maintenance of MDSC 
 Considering the lack of responses to cytokines/chemokines that were found to be 
secreted by MMC and were injected in vivo, we decided to look at responses to these 
cytokines in vitro. Since GM-CSF is a well-established adjuvant therapy for the 
differentiation of dendritic cells in vivo, (244, 245)  we wanted to determine if GM-CSF 
had any effect specifically on MDSC. Bone marrow was therefore isolated from naïve 
FVBN202 mice and was cultured for 6 days in the presence of 100ng/mL of GM-CSF. 
Flow cytometry staining was done for CD11b and Gr1 on day 6. As shown in Figure 58A, 
77% of the bone marrow of FVBN202 mice is comprised of CD11b+Gr1+ cells on day 0, 
while 5% of the cells are CD11b-Gr1+, 4% of the cells are CD11b+Gr1-, and 14% of the 
cells are CD11b-Gr1- undifferentiated progenitor cells. In contrast, on day 6, only 25.1% 
of the bone marrow cells remained as CD11b+Gr1+, while the CD11b-Gr1+ population 
had decreased to 0.6% and the population of progenitor cells had decreased to 1.8% 
However, 72.6% of the cells on day 6 were CD11b+Gr1- cells, a phenotype that is 
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indicative of mature dendritic cells and macrophages. GM-CSF may therefore cause the 
differentiation of CD11b+Gr1+ cells into CD11b+Gr1- cells, the expansion of 
CD11b+Gr1- cells, or the differentitation of CD11b-Gr1- progenitor cells. Because the 
absolute number of CD11b+Gr1+ cells actually increased on day 6 as compared to day 0 
(6.0X10
6
 MDSC on day 0 as compared t0 10.9X10
6 
MDSC on day 6, Fig. 58B), we 
hypothesized that instead of maturing these cells, that GM-CSF was actually maintaining a 
population of these cells, and even causing the generation of more MDSC. We also wanted 
to determine if a 6 day culture with GM-CSF affected the differentiation/ migration status 
of MDSC. Flow cytometry was therefore done on day 6 for CD11b, Gr1, and CD86 as well 
as CD11b, Gr1, and CCR7. Figure 59A shows that the maturation marker CD86 was 
greatly increased from being expressed on 22.7% of MDSC on day 0 to being expressed on 
58.3% of MDSC on day 6 (p=0.008). Furthermore, CCR7, a chemokine receptor that has 
been demonstrated to be essential for lymphocyte homing to peripheral lymphoid organs 
(246, 247) and expression of which has been correlated with dendritic cell maturation 
(248) was observed to be down-regulated after 6 days of culture with GM-CSF (58.4% of 
MDSC expressed CCR7 on day 0 and 35.9% of MDSC expressed CCR7 on day 6, 
P=0.00078, Fig. 59B). This suggests that GM-CSF, which is secreted by MMC cells, may 
have a direct effect on MDSC and affect their generation and/or maintenance in the 
periphery.   
In order to further test the effect that GM-CSF may be having specifically on 
MDSC or MDSC progenitors and to determine which MMC-derived cytokine was 
necessary for the increased production of MDSC, bone marrow cells from naïve FVBN202 
   
 213 
   
 214 
  
   
 215 
mice were harvested, stained with antibodies against CD11b and Gr1, and were sorted into 
2 populations: CD11b+Gr1+ cells and CD11b-Gr1- cells. The purity of the sorted cells was 
>96% (Fig. 60A). Sorted cells were cultured separately in the presence of GM-CSF 
(100ng/mL), VEGF (50ng/mL), MCP-1 (50ng/mL), M-CSF (50ng/mL), G-CSF (50ng/mL) 
or MMC cells on top of a Transwell insert. Control wells contained medium only. Media 
was changed on day 3 and fresh cytokine or tumor cells added where applicable. On day 6, 
cells were subjected to flow cytometry analysis to determine generation of MDSC from 
CD11b-Gr1- progenitor cells or maintenance of existing CD11b+Gr1+ MDSC in vitro. 
Figure 60B shows that MMC-derived soluble factors or GM-CSF caused the generation of 
MDSC from hematopoietic CD11b-Gr1- cells while the presence of media resulted in a 
negligible effect. At the end of a 6-day culture 46.9% and 56.8% of cells were MDSC in 
the presence of MMC (P=0.007 as compared to media alone) and GM-CSF (P=0.001 as 
compared to media alone), respectively. A Similar observation was made when GM-CSF 
was used at a lower concentration of 10ng/mL (data not shown). VEGF or MCP-1, M-
CSF, and G-CSF did not induce generation of MDSC from CD11b-Gr1- cells (data not 
shown). Figure 60C shows that sorted CD11b+Gr1+ MDSC exhibited a significant drop in 
CD11b+Gr1+ levels from day 0 in all culture conditions. However, both GM-CSF (61.0%) 
and MMC (42.5%), supported the maintenance of CD11b+Gr1+ cells when compared with 
media alone (10.5%) (P=0.013 and P=0.006, respectively). Each cytokine/chemokine was 
also tested for the induction of proliferation in sorted CD11b+Gr1+ cells, and it was 
determined that none could induce proliferation of MDSC exceeding the baseline level 
(data not shown). Therefore, GM-CSF was found to be the major cytokine involved in the 
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conversion of CD11b-Gr1- cells to MDSC as well as maintenance, but not proliferation of 
existing MDSC.  
Since one of the characteristics of MDSC is their short half-life and high turnover 
rates, (216) we sought to determine if any of the MMC-derived soluble factors could 
inhibit apoptosis of newly arising MDSC or existing MDSC. Bone marrow cells were 
harvested as before and were sorted into CD11b+Gr1+ and CD11b-Gr1- populations. Cells 
were stained with Annexin V after sorting to determine the viability of each population just 
before culture. The double negative and double positive sorted populations contained 
63.0% and 36.8% Annexin V positive apoptotic cells, respectively (representative data of 
duplicate experiments are shown in Fig. 61A). Cells were then cultured in conditions as 
described for Figure 60 and were stained on day 6 with antibodies against CD11b and Gr1, 
and with Annexin V. Figure 61B shows levels of apoptosis in the newly converted MDSC. 
GM-CSF significantly reduced the percentage of apoptotic MDSC as compared to the 
proportion of apoptotic cells in the presence of media alone (18.7% vs. 92.3%, 
P=0.00005). Annexin V levels were also reduced in MDSC cultured with MMC in 
Transwell as compared to those cultured in media alone (58.3% vs. 92.3%, P=0.024). 
Interestingly, apoptosis was significantly reduced in MDSC when progenitor CD11b-Gr1- 
cells were cultured with GM-CSF as compared to those cells cultured with MMC in 
transwell (18.7% vs 58.3%, P=0.003). Figure 61C shows levels of apoptosis in previously 
generated MDSC after a 6-day culture in vitro. The CD11b+Gr1+ sorted cells exhibited 
significantly reduced apoptosis when cultured with GM-CSF as compared to media alone 
(38.8% vs. 91.1%, P=0.0001). Annexin V positive MDSC were significantly reduced in 
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the presence of MMC in Transwell as compared to media alone (65.0% vs. 91.1%, 
P=0.001). Apoptosis was also significantly reduced when comparing Annexin V positive 
MDSC in the presence of GM-CSF compared to those cultured with MMC in Transwell 
(38.8% vs 65.0%, P=0.003). Levels of apoptosis in CD11b+Gr1+ cells on day 0 (Fig. 61A) 
were similar to those seen on day 6 after culture with GM-CSF (Fig. 61C) (36.8% on day 0 
vs. 38.8% on day 6), whereas CD11b-Gr1- cells cultured with GM-CSF showed decreased 
Annexin V levels on day 6 (Fig. 61B) compared to day 0 (Fig. 61A) (63.0% on day 0 vs 
18.7% on day 6, P=0.017). Therefore, GM-CSF seems to augment the survival of early 
stage MDSC as compared to late stage MDSC. Annexin V staining on CD11b+Gr1+ cells, 
both newly converted and existing, cultured with VEGF, MCP-1, or G-CSF were similar to 
Annexin V levels on MDSC cultured in media alone (data not shown). 
FVBN202 Mice Display Unique Subsets of MDSC with GM-CSF Selectively Driving 
the Generation of the Suppressive Ly6G-Ly6C+ Subset 
It has recently been reported that various subsets of MDSC exist and can be distinguished 
based on their differential expression of two epitopes of the Gr1 molecule; Ly6G, 
corresponding to a granulocytic/ neutrophil phenotype, and Ly6C, corresponding to a 
monocytic phenotype (171, 215, 216). We report here that our model of neu+ tumor-
bearing FVBN202 mice, which has yet to be investigated, displays novel phenotypes and 
characteristics of MDSC. Two main subsets exist in FVBN202 mice, Ly6G-Ly6C
low/int
, 
and Ly6G+Ly6C
high
, with the former displaying suppressive capabilities while the latter 
showed no suppression against CD3/CD28 stimulated T cells (Fig. 35). Previously 
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reported subsets include Ly6G-Ly6C
high
, Ly6G
+/hi
Ly6C
low/int
, and Ly6G
int/dull
Ly6C
hi 
 (171, 
215, 216). These phenotypes display an inverse correlation between Ly6G and Ly6C 
expression, where high Ly6G expression is associated with intermediate or low Ly6C 
expression and low or absent Ly6G expression is associated with high Ly6C expression, 
which is in direct contrast to the phenotypes we present here. Furthermore, reports have 
differed in regards to which subset exhibits greater expansion and/or suppressive function. 
Figure 62A shows CD11b+ cells from the spleens of tumor-free and tumor-bearing 
FVBN202 mice, both of which display a smaller proportion of Ly6G-Ly6C
int
 (17% in 
tumor-free and 16% in tumor-bearing) and a much larger proportion of Ly6G+Ly6C
high
 
cells (24% in tumor-free and 83% in tumor-bearing). Figure 62C shows a significant 
expansion of both the Ly6G-Ly6C
int
 and Ly6G+Ly6C
high
 fractions (P=0.008 and 0.003, 
respectively) in the whole spleens of tumor bearing mice as compared to tumor free mice. 
Similar phenotypes and proportions of cells are seen in the bone marrow. As shown in 
Figure 62B, tumor-free mice contain a population of Ly6G-Ly6C
low
 cells, with a lower 
MFI than that seen in the spleen or in the bone marrow of tumor-bearing animals. Like 
Ly6G-Ly6C
int
 cells, Ly6G-Ly6C
low
 cells are found at a lower proportion (19%) than 
Ly6G+Ly6C
high
 cells (80%) in the bone marrow of tumor-free mice. Although these 
proportions are similar in the bone marrow of tumor-bearing animals, the expression of 
Ly6C per cell increases on the Ly6G- fraction, creating a population of Ly6G-Ly6C
int 
cells 
as seen in the spleen (Fig 62B). Figure 62D shows significant expansion of both the Ly6G-
Ly6C
low/int
 population (P=0.002) and the Ly6G+Ly6C
high
 population (P=0.001) in the 
whole bone marrow of tumor-bearing animals as compared to tumor-free animals. It is 
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noteworthy that both fractions expand similarly in the bone marrow (3.2 fold expansion of 
the Ly6G-Ly6C
low/int
 fraction and 3.1 fold expansion of the Ly6G+Ly6C
high
 fraction), 
while expansion in the spleens of tumor-bearing mice showed a 23.6-fold increase in 
Ly6G-Ly6C
low/int
 MDSC as compared to splenocytes from tumor free mice (P=0.008), 
whereas the Ly6G+Ly6C
high
 fraction showed a drastic 64.2-fold increase in tumor bearing 
spleens (P=0.003). 
Given the presence of these unique subsets and the fact that GM-CSF and MMC-
derived soluble factors induced the generation of MDSC from CD11b-Gr1- cells (Fig. 60), 
we next sought to determine the effects of GM-CSF and MMC on MDSC subsets. Bone 
marrow cells were therefore sorted from tumor-free FVBN202 mice as before and cultured 
in the presence of GM-CSF, MMC in Transwell, or media alone for 6 days. Flow 
cytometry was performed on day 0 and day 6 to analyze the expression of Ly6G and Ly6C. 
As shown in Figure 62B, MDSC in the bone marrow of tumor free mice on day 0 were 
comprised of 19% Ly6G-Ly6C+,
 
correlating with a suppressive phenotype and 80% 
Ly6G+Ly6C+ correlating with non-suppressive phenotype. Interestingly, culture of the 
progenitor cells in the presence of MMC or GM-CSF resulted in a significant increase in 
the suppressive Ly6G-Ly6C+ subset as compared to day 0 (58% with MMC, P=0.018 and 
72% with GM-CSF, P=0.015, Fig. 63A). Furthermore, the amount of suppressive cells 
generated from culture with GM-CSF was significantly higher than that generated from 
culture with MMC in Transwell (Fig. 63A: 72% with GM-CSF and 58% with MMC, 
P=0.045). It is noteworthy here that the mean fluorescent intensity (MFI) of Ly6C was 
increased substantially in the Ly6G- fraction after culture with GM-CSF, and even more so 
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after culture with MMC, as compared to levels seen in tumor free bone marrow on day 0 
(Fig. 62B). This is consistent with an increase in Ly6C MFI that we have observed in the 
bone marrow of tumor-bearing mice when compared to tumor free mice (Fig. 62B). 
Residual MDSC in the presence of medium alone showed a negligible percent of viable 
cells of either population (data not shown). Figure 63B shows that culture of CD11b+Gr1+ 
cells with MMC maintained a proportion of Ly6G-Ly6C
low/int
 cells similar to that on day 0 
(17% vs. 19%), while the percentage of Ly6G+Ly6C
high
 non-suppressive cells decreased 
significantly from day 0 (47% vs. 80%, P=0.001). Culture of sorted CD11b+Gr1+ cells 
with GM-CSF, however, resulted in a significantly reduced percentage of Ly6G-Ly6C
low/int
 
cells (8% vs. 19%, P=0.011) as well as a significant reduction in Ly6G+Ly6C
high 
cells 
(41% vs. 80%, P=0.0004, Fig. 63B). Again, MDSC in the presence of medium alone 
showed negligible percent of viable Ly6G-Ly6C
low/int
 or Ly6G+Ly6C
high
 cells (data not 
shown).  
We next wanted to determine if culture of bone marrow progenitor cells with MMC 
in Transwell or with GM-CSF could affect the status of MHC class I and MHC class II 
molecules on MDSC, as we have observed previously (Figs. 46,47). Sorted CD11b-Gr1- 
bone marrow cells from tumor free FVBN202 mice were therefore cultured for 6 days as 
before. Flow cytometry analysis on day 6 shows that culture with MMC or GM-CSF 
causes the downregulation of H-2
q
 on the surface of MDSC. Representative data in Figure 
64A shows that, of MDSC cultured in media alone, 72.3% expressed H-2
q
 as compared to 
18.6% and 26.5% of newly-derived MDSC expressing H-2
q
 after culture with MMC and 
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GM-CSF, respectively (Fig 64A). These data differed slightly after subtraction of 
background levels of autofluorescence, with H-2
q
 expression on MDSC after culture in 
GM-CSF being lower than that seen on MDSC after culture with MMC, however this was 
not a significant difference. On the other hand, both of these adjusted values are 
significantly lower than those seen in media alone (P=0.003 and P=1.9X10
-5 
in comparing 
media to MMC and GM-CSF cultures, respectively).  Likewise, the expression of the 
MHC class II molecule I-A
q
 was also reduced after culture with both MMC and GM-CSF. 
Culture with media alone resulted in 54.9% of MDSC expressing I-A
q
, while culture with 
MMC reduced this number to 14.7% and culture with GM-CSF resulted in 24.2% of 
MDSC expressing I-A
q
 (Fig. 64B top row). As previously, subtraction of background 
autofluorescence yielded even more substantial differences between the cells cultured in 
media and those cultured with MMC (P=0.005 as compared to media alone) or GM-CSF 
(P=0.0098 as compared to media alone) (Fig. 64B bottom graph). We further wanted to 
elucidate if existing MDSC are able to proliferate in response to GM-CSF or MMC-
derived soluble factors in vitro. To clarify this point, sorted CD11b+Gr1+ cells from the 
bone marrow of tumor free mice were pulsed with BrdU on day 0 of the culture period and 
then were cultured for 3 days with media alone, MMC on a Transwell insert, or 100ng/mL 
of GM-CSF. On day 3, cells were harvested and strained for CD11b and Gr1 as well as for 
the intracellular incorporation of BrdU. Figure 65A shows the change in the percentage of 
BrdU+ CD11b+Gr1+ cells cultured with MMC or GM-CSF as compared to media alone. 
The increase in BrdU incorporation over baseline was less than 10% in both cases and was 
not statistically significant. This is recapitulated by the absolute cell numbers in Figure 
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64B. As indicated by the diamonds, the starting cell number on day 0 was 1.5X10
5
 cells. 
The bars under the diamonds indicate the number of viable cells remaining on day 6. There 
was no proliferation seen in any of the cultures as assessed by absolute cell numbers (Fig. 
65B).  
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III. Conclusions and Significance 
 These studies clearly demonstrate that MMC-derived soluble factors do, in fact, 
cause the increase in MDSC in the spleen, blood, and bone marrow of FVBN202 mice. 
Furthermore, MHC class II expression was decreased on both CD11b+ and Gr1+ cells and 
CD11b+Gr1- cells. Cell sorting and subsequent culture with one of the predominant 
cytokines or chemokines secreted by MMC showed that GM-CSF, but not VEGF, IL-6, or 
MCP-1, specifically supported the maintenance of existing MDSC and the generation of 
new MDSC. GM-CSF was also increased the viability in both cell populations, although 
CD11b-Gr1- cells were more highly affected by GM-CSF than were CD11b+Gr1+ cells. 
CD11b+Gr1+ cells were not observed to proliferate in responses to GM-CSF; we therefore 
conclude that increases in MDSC can result from both the generation of new MDSC from 
bone marrow progenitor cells and the maintenance and survival of existing MDSC, but not 
from proliferation of MDSC, in response to GM-CSF. Strikingly, GM-CSF was found to 
specifically increase the suppressive CD11b+Ly6G-Ly6C+ phenotype of MDSC while 
decreasing the non-suppressive population arising from sorted CD11b-Gr1- progenitor 
cells, a trend not recapitulated with culture of existing MDSC. Exposure to GM-CSF also 
resulted in significant decreases of MHC class I and MHC class II on the surface of newly 
converted MDSC, an effect not seen with culture of existing MDSC. Therefore, exposure 
to GM-CSF at an early stage of differentiation can profoundly affect the resultant cellular 
profile, with increases in CD11b+Ly6G-Ly6C+ MDSC as well as sustained decreases in 
MHC class I and class II molecules, resulting in suppressive populations of granulocytes 
that do not express molecules for antigen presentation.  
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 These results offer significant findings as to the mechanisms of MDSC 
accumulation and identify GM-CSF as a major tumor-derived soluble factor responsible 
for these effects which is of substantial clinical important given that many tumor vaccines 
use GM-CSF as an adjuvant and most human tumors also secrete GM-CSF, which has 
been correlated with increased levels of circulating myeloid cells (210, 244, 249). We 
propose that the use of GM-CSF as an adjuvant, in combination with tumor-derived GM-
CSF, may elevate overall serum levels to a detrimental level and result in increases in 
MDSC in vivo as suggested by the finding that peptide vaccination coupled with GM-CSF 
in melanoma patients caused an increase in MDSC that was not observed in patients 
receiving peptide vaccination alone (213). Furthermore, neutralization of GM-CSF in 
patients with elevated serum levels may offer clinical benefit in conjunction with other 
immunotherapies.  
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Discussion 
 
I. Chapter 1 
Neu+ tumors in FVBN202 Mice Cause an Increase in MDSC that Prevents Successful 
Adoptive Immunotherapy 
 We have observed significant increases in granulocytes in the spleens, bone 
marrow, and blood of FVBN202 mice bearing MMC tumors, and found that the absolute 
number of granulocytes in these mice was significantly increased as well.  These 
observations were concurrent with a significant decrease in the absolute number of cells in 
the lymphocyte region from the bone marrow of the tibias and femurs of tumor-bearing 
mice. This indicates that granulocytic precursors are able to overtake or out compete 
lymphocytic precursors in the bone marrow, or that lymphocytic precursors in the bone 
marrow may be more sensitive to inhibition by MDSC than mature lymphocytes in the 
spleen, where no significant decrease in absolute number was observed.. This population 
of granulocytes in tumor-bearing mice was found to be mainly comprised of CD11b+Gr1+ 
cells and we found a dramatic increase in these cells in both the total population and within 
the granulocyte population in the spleen, bone marrow, and blood. The increase in MDSC 
in the spleens of TB mice is also associated with a decrease in CD11b single positive cells, 
although this phenomenon is not seen in the bone marrow. There is also a decrease in 
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CD11b+ cells in the granulocyte region of the blood, showing that although similar 
numbers of CD11b+ cells are present in the BM of tumor bearing and naïve mice, fewer of 
these cells are making it to the periphery. This increase in CD11b+Gr1+ cells and decrease 
in CD11b+ cells results in a decreased APC to T cell ratio, thus hindering antigen 
presentation in vivo. Given the prevalence of these cells in tumor- bearing mice, we 
hypothesized that these cells could be responsible for the failure of adoptively transferred 
neu-specific T cells to reject neu-positive mammary carcinomas.  
Although the adoptive transfer of tumor-specific T cells that have been activated 
and expanded in vitro is a promising means of systemically treating residual cancers after 
resection of the primary tumor, the presence of immune suppressor cells may be a 
substantial obstacle to the success of these treatments. In particular, CD11b+Gr1+ MDSC 
represent a potent population of suppressor cells that are elevated in many different types 
of cancer and have been associated with suppression of T cell responses by multiple 
mechanisms.  
 To test our hypothesis, T cells from donor FVB mice donor mice that had rejected a 
challenge with neu+ MMC cells were activated with bryostatin and ionomycin and 
expanded in IL-2 for subsequent adoptive transfer. Although activation and expansion of 
these cells resulted in activated CD44+CD62L- and CD44+CD62L+ effector and memory 
T cells that showed cytotoxic effects against MMC in vitro, the transfer of these T cells 
offered no protection against MMC tumors in FVBN202 mice. In contrast, the profound 
inhibition of MMC tumors that we observed in mice that were given AIT in conjunction 
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with MDSC depletion confirmed the hypothesis that elevated MDSC can result in the 
failure of AIT. Importantly, the level of MDSC remaining in tumor-bearing mice was 
inversely correlated with the ability to reject tumors, showing the importance of effectively 
depleting MDSC in vivo. Furthermore, AIT coupled with MDSC depletion resulted in a 
robust antibody response generated against the extracellular domain of neu, which was not 
seen in the control group or the group receiving AIT alone. The presence of higher 
percentages of activated (CD25+) CD4+ and CD8+ T cells in the spleens of mice that 
received AIT alone as compared to both control mice and mice that received MDSC 
depletion is indicative of the a continued response by transferred T cells against MMC 
tumors in these mice. Mice that received MDSC depletion and exhibited tumor regression 
showed substantially lower levels of activated T cells most likely because these cells had 
undergone the contraction phase of the immune response, making the percentage of 
activated T cells similar to that seen in mice not receiving adoptive transfer. Therefore, the 
depletion of MDSC in vivo results in an anti-neu immune response which is capable of 
rejecting neu+ mammary tumors and tumor rejection requires both MDSC depletion and 
the presence of anti-tumor effector T cells, given that depletion of MDSC alone offered no 
protection against neu+ tumors.  
T cell Expansion Using Alternating Gamma Chain Cytokines Results in Greater 
Expansion, Cytotoxicity, and Viability 
 In an effort to generate highly aggressive T cells that may overcome the 
suppressive effects of MDSC, we compared the phenotypes of T cells after expansion with 
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either IL-2 alone, IL-7/IL-15 alone, or with all three cytokines, called “alternating” 
cytokine expansion. We found expansion in alternating gamma chain cytokine conditions 
to be more effective than IL-2 alone or IL-7/IL-15 alone for the generation of large 
numbers of neu-specific anti-tumor effector T cells. Having compared IL-2 and IL-7/IL-15 
with alternating gamma chain cytokines, we found that the alternating cytokine expansion 
was superior to expansion in IL-2 and equal to expansion in IL-7/IL-15 in terms of 
generating highly viable T cells. This is likely because IL-2 is known to up-regulate 
Fas/FasL and cause activation induced cell death (141) as well as the fact that IL-7 and IL-
15 are important for the maintenance of memory T cells (130, 146, 223, 250, 251). Thus, 
cultures containing exogenous IL-7/IL-15 had more viable cells than cultures with IL-2 
alone. Along with increased viability, cultures with added IL-7/IL-15 had more CD8+ T 
cells, with the proportions of CD4+ and CD8+ T cells being roughly equal, whereas 
cultures expanded in IL-2 alone showed fewer CD8+ T cells and a higher proportion of 
CD4+ T cells. IL-15 had been shown to be an important growth factor and activator of 
CD8+ T cells, as well as being shown to enhance the anti-tumor effects of CD8+ T cells. 
Furthermore, IL-7 and IL-15 in conjunction have been shown to be imperative for the 
homeostatic proliferation of memory CD8+ T cells (131, 148, 252).  In addition to 
increased overall CD8+ T cells, the important role of IL-7/IL-15 in the generation and 
maintenance of memory T cells is also apparent. Expansion with IL-7/15 alone elicited 2 
distinct populations of memory cells: CD62L
low
CD44
high
 effector memory T cells and
 
CD62L
high
 CD44
low 
central memory T cells, while expansion with IL-2 or with alternating 
cytokines both resulted in only T cells of the effector memory phenotype. This implies that 
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the addition of exogenous IL-2 for even s short period results in increased proportions of 
cells with effector-like phenotypes. This is further confirmed by the fact that expansion in 
IL-7/15 alone elicited substantially decreased levels of CD62L-CD44+ effector cells than 
either IL-2 or alternating cytokine expanded cells.  Concurrent with the fact that alternating 
cytokine expansion resulted in the highest percentage of CD62L-CD44+ T cells, these cells 
showed a higher anti-tumor efficacy than IL-2-expanded T cells in vitro, as evaluated by 
cytotoxicity assays.  
The markedly reduced expansion levels seen in cultures using IL-7/15 are a result 
of a lack of expression of the IL-2Rα chain (CD25) and the IL-7Rα chain and on both 
CD4+ and CD8+ T cells. IL-2 is a necessary T cell growth factor that is secreted by 
activated T cells and can work in an autocrine or paracrine fashion; cells expanded in IL-
7/15 alone are not able to expand in response to IL-2 being made in the culture (253). 
Furthermore, since CD25 expression is augmented by IL-2 itself, the low levels of CD25 
expression attest to the fact that these cells are most likely making very low levels of IL-2 
and are therefore not highly activated T cells. Importantly, IL-2 has also been shown to 
promote the expression of the IL-7Rα chain, which is needed to maintain memory T cells 
(223). Expression of this receptor was the highest on T cells expanded in alternating 
gamma chain cytokines, indicating these cells may be able to respond better to homeostatic 
cytokines once in vivo and that just a one-time pulse of IL-2 was in fact sufficient to 
prevent receptor downregulation by IL-7. It is noteworthy that although IL-2 increases IL-
7Rα expression while IL-7 causes its downregulation (254), T cells expanded in alternating 
cytokines had the highest expression of the IL-7Rα chain, exceeding levels seen in IL-2 
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culture alone, despite the fact that staining was done 4 days after the removal of IL-2 from 
culture. When combined with the fact that CD25 expression on CD8 T cells expanded in 
alternating cytokines are at an intermediate level, thus reducing activation induced cell 
death, we can conclude that T cell expansion in alternating gamma chain cytokines 
provides a superior method by which to generate highly viable, cytotoxic T cells in vitro. 
In addition to T cell phenotype, function, and viability, we wanted to minimize the 
expansion of regulatory T cells during the in vitro expansion of neu specific activated T 
cells. Staining for CD4+CD25+Foxp3+ cells was done after expansion in each of the three 
cytokine regimens. Expansion with IL-7/15 generated the lowest percentage of 
CD4+CD25+Foxp3+ cells and also resulted in the lowest absolute numbers of cells on day 
7. Alternatively, while expansion with alternating cytokines generated the highest 
percentage of CD4+CD25+Foxp3+ cells, this method also resulted in the greatest fold 
expansion in vitro. In particular, the development of regulatory T cells has been of concern 
when using IL-2 for T cell expansion, as IL-2 has been shown to be essential for regulatory 
T cell development (142). However, although we saw that 10% of CD4+CD25+ cells were 
also positive for Foxp3 expression after IL-2 expansion, these cells exhibited an almost 10-
fold expansion, whereas IL-7/15 expanded cells caused only 4% of CD4+CD25+ cells to 
express Foxp3 and expanded only about 6-fold. Therefore, the generation of cells with a 
regulatory T cell phenotype by IL-2 in in vitro expansions does not seem to suppress 
cytokine-driven T cell proliferation.  
AIT Using T cells Expanded in Alternating Gamma Chain Cytokines is only 
Effective when Combined with MDSC Depletion 
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Despite the advantages of T cell expansion in alternating gamma chain cytokines, 
adoptive transfer of these T cells did not overcome the pre-existing immune suppressive 
microenvironment in FVBN202 animals. We have previously shown that these mice have 
increased levels of MDSC, even at the pre-malignant stage of mammary hyperplasia (172, 
221). However, the combination of depleting MDSC in vivo with AIT expanded in 
alternating cytokines resulted in a robust tumor regression as seen previously with IL-2 
expanded T cells and MDSC depletion and the generation of an antibody response against 
neu. Complete rejection of MMC tumors by the effector T cells, however, was hindered by 
the fact that antibody-mediated MDSC depletion in FVBN202 mice was incomplete. This 
resulted from increasing numbers of MDSC in tumor-bearing mice over time following the 
cessation of injection of anti-Gr1 antibody, as preliminary depletions (9 days after tumor 
challenge) were nearly 100% effective. However, by day 35 these levels had increased 
dramatically and we were not able to inject the rat anti-mouse Gr1 antibody more than 6 
times because of its toxicity.  
It is important to note that when comparing the distributions of T cell phenotypes 
and the absolute numbers of T cells from the spleens of mice that received either AIT alone 
or AIT with MDSC depletion, there were no substantial differences. Mice receiving AIT 
with MDSC depletion did not retain a greater number of either CD4 or CD8 T cells than 
mice that received only AIT or MMC. Furthermore, MDSC depletion in mice receiving 
AIT did not aid in maintaining higher proportions of activated, memory, or effector T cells 
in comparison to mice that received AIT alone. Therefore, it can be concluded that tumor 
rejection resulted from a lack of MDSC during the effector phase of the injected T cells 
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prior to contraction and not from any subsequent alteration in T cell phenotype, number, or 
distribution pattern. To confirm that the type of T cells (effector vs. central memory) and 
migratory patterns were not the main determinant of the efficacy of AIT, we injected mice 
with either CD62L+ cells (mostly effector memory and a small number of naïve) that 
would home to the lymph nodes, or CD62L- cells (mostly effector cells) that could go 
directly to the tumor site, after expansion in alternating cytokines. We found that AIT with 
either population, in the absence of MDSC depletion, resulted in tumor growth rates 
extremely similar to control mice receiving MMC alone. Furthermore, neither group 
generated an antibody response, confirming that MDSC depletion alone, and not the state 
of T cell differentiation or homing pattern, is responsible for the generation of antibodies 
and tumor rejection.  
The fact that these experiments use expanded T cells that recognize neu as foreign, 
yet still fail to reject MMC tumors by themselves, attests to the strength of in vivo 
suppression by MDSC, and upon proving that MDSC depletion does indeed facilitate an 
otherwise ineffective AIT, we would next hope to use these procedures with the expansion 
of splenocytes from tumor sensitized FVBN202 mice. In order to mimic the high affinity 
response seen from FVB lymphocytes, FVBN202 lymphocytes can be expanded while 
excluding those T cells having a lower affinity for the neu antigen. MHC-tetramer staining 
complexes loaded with a cocktail of the most immunodominant epitopes of neu, and 
fluorescently labeled, could be used to sort high affinity FVBN202 T cells at the start of 
the procedure. The allogeneic model of rat neu expression in FVBN202 mice is a relevant 
model in which to investigate breast cancer immunotherapy because, like human tumors, 
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the oncogenic protein is largely tolerated. The presence of this rat protein could mimic the 
fact that human tumors frequently have mutated oncogenes, which are no longer 
completely tolerated as a normal syngeneic protein would be.  
Although other groups have reported the role of MDSC in suppression of anti-
tumor T cell responses (166, 167, 255), we have found that MDSC also suppress humoral 
immune responses following AIT so that depletion of MDSC in vivo restored anti-neu 
antibody responses in FVBN202 mice. This is very important because it has been reported 
that collaboration of humoral and cellular immune responses is required for optimal 
elimination of HER2/neu positive tumors (228). In addition, a novel HER2/neu specific 
antibody, Pertuzumab, is currently in phase III trials and has been shown to have anti-
tumor function through recognition and blockade of the dimerization domain of 
HER2/neu, ECDII (256). Curiously, there was no antibody response in the groups that 
received AIT alone, indicating that the presence of adoptively transferred CD4+ T cells 
alone is not sufficient to facilitate IgG1 isotype switching by the recipients’ B cells 
because of the presence of MDSC. It is unclear at this point whether the restoration of the 
antibody response results from lifting MDSC suppression of B cells as well. The role of 
MDSC in the suppression of the humoral response should be further investigated and could 
have many applications beyond cancer immunotherapy, since increased MDSC have also 
been seen in some parasitic infections such as Trypanosoma cruzi (257) and in cases of 
polymicrobial sepsis (258).  
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AIT in Conjunction with Gemcitabine Results in Complete Tumor Rejection and 
Long-Lasting Immunological Memory 
In light of these findings, we thought it extremely important to develop a regimen 
of AIT with MDSC inhibition or depletion that could be more clinically relevant. Previous 
studies have shown that the use of Gemcitabine can eliminate CD11b+Gr1+ cells in Balb/c 
mice with neu-expressing tumors, and shows promise when used in conjunction with 
vaccination strategies (259). We therefore decided to test Gemcitabine in conjunction with 
AIT for the treatment of MMC tumors. Gemcitabine did in fact significantly reduce MDSC 
in tumor-bearing FVBN202 mice, and by itself caused a significant inhibition of tumor 
growth. However, the combination of Gemcitabine with AIT resulted in 100% complete 
tumor rejection in FVBN202 mice. The effect of Gemcitabine in inhibiting MDSC has 
recently been shown to be independent of its direct anti-tumor effects, as a single dose of 
Gemcitabine to mice with established 4T1 mammary carcinomas was able to significantly 
reduce the MDSC burden in as little as 24-48 hours, prior to any noticeable reduction in 
tumor volume (260). It is also important to note that lymphocytes isolated 24-48 hours 
after a single dose of Gemcitabine exhibited increased IFN-γ responses towards 4T1 cells 
and increased expansion in vitro as compared to lymphocytes isolated from the spleens of 
control mice (260), thus confirming the functional significance of specific MDSC 
inhibition by Gemcitabine treatment. The modest tumor inhibition seen in mice receiving 
Gemcitabine alone or AIT alone in these studies confirms the previous finding that both 
effector T cells and MDSC inhibition are needed to facilitate tumor rejection. Importantly, 
mice treated with Gemcitabine and AIT also maintained a healthy weight and appearance 
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and exhibited strong antibody responses against ECDII of neu, which was not the case in 
mice treated with Gemcitabine alone. The generation of an antibody response specifically 
against ECDII of neu is significant in the fact that we have shown that in FVB mice, 
responses against this domain are protective and sufficient for tumor rejection, while 
responses against ECDIV are not protective. Antibody responses against ECDII of neu are 
of great importance since this could inhibit the dimerization of neu with all other ErbB 
molecules.  
Since one important goal of AIT is to generate immunological memory, we decided 
to re-challenge all 5 mice that had previously received AIT and Gemcitabine and rejected 
MMC tumors. Re-challenge was done 74 days after the initial challenge to test for long-
lasting immunity. All mice received only 2 doses of Gemcitabine, as the recall response 
was powerful enough to eliminate the need for the third dose of Gemcitabine. None of the 
5 mice grew tumors large enough to be accurately measured by a digital caliper, and all 5 
mice quickly became tumor free. Serum taken 12 days after this re-challenge showed very 
high antibody titers in 2 mice, slightly elevated titers in 2 mice, and a low titer in one 
mouse. It is important to note that several of the titers reached levels much higher than 
those observed after the first challenge, consistent with the increased strength characteristic 
of a recall response. IFN-γ responses to MMC from 2 of the mice confirmed the strong 
recall response against MMC and indicated that tumor rejection was most likely immune 
mediated and not mediated by Gemcitabine. Therefore, 18 days after the first re-challenge, 
the 3 remaining mice were challenged again with MMC but were not treated with 
Gemcitabine. Two of the mice never developed measurable tumors, while the third 
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developed a small tumor that was subsequently rejected. Serum taken16 days after this 
second re-challenge indicated that antibody titers were again elevated against sudomain II 
of neu. The fact that no Gemcitabine was given after this re-challenge suggests that the 
existing high antibody titers in these mice against ECDII was able to mediate tumor 
rejection without allowing tumors to reach a size that would cause an increase in MDSC. It 
is interesting to note that the mouse that developed a small tumor after the second re-
challenge was the mouse with the lowest antibody titer out of the three on day 16. 
Therefore, while we have shown that Gemcitabine does reduce MDSC, treatment with 
Gemcitabine alone is not sufficient for the rejection of MMC tumors. However, the 
combination of Gemcitabine with AIT results in complete tumor rejection, the generation 
of antibody responses, and long-lasting humoral and cellular immunity capable of rejecting 
further challenge without the anti-tumor effects of Gemcitabine.   
Ongoing studies include long-term follow-up of mice treated with AIT and 
Gemcitabine in order to determine if these mice develop relapsed tumors that may lack 
expression of neu, as has been observed in one mouse thus far. We have previously shown 
that IFN-γ can cause downregulation of neu expression on MMC cells in vitro and the 
emergence of ANV cells in vivo after initial immune-mediated rejection of MMC cells in 
FVB mice (136). Therefore, it is important to determine if the anti-tumor response that was 
able to reject 3 MMC challenges in FVBN202 mice given AIT and Gemcitabine may lead 
to tumor relapse through the process of tumor immunoediting (136). The ANV phenotype 
of one relapsed tumor (Fig. 33) indicates, along with the in vitro IFN-γ responses observed 
(Fig. 31) indicates, preliminarily, that strong IFN-γ reponses may lead to immune-mediated 
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tumor escape variants with a more aggressive phenotype. Also of importance is to 
determine if T cell-mediated rejection of MMC challenge can be achieved when T cells are 
isolated from tolerant FVBN202 mice, expanded in alternating gamma chain cytokines, 
and used in conjunction with Gemcitabine. The improved expansion method may be 
capable of generating highly effective anti-tumor T cells even from FVBN202 mice and 
the ability of Gemcitabine to directly inhibit MDSC could eliminate any tolerance that may 
be exerted on these cells. In the clinical setting, where T cells would be taken from a 
tumor-bearing individual, it may be important to pre-treat the individual with Gemcitabine, 
as has been done by Le et al in the 4T1 mouse model of mammary carcinoma. Pre-
treatment of tumor-bearing mice with Gemcitabine resulted in significantly higher levels of 
lymphocyte expansion and increased subsequent IFN-γ secretion after sacrifice (260). 
However, these expanded cells were not able to mediate tumor regression when transferred 
into mice with established 4T1 tumors (260). In this experiment, the recipient mice were 
not treated with Gemcitabine, and, given their established tumors, likely had elevated 
levels of MDSC which inhibited the transferred T cells. Future studies should therefore use 
Gemcitabine to pre-treat the donor prior to the isolation of cells for expansion, and should 
subsequently treat the recipient with Gemcitabine to allow the transferred T cells to be 
effective.  
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II. Chapter 2 
Suppression by MDSC is Contact-Dependent 
In order to further confirm that failure of AIT to induce regression of MMC in 
FVBN202 mice was indeed a result of inhibition of T cell function by MDSC, we 
performed in vitro assays to assess MDSC-mediated inhibition of T cell proliferation. 
Consistent with the fact that tumor-bearing animals exhibit about a 4-fold increase of 
MDSC in the granulocyte region of their splenocytes (172), total splenocytes from tumor-
bearing mice showed a marked reduction in the number and percentage of proliferating T 
cells. Significantly, depleting the MDSC from the culture using either an anti-CD11b or an 
anti-Gr1 antibody caused the restoration of TCR-mediated T cell proliferation. These 
observations suggest that MDSC suppress TCR-induced proliferation of T cells. To further 
determine exactly which MDSC were suppressive against CD3/CD28 stimulation, 
CD11b+ cells were isolated from tumor bearing mice and sorted based on the differential 
expression of the Gr1 epitopes, Ly6G and Ly6C. Sorting based on these parameters 
resulted in 2 populations, one that was Ly6G+Ly6C+ and one that was Ly6G-Ly6C+. 
Suppression assays using these cells instead of whole CD11b+Gr1+ MDSC showed a 
significant reduction in CD3/CD28 mediated T cell proliferation only in the presence of 
Ly6G-Ly6C+ cells. This is in contrast to recent reports that have shown different subsets 
of MDSC to be equally suppressive. Specifically, reports by Movahedi et al using MDSC 
from EG7 thymomas and BW-Sp3 lymphomas and Youn et al, using MDSC from EL-4 
thymomas have shown that both subsets of MDSC are suppressive against OT-1 
splenocytes stimulated with specific peptide; however, neither group reported suppression 
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against splenocytes stimulated with anti-CD3/CD28(171, 215).
 
Our subsets reported here, 
therefore, may represent unique populations of MDSC found in MMC tumor-bearing 
FVBN202 mice. Consequently, in this model, broadly defining MDSC as CD11b+Gr1+ 
cells is inaccurate as not all of these cells are suppressive. The term MDSC in regards to 
the FVBN202 mouse model should therefore be defined specifically as CD11b+Ly6G-
Ly6C+ cells.  
The possible contact-dependent mechanism of T cell suppression by MDSC has 
been an area of some debate. Using different tumor models, most groups have found 
suppression of T cells by MDSC to be mediated by soluble factors such as arginase-1, 
nitric oxide, reactive oxygen species and peroxynitrites (173, 261). In particular, arginase-1 
has been implicated in downregulation of the TCR zeta chain and the induction of this 
enzyme has been linked to tumor-derived soluble factors such as prostaglandin E2 as well 
as IL-4 and IL-13 (173, 182, 188). Furthermore, arginine-depleted conditions can cause 
TCR zeta downregulation in the absence of cell-to-cell contact (188). Indoleamine 2,3-
dioxygenase, has also been found to be expressed in macrophages and dendritic cells as 
well as human tumors and contributes to T cell anergy CD8 T cell suppression through the 
catabolism of tryptophan(186, 187, 262). Inconsistent expression of IL-10 and extremely 
low expression of IDO lead us to conclude that these molecules were not paramount in 
mediating suppression by MDSC. Furthermore, a role for TGF-β was excluded as higher 
expression of this molecule was seen in the non-suppressive population of 
CD11b+Ly6G+Ly6C+ cells than was observed in the CD11b+Ly6G-Ly6C+ suppressive 
population. This led us to hypothesize that suppression by MDSC in our model may be 
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contact-dependent. Indeed, Transwell assays confirmed that cell-to-cell contact was 
required for the suppression of T cell proliferation. Although other mechanisms may be 
involved in suppression of cytotoxic responses by T cells, we report here that no 
suppression of T cell proliferation was seen when MDSC were added to the top chamber of 
a transwell insert. Nagaraj et al have recently shown that direct cell-to-cell contact between 
CD8+ T cells and MDSC causes nitration of tyrosines in the TCR-CD8 complex, therefore 
disrupting binding of specific antigen-MHC class I complexes to the TCR’s of OT-1 
transgenic T cells (183). It is unclear, however, if the effects of this nitration may be 
exaggerated by transgenic expression of the TCR and what role this mechanism may play 
in a TCR non-transgenic model. Furthermore, Gabrilovich et al have reported that blocking 
the MHC class I molecules expressed on the surface of MDSC can reverse suppression of 
CD8+ T cells, which involved MDSC production of nitric oxide, but reported that these 
cells did not suppress CD4+ T cell responses towards MHC class II presented peptides 
(166). In 2000, Kusmartsev et al. showed inhibition of CD3/CD28 T cell activation by 
MDSC isolated from mice bearing MCA-26 colon carcinomas. However, this suppression 
was reversed by the addition of a superoxide dismutase mimetic and a nitric oxide synthase 
inhibitor and a possible role of contact was not investigated, and proliferation was not 
determined in separate populations of CD4+ and CD8+ T cells (170). In contrast, we show 
here that MDSC from mice bearing neu+ mammary carcinomas inhibit the proliferation of 
both CD4+ and CD8+ T cells in contact-dependent manner. Therefore, although contact 
between MDSC and CD8+ T cells has been speculated to be important in inhibiting the 
IFN-γ response of CD8+ T cells towards specific peptide, we show here that contact is also 
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necessary to inhibit CD3/CD28 T cell stimulation and can affect the proliferation of both 
the CD4+ and CD8+ T cells populations.  
Contact-Dependent Suppression is Independent of CD86, LFA-1, and PD-L1 
The inhibitory receptor CTLA-4 (CD152) is rapidly upregulated upon T cell 
activation and has a higher affinity for the co-stimulatory molecule CD86 (B7-2) than its 
stimulatory counterpart, CD28 (263, 264). Furthermore, CD86, while expressed at low 
levels on resting APC, is also rapidly upregulated following activation (265). We therefore 
hypothesized that increased expression of CD86 on activated MDSC from tumor-bearing 
mice may cause the inhibition of T cells through CTLA-4. While this mechanism is 
normally in place as a regulator of the immune response, the increased frequency of 
MDSC present in tumor-bearing individuals could potentially cause an overwhelming 
amount of negative signaling through CTLA-4 and negate any and all positive signals 
though CD28. However, we were surprised to see that the percentage of CD11b+Gr1+ 
cells from tumor-bearing mice expressing CD86 was actually significantly lower than 
CD86 expression on CD11b+Gr1+ cells from tumor free mice. Although it is therefore 
unlikely the CD86 is a mediator of active suppression by MDSC, considering that MDSC 
make up over 90% of the granulocyte region in tumor-bearing mice (see Figure 5) and only 
about 30% of these MDSC express CD86, it is likely that contact between TCR-MHC of T 
cells and MDSC results in T cell anergy, which results from TCR activation in the absence 
of co-stimulation (266).  
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In addition to CD86, we were also able to rule out MDSC-mediated interactions 
through LFA-1, which is also highly expressed by CD11b-Gr1- cells and therefore would 
not limit suppression to the CD11b+Gr1+ population. Contact of the PD-1 molecule on T 
cells by PD-L1 on MDSC’s seemed likely as PD-L1 is known to be expressed on dendritic 
cells and macrophages and can inhibit TCR-induced proliferation, induce T cell anergy, or 
cause apoptosis (241-243). However, we saw no expression of PD-L1 on CD11b+Gr1+ 
cells, and therefore are able to rule out contact through the PD-1/PD-L1 axis as a means of 
contact-dependent suppression. We can therefore conclude that tumor-bearing FVBN202 
mice have unique subsets of MDSC, only one of which is suppressive, and that this 
suppression requires direct contact with T cells that is independent of interactions with 
LFA-1, PD-L1, and CD86. Future studies aim to identify the exact point or points of 
contact required between T cells and MDSC for MDSC to mediate T cell suppression.  
 
 
III. Chapter 3 
 
MMC-Derived Soluble Factors Drive the Accumulation of MDSC 
 
The accumulation of MDSC in tumor-bearing hosts is a major obstacle to the 
effective treatment of cancer (267) and many studies have shown a link between tumor-
derived soluble factors and increased MDSC. Identification of such soluble factors could 
offer therapeutic intervention to avoid generation of MDSC. Injection of MMC 
conditioned medium confirmed that MMC-derived soluble factors did indeed cause a 
significant increase in the proportion of the granulocytes that were MDSC, as well as 
causing a significant difference in the overall percentage and absolute numbers of MDSC 
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in the spleen, blood, and bone marrow of the tibias and femurs. The fact that MMC-
derived soluble factors also caused a significant decrease in the percentage of MDSC 
expressing the MHC class II molecule I-A
q
 lead us to hypothesize that in addition to 
increasing MDSC, tumor-derived soluble factors may also play a role in dampening the 
immune response by reducing antigen presentation. In support of this hypothesis, we did in 
fact find expression of I-A
q
 to be significantly decreased in the CD11b+Gr1- DC 
population in mice receiving injection of MMC conditioned medium as compared to mice 
receiving control medium. Since mature APC’s are one of only a few cell types that 
constitutively express MHC class II molecules, and since antigen stimulated helper CD4+ 
T cells are imperative for somatic hypermutation and isotype switching of B cells as well 
as for the induction of cytotoxic CD8+ T cell responses, the decrease in APC’s expressing 
MHC class II could negatively affect the ability of the host to respond to tumor antigens 
and mount an effective anti-tumor response (268). Interestingly, there was not a 
measurable difference in the expression of the MHC class I molecule, H-2
q
 on 
CD11b+Gr1- cells, indicating that inhibition of the anti-tumor response occurs mainly 
through the inhibition of helper T cells. Our studies also found that MMC derived 
supernatant did not influence the expression of AnnexinV, CD86, CD11c, H-2
q
, Qa1, or 
CCR7 on CD11b+Gr1+ cells. 
 A multiplex cytokine array to determine the main soluble factors secreted by MMC 
returned interesting results. We found that MMC cells secrete large amounts of VEGF and 
MCP-1 and IL-6, as well as smaller amounts of GM-CSF. It is also important to note that 
these cells do not produce substantial mIL-1β, which has been shown by Bunt et al to 
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increase MDSC’s in a 4T1 model (269). Also they do not secrete measurable IL-4 or IL-
13; it has been published that MDSC’s can respond to IL-4 and IL-13 in a way that causes 
them to take on an alternatively activated phenotype (167). The lack of secretion of IL-10, 
which is important in inducing the suppressive phenotypes in Tregs, indicates that these 
cells probably do not play a crucial role in this model (270).  
 Despite secretion of GM-CSF, VEGF, IL-6, and MCP-1 by MMC cells, injection 
of these cytokines in vivo did not result in statistically significant increases in MDSC in the 
spleen, bone marrow, and blood of FVBN202 mice, as was seen after injection of MMC-
conditioned media. We believe this is because of the short half –lives of these molecules, 
as groups that have seen in vivo responses have used a means of continuous in vivo 
administration such as the use of GM-CSF-transfected melanoma cells that secrete up to 
6000ng per 1X10
6
 cells per hour, or subcutaneously implanted osmotic pumps delivering 
VEGF at a constant rate of 50 or 100ng per hour, which has been shown to have a half life 
of only 25 minutes (208, 271, 272). We therefore decided to use in vitro studies to analyze 
the effects of these cytokines/ chemokines on sorted populations of both CD11b-Gr1- 
progenitor cells and CD11b+Gr1+ MDSC from the bone marrow of FVBN202 mice. 
GM-CSF is the Main Determinant of MDSC Generation and Survival 
GM-CSF has been used in dendritic cell vaccination strategies to induce tumor-
specific immune responses. For example, Driessens et al have recently found that 
administration of GM-CSF-transduced renal cell carcinoma cells along with dendritic cells 
is able to mediate responses in 50% of mice and also resulted in immunological memory 
(273). GM-CSF is a crucial factor in the generation of dendritic cells and plays an 
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important role in regulating and activating these cells and has been shown to increase 
numbers of circulating dendritic cells in patients receiving exogenous GM-CSF with along 
with either G-CSF or Flt3 (274, 275). Patients who received GM-CSF with Flt3 generated 
increased numbers of DC1 cells, which stimulate a Th1 response, while patients who 
received GM-CSF in conjunction with G-CSF showed increased DC2 cells, which cause a 
Th2 polarization (275). This is not surprising given fact that GM-CSF has a broad range of 
biological activity and can exert different effects in varying cells types depending on 
concentration, differentiation status, and surrounding environment and cytokine milieu 
(276). Showing the diversity of responses elicited by GM-CSF, a recent study in patients 
with stage IV melanoma has shown that administration of GM-CSF in combination with a 
multi-epitope vaccine offered no improvement in anti-tumor immune responses as 
compared to those seen in patients that received vaccination alone (277), while another has 
shown that vaccination of patients with metastatic melanoma using irradiated autologous 
melanoma cells engineered to express GM-CSF resulted in anti-tumor responses in 11 out of 16 
patients (278).  
Given that the role of GM-CSF on MDSC has only recently been investigated and 
considering the heterogeneity of responses that can occur as a result of GM-CSF, we found 
it imperative to investigate the role of this cytokine in MDSC generated in the FVBN202 
mouse model. In agreement with literature that has implicated GM-CSF as an important 
factor in the development and differentiation of a variety of hematopoietic cells (276), we 
found that total bone marrow cells, most of which were CD11b+Gr1+, cultured with GM-
CSF resulted in the generation of a large population of CD11b+Gr1- dendritic cells 
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(72.6%). Despite the fact that the CD11b+Gr1+ population dropped from 77% of the total 
bone marrow on day 0 to 25% on day 6, quantification of the absolute number of these 
cells showed that this population actually increased, albeit not significantly, during this 
time period. This led us to conclude that GM-CSF is in fact maintaining the MDSC 
population throughout the culture period. Furthermore, CD86 expression on MDSC was 
significantly increased by day 6 of culture, which is of interest given the previous finding 
that CD86 levels on MDSC were significantly reduced on MDSC from tumor-bearing 
mice as compared to those from tumor-free mice (see Figure 39). Therefore while GM-
CSF alone may result in MDSC with a slightly more mature phenotype, the presence of 
other tumor-derived soluble factors in conjunction with GM-CSF negates this effect. 
Although we did not see a significant difference in CD86 expression on MDSC after 
injection with MMC-derived supernatant, it is possible that a longer time period is required 
for this effect, as only 3 injections of MMC supernatant over the course of 3 days were 
given. Contrary to the increase in CD86, 6 days of culture with GM-CSF caused MDSC in 
the bone marrow to drastically downregulate their expression of the chemokine receptor 
CCR7. CCR7 has only 2 ligands, CCL19 and CCL21, which are important in guiding 
CCR7-expressing cells through high endothelial venules and into the lymph nodes (279). 
CCR7 is expressed only on semi-mature and mature DC’s, and like CD86, is greatly 
upregulated upon DC maturation. Although DC’s in Ccr7
-/- 
mice do not migrate to the 
draining lymph nodes after activation, T cells lacking CCR7 are still found in the red pulp 
of the spleen and B cells were found in both the red and white pulp of the spleen, 
indicating that migration into the spleen is still possible in the absence of CCR7 (246). 
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Furthermore, it has been found that the addition of CCL19 to DC cultures induced their 
maturation and that CCR7 ligands can increase the ability of mature DC’s to take up 
antigen (280, 281). In light of these findings, although the upregulation of CD86 on MDSC 
may indicate a maturing effect of GM-CSF on these cells, the concurrent downregulation 
of CCR7 may prevent complete maturation, antigen uptake, and migration to the lymph 
nodes while explaining the preponderance MDSC present in the spleens and periphery of 
tumor-bearing mice, while increases have not been observed in the lymph nodes 
(unpublished observation). We next sought to determine the effects of GM-CSF 
specifically on existing MDSC or on the generation of MDSC by using pure sorted cells 
populations.  
The important role of GM-CSF in the expansion of MDSC has been suggested 
previously by other studies. For example, GM-CSF-secreting tumors and GM-CSF 
administration in vivo (5µg twice daily for 3 days) have been implicated in increased 
numbers of MDSC (282).It was determined that only high-dose GM-CSF had such 
deleterious effects (271), though differential effects of GM-CSF on progenitor cells versus 
existing MDSC were not determined. We have determined that GM-CSF is the major 
tumor-derived soluble factor that causes both the generation of MDSC from sorted CD11b-
Gr1- cells and maintains existing sorted CD11b+Gr1+ MDSC for the duration of a 6 day 
culture. Interestingly, CD11b+Gr1- cells were not abundant after culture of either of the 
sorted fractions with GM-CSF, indicating that these cells may have, in part, expanded from 
the existing 4% present on day 0 (see Figure 58). However, there was a substantial 
difference on day 6 between cells cultured in GM-CSF as compared to cells cultured with 
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MMC in Transwell. While the presence of GM-CSF alone with sorted CD11b-Gr1- cells 
drove the production of a majority of MDSC, the presence of MMC with CD11b-Gr1- 
cells resulted in an almost equal distribution of CD11b+Gr1+ cells and CD11b+Gr1- cells 
on day 6. This indicates that tumor-derived soluble factors other than GM-CSF are 
responsible for the generation of CD11b+Gr1- cells and explains a previous observation 
that the tumor site contains a higher proportion of CD11b+Gr1- cells than the spleen, bone 
marrow, or blood of FVBN202 mice (see Figure 5). In contrast, the effect on sorted 
CD11b+Gr1+ cells was reversed, with culture with GM-CSF alone resulting in a greater 
percentage of CD11b+Gr1- cells (21.8%) than culture with MMC in Transwell (only 
7.3%). This shows that CD11b+Gr1+ cells are in fact capable of converting into 
CD11b+Gr1- cells, but that the presence of other tumor-derived soluble factors besides 
GM-CSF largely prevents this from occurring. Secondly, this highlights the drastically 
different effects that the same treatment (GM-CSF or MMC cells) can have on these two 
different cell populations. In fact, our data indicated that sorted CD11b-Gr1- progenitor 
cells were more susceptible to the effects of GM-CSF not only in the generation of MDSC, 
but also for the survival of these MDSC as compared to CD11b+Gr1+ bone marrow cells. 
Although GM-CSF, and to a lesser extent MMC-derived soluble factors, significantly 
augmented the viability of both existing and newly generated MDSC, lower AnnexinV 
staining in newly generated MDSC derived from CD11b-Gr1- cells may be a result of high 
turnover rates in MDSC such that previously generated MDSC are more prone to apoptosis 
than newly generated MDSC even in the presence of GM-CSF. Interestingly, in both cases, 
the protective effects of GM-CSF on MDSC appeared to be dose-dependent, because 
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culture with GM-CSF at 100ng/mL caused a significant reduction in apoptosis as 
compared to MMC secreting ~350 pg/mL GM-CSF.  
MMC-Derived Soluble Factors or GM-CSF Support the Generation of a Suppressive 
Ly6G-Ly6C+ MDSC Subset. 
Identifying MDSC subsets is an important factor that may lead to more efficient 
therapeutic means of eliminating or inhibiting these specific cell populations, while 
minimizing undesirable side effects. We therefore sought to further characterize MDSC 
subsets in FVBN202 mice through differential expression of the Gr1 epitopes Ly6G and 
Ly6C. It has recently been reported that expression of Ly6G correlates with a granulocytic 
phenotype, while expression of Ly6C correlates with a monocytic phenotype (171, 215). 
The tumor-bearing FVBN202 transgenic mouse model of neu positive mammary 
carcinoma displays novel phenotypes and characteristics of MDSC. Although Youn et al 
observed increases in MDSC subsets in FVBN202 mice with ANV tumors, FVBN202 
bearing MMC tumors were not evaluated (171). Two distinct subsets exist in MMC tumor-
bearing FVBN202 mice, Ly6G-Ly6C
low/int
, and Ly6G+Ly6C
high
.
 
Previously reported 
subsets include Ly6G-Ly6C
high
, Ly6G
+/hi
Ly6C
low/int
, and Ly6G
int/dull
Ly6C
hi 
(171, 215, 216). 
These phenotypes display an inverse correlation between Ly6G and Ly6C expression, 
where high Ly6G expression is associated with intermediate or low Ly6C expression and 
low or absent Ly6G expression is associated with high Ly6C expression, which is in direct 
contrast to the phenotypes presented here.  
In addition to previously reported differences in suppressive activity of these two 
subsets (see Figure 35), the expansion of MDSC subpopulations has also differed among 
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groups. Like Youn et al, we observed the greatest expansion in the Ly6G positive subset in 
the spleens of tumor-bearing mice as compared to tumor-free mice (Figure 62), however 
we observed similar expansion of the two subsets in the bone marrow (171). In contrast, 
Movahedi et al have reported a roughly equal distribution of Ly6G+ and Ly6G- subsets in 
tumor-bearing spleens, and have also found both populations to expand with similar 
kinetics (171, 215).  
We next sought to determine the effects that GM-CSF or MMC would have on the 
distribution or expansion of these MDSC subsets. Strikingly, culture with 100ng/mL of 
GM-CSF, and to a lesser extent MMC, also resulted in a significantly higher percentage of 
Ly6G- cells, previously found to be suppressive, and a significantly lower percentage of 
Ly6G+ cells, which have shown no suppressive activity in this model. Like the protective 
effects of GM-CSF, the reversal of the distribution of these cell populations seems to be 
concentration dependent, as the Ly6G- population was also significantly increased as 
compared to that seen after culture with MMC. It is interesting to note that the MFI if 
Ly6C was greatly increased after culture with GM-CSF or MMC as compared to that seen 
in the bone marrow on day 0. Considering there is a slight increase in the MFI of Ly6C in 
the bone marrow of tumor-bearing versus tumor free mice, high expression of Ly6C may 
represent a marker of activated MDSC with increased suppressive activity. The 
suppressive capacity of Ly6G-Ly6C
high
 cells remains to be determined and shoule be 
compared to the suppressive effect seen previously in the Ly6G-Ly6C
low/int
 population. 
Additionally, variances in the amount of GM-CSF secreted by other tumor cell lines may 
explain the different subsets that have been found in different models.   
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Further characterization of the effects of GM-CSF and MMC-derived soluble 
factors on sorted CD11b-Gr1- progenitor cells revealed that, consistent with previous 
findings, both the MHC class I (H-2
q
) and the MHC class II (I-A
q
) molecules were 
significantly reduced on MDSC that had arisen from these cells after 6 days. This suggests 
that any cells arising under conditions of elevated GM-CSF may have stunted antigen 
presentation capabilities. We did not, however, observe significant differences in H-2
q
 and 
I-A
q
 levels after the culture of sorted CD11b+Gr1+ cells, again highlighting the increased 
susceptibility of progenitor cells to the effects of GM-CSF. This also explains the more 
pronounced difference seen in the expression of these molecules as compared to that seen 
previously after injection of MMC-conditioned medium, since these populations would 
include cells that were already CD11b+Gr1+ as well as cells that were CD11b-Gr1- at the 
time of injection (see Figures 46 and 47). Therefore, it has been consistently found that the 
presence of GM-CSF, either alone or as secreted by MMC, can reduce the antigen 
presentation abilities of both CD11b+Gr1+ as well as CD11b+Gr1- cells and may play a 
role in preventing the full maturation of these cells, which is characterized by increases in 
MHC class II expression, upon antigen uptake (279). GM-CSF does not, however, cause 
the proliferation of existing sorted MDSC which is consistent with the fact that we did not 
see a statistically significant difference between the absolute number of MDSC recovered 
from the bone marrow of the tibias and femurs on day 0 as compared to after 6 days of 
culture with GM-CSF. This is likely a result of the rapid turnover rate of MDSC in which 
existing MDSC are more prone to apoptosis and will be replaced by newly arising MDSC 
from the bone marrow. It is likely, however, that the accumulation of increasing numbers 
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of MDSC is a result of the generation of new MDSC outpacing the apoptosis of existing 
MDSC, and this may also account for the non-significant increase in MDSC numbers seen 
in Figure 58 as GM-CSF drove the production of CD11b+Gr1+ cells from CD11b-Gr1- 
bone marrow progenitor cells.  
Given the effects of GM-CSF on CD11b+Gr1+ and CD11b+Gr1- cells, it is  
conceivable that, since GM-CSF has been found to be secreted in 31% of tested human 
tumor cell lines (282), administering GM-CSF in the clinical setting may have an additive 
effect with tumor-secreted GM-CSF and therefore support the generation of MDSC from 
bone marrow progenitor cells, as well as maintaining existing populations of MDSC and 
driving the production of highly suppressive subsets of MDSC. A recent review on the 
opposing effects of GM-CSF as an adjuvant in cancer patients also suggested activation 
and expansion of MDSC by endogenous tumor-derived or exogenous GM-CSF (211). 
However, a study on patients with high-risk melanoma treated with adjuvant GM-CSF 
showed that GM-CSF mainly expanded DCs rather than MDSC (283). The authors used 
CD33+HLA-DR- as markers for MDSC whereas, using CD34+ as a marker for MDSC, 
others found that patients with head and neck squamous cell carcinoma (HNSCC) had 
profound immune deficiencies associated with an increased intra-tumoral presence of 
immune-suppressive CD34+ progenitor cells (210). Therefore different observations may 
be attributed to different markers used for identification of human MDSC. Although 
markers of MDSC in humans are not as well characterized as in mouse, we made similar 
observations in mice when using unfractionated bone marrow cells in culture with GM-
CSF. This suggests a dual role for GM-CSF in the generation of DCs and MDSC. The 
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frequency of distinct progenitor cells for DCs or MDSC in the bone marrow of cancer 
patients may determine which effect of GM-CSF may prevail. Given these findings, 
existing serum levels of MDSC in patients should be considered before administering GM-
CSF as an adjuvant therapy and levels should be monitored closely during treatment in an 
effort to minimize the deleterious effects of GM-CSF.  
Interestingly, we observed a complete lack of response when using either VEGF or 
MCP-1 in culture with sorted CD11b-Gr1- cells or CD11b+Gr1+ cells. This was somewhat 
surprising given that MMC cells secrete over 4.5 times as much VEGF and over 3 times as 
much MCP-1 as GM-CSF. In particular, recent evidence has pointed towards VEGF as an 
important mediator of myeloid cell accumulation and differentiation through the activation 
of STAT3 which has been shown to prevent the differentiation of myeloid cells (201). 
Increased levels of VEGF have also been shown to result in the inhibition of DC 
development and the accumulation of Gr1+ cells (208, 272). Likewise, the link between 
the chemokine MCP-1 (CCL2) and elevated levels of detrimental tumor-associated 
macrophages in breast cancer patients made it a likely candidate for causing the generation 
of suppressive macrophage and/or MDSC populations (284, 285). We have indeed 
observed a higher percentage of CD11b+Gr1- cells at the tumor site, an effect that is 
recapitulated in Figure 60B with sorted CD11b-Gr1- progenitor cells cultured with MMC 
in transwell converting to 43.8% CD11b+Gr1- cells by day 6. However, neither sorted 
populations of progenitor cells nor MDSC responded to either VEGF or MCP-1 alone. 
GM-CSF, secreted at an average of 336pg/mL by MMC cells, is therefore the main 
determinant of MDSC generation and maintenance.  
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We showed that MMC or GM-CSF specifically supported the generation of the 
suppressive Ly6G-Ly6C+ subset in vitro. On the other hand, tumor-bearing mice showed a 
higher percentage of Ly6G+Ly6C+ than Ly6G-Ly6C+. Such discrepancies between in 
vitro and in vivo observations could be attributed to the higher dose of GM-CSF or MMC 
in co-culture with the progenitor cells compared to that in vivo. Alternatively, immune 
responses against the tumor may compromise the effects of tumor-derived soluble factors 
in vivo and reduce the proportion of the suppressive subset. This possibility is supported by 
recent reports showing that immunological tolerance was broken against the neu positive 
tumors in FVBN202 transgenic mice (221, 286).  
GM-CSF therefore is the main factor having the ability to drive the production of 
new MDSC from bone marrow CD11b-Gr1- progenitor cells, and, more specifically 
augments the generation of a novel Ly6G-Ly6C+
 
suppressive subset of MDSC. In contrast, 
VEGF and MCP-1, both previously linked to MDSC accumulation, had no effect on the 
generation or maintenance of MDSC. Future studies will determine the suppressive 
activities of the Ly6G-Ly6C+ and Ly6G+Ly6C+ subsets generated after culture with either 
GM-CSF or MMC to elucidate if the highly expanded Ly6G-Ly6C+ subset remains 
suppressive. Furthermore, comparisons between the suppressive activities of 
CD11b+Ly6G-Ly6C
low
 cells found in naïve FVBN202 mice, the CD11b+Ly6G-Ly6C
int 
cells found in tumor-bearing mice, and the CD11b+Ly6G-Ly6C
high 
cells generated after 
culture with MMC or GM-CSF should be conducted to determine if expression of the 
Ly6C molecule may be a prognostic marker for identifying suppressive populations of 
MDSC.  
   
 267 
 
 
 
 
 
 
 
 
Literature Cited 
   
 268 
 
 
Literature Cited 
 
1. Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, and M. J. Thun. 2008. Cancer 
statistics, 2008. CA Cancer. J. Clin. 58: 71-96. 
 
2. seer.cancer.gov/csr/1975_2000/results_merged/topic_lifetime_risk.pdf 
 
3. Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. G. Wong, D. E. Keith, W. J. 
Levin, S. G. Stuart, J. Udove, and A. Ullrich. 1989. Studies of the HER-2/neu proto-
oncogene in human breast and ovarian cancer. Science 244: 707-712. 
 
4. Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 
1987. Human breast cancer: correlation of relapse and survival with amplification of the 
HER-2/neu oncogene. Science 235: 177-182. 
 
5. Bhattachary, R., R. Bukkapatnam, I. Prawoko, J. Soto, M. Morgan, and R. R. Salup. 
2002. Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-
eGFP fusion protein against prostate cancer in rats. Int. Immunopharmacol. 2: 783-796. 
 
6. Cohen, S. 1965. The stimulation of epidermal proliferation by a specific protein (EGF). 
Dev. Biol. 12: 394-407. 
 
7. Carpenter, G., K. J. Lembach, M. M. Morrison, and S. Cohen. 1975. Characterization of 
the binding of 125-I-labeled epidermal growth factor to human fibroblasts. J. Biol. Chem. 
250: 4297-4304. 
 
8. Carpenter, G., L. King Jr, and S. Cohen. 1978. Epidermal growth factor stimulates 
phosphorylation in membrane preparations in vitro. Nature 276: 409-410. 
 
9. Downward, J., Y. Yarden, E. Mayes, G. Scrace, N. Totty, P. Stockwell, A. Ullrich, J. 
Schlessinger, and M. D. Waterfield. 1984. Close similarity of epidermal growth factor 
receptor and v-erb-B oncogene protein sequences. Nature 307: 521-527. 
 
10. Coussens, L., T. L. Yang-Feng, Y. C. Liao, E. Chen, A. Gray, J. McGrath, P. H. 
Seeburg, T. A. Libermann, J. Schlessinger, and U. Francke. 1985. Tyrosine kinase receptor 
with extensive homology to EGF receptor shares chromosomal location with neu 
oncogene. Science 230: 1132-1139. 
   
 269 
11. Burgess, A. W., H. S. Cho, C. Eigenbrot, K. M. Ferguson, T. P. Garrett, D. J. Leahy, 
M. A. Lemmon, M. X. Sliwkowski, C. W. Ward, and S. Yokoyama. 2003. An open-and-
shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12: 541-
552. 
 
12. Hynes, N. E. and H. A. Lane. 2005. ERBB receptors and cancer: the complexity of 
targeted inhibitors. Nat. Rev. Cancer. 5: 341-354. 
 
13. Schlessinger, J. 2002. Ligand-induced, receptor-mediated dimerization and activation 
of EGF receptor. Cell 110: 669-672. 
 
14. Garrett, T. P., N. M. McKern, M. Lou, T. C. Elleman, T. E. Adams, G. O. Lovrecz, H. 
J. Zhu, F. Walker, M. J. Frenkel, P. A. Hoyne, R. N. Jorissen, E. C. Nice, A. W. Burgess, 
and C. W. Ward. 2002. Crystal structure of a truncated epidermal growth factor receptor 
extracellular domain bound to transforming growth factor alpha. Cell 110: 763-773. 
 
15. Ogiso, H., R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, J. H. Kim, K. Saito, A. 
Sakamoto, M. Inoue, M. Shirouzu, and S. Yokoyama. 2002. Crystal structure of the 
complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 
775-787. 
 
16. Garrett, T. P., N. M. McKern, M. Lou, T. C. Elleman, T. E. Adams, G. O. Lovrecz, M. 
Kofler, R. N. Jorissen, E. C. Nice, A. W. Burgess, and C. W. Ward. 2003. The crystal 
structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to 
interact with other ErbB receptors. Mol. Cell 11: 495-505. 
 
17. Graus-Porta, D., R. R. Beerli, J. M. Daly, and N. E. Hynes. 1997. ErbB-2, the preferred 
heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO 
J. 16: 1647-1655. 
 
18. Kurebayashi, J. 2001. Biological and clinical significance of HER2 overexpression in 
breast cancer. Breast Cancer 8: 45-51. 
 
19. Maguire, H. C.,Jr and M. I. Greene. 1989. The neu (c-erbB-2) oncogene. Semin. Oncol. 
16: 148-155. 
 
20. Eladdadi, A. and D. Isaacson. 2008. A mathematical model for the effects of HER2 
overexpression on cell proliferation in breast cancer. Bull. Math. Biol. 70: 1707-1729. 
 
21. Beerli, R. R., D. Graus-Porta, K. Woods-Cook, X. Chen, Y. Yarden, and N. E. Hynes. 
1995. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and 
displays a differential requirement for ErbB-2. Mol. Cell. Biol. 15: 6496-6505. 
   
 270 
22. Graus-Porta, D., R. R. Beerli, and N. E. Hynes. 1995. Single-chain antibody-mediated 
intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth 
factor signaling. Mol. Cell. Biol. 15: 1182-1191. 
 
23. Guy, P. M., J. V. Platko, L. C. Cantley, R. A. Cerione, and K. L. Carraway 3rd. 1994. 
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. 
Acad. Sci. U. S. A. 91: 8132-8136. 
 
24. Di Fiore, P. P., J. H. Pierce, M. H. Kraus, O. Segatto, C. R. King, and S. A. Aaronson. 
1987. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 
178-182. 
 
25. Guy, C. T., M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, and W. J. Muller. 
1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice 
induces metastatic disease. Proc. Natl. Acad. Sci. U. S. A. 89: 10578-10582. 
 
26. Gschwind, A., O. M. Fischer, and A. Ullrich. 2004. The discovery of receptor tyrosine 
kinases: targets for cancer therapy. Nat. Rev. Cancer. 4: 361-370. 
 
27. Chen, F. L., W. Xia, and N. L. Spector. 2008. Acquired resistance to small molecule 
ErbB2 tyrosine kinase inhibitors. Clin. Cancer Res. 14: 6730-6734. 
 
28. Bjorge, J. D., T. O. Chan, M. Antczak, H. J. Kung, and D. J. Fujita. 1990. Activated 
type I phosphatidylinositol kinase is associated with the epidermal growth factor (EGF) 
receptor following EGF stimulation. Proc. Natl. Acad. Sci. U. S. A. 87: 3816-3820. 
 
29. Dillon, R. L., D. E. White, and W. J. Muller. 2007. The phosphatidyl inositol 3-kinase 
signaling network: implications for human breast cancer. Oncogene 26: 1338-1345. 
 
30. Viglietto, G., M. L. Motti, P. Bruni, R. M. Melillo, A. D'Alessio, D. Califano, F. Vinci, 
G. Chiappetta, P. Tsichlis, A. Bellacosa, A. Fusco, and M. Santoro. 2002. Cytoplasmic 
relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by 
PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 8: 1136-1144. 
 
31. Zhou, B. P., Y. Liao, W. Xia, B. Spohn, M. H. Lee, and M. C. Hung. 2001. 
Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-
2/neu-overexpressing cells. Nat. Cell Biol. 3: 245-252. 
 
32. Datta, S. R., H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, and M. E. Greenberg. 
1997. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death 
machinery. Cell 91: 231-241. 
   
 271 
33. del Peso, L., M. Gonzalez-Garcia, C. Page, R. Herrera, and G. Nunez. 1997. 
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 
278: 687-689. 
 
34. Ozes, O. N., L. D. Mayo, J. A. Gustin, S. R. Pfeffer, L. M. Pfeffer, and D. B. Donner. 
1999. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine 
kinase. Nature 401: 82-85. 
 
35. Romashkova, J. A. and S. S. Makarov. 1999. NF-kappaB is a target of AKT in anti-
apoptotic PDGF signalling. Nature 401: 86-90. 
 
36. Li, X. and G. R. Stark. 2002. NFkappaB-dependent signaling pathways. Exp. Hematol. 
30: 285-296. 
 
37. Roberts, P. J. and C. J. Der. 2007. Targeting the Raf-MEK-ERK mitogen-activated 
protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310. 
 
38. Smith, M. R., S. J. DeGudicibus, and D. W. Stacey. 1986. Requirement for c-ras 
proteins during viral oncogene transformation. Nature 320: 540-543. 
 
39. McKay, M. M. and D. K. Morrison. 2007. Integrating signals from RTKs to 
ERK/MAPK. Oncogene 26: 3113-3121. 
 
40. Malumbres, M. and M. Barbacid. 2003. RAS oncogenes: the first 30 years. Nat. Rev. 
Cancer. 3: 459-465. 
 
41. Birnbaum, D., F. Sircoulomb, and J. Imbert. 2009. A reason why the ERBB2 gene is 
amplified and not mutated in breast cancer. Cancer. Cell. Int. 9: 5. 
 
42. Lynch, T. J., D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. 
Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. 
Christiani, J. Settleman, and D. A. Haber. 2004. Activating mutations in the epidermal 
growth factor receptor underlying responsiveness of non-small-cell lung cancer to 
gefitinib. N. Engl. J. Med. 350: 2129-2139. 
 
43. Stephens, P., C. Hunter, G. Bignell, S. Edkins, H. Davies, J. Teague, C. Stevens, S. 
O'Meara, R. Smith, A. Parker, A. Barthorpe, M. Blow, L. Brackenbury, A. Butler, O. 
Clarke, J. Cole, E. Dicks, A. Dike, A. Drozd, K. Edwards, S. Forbes, R. Foster, K. Gray, C. 
Greenman, K. Halliday, K. Hills, V. Kosmidou, R. Lugg, A. Menzies, J. Perry, R. Petty, K. 
Raine, L. Ratford, R. Shepherd, A. Small, Y. Stephens, C. Tofts, J. Varian, S. West, S. 
Widaa, A. Yates, F. Brasseur, C. S. Cooper, A. M. Flanagan, M. Knowles, S. Y. Leung, D. 
N. Louis, L. H. Looijenga, B. Malkowicz, M. A. Pierotti, B. Teh, G. Chenevix-Trench, B. 
L. Weber, S. T. Yuen, G. Harris, P. Goldstraw, A. G. Nicholson, P. A. Futreal, R. Wooster, 
   
 272 
and M. R. Stratton. 2004. Lung cancer: intragenic ERBB2 kinase mutations in tumours. 
Nature 431: 525-526. 
 
44. McCarthy, S. A., M. L. Samuels, C. A. Pritchard, J. A. Abraham, and M. McMahon. 
1995. Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin 
receptor expression by Raf and Ras oncogenes. Genes Dev. 9: 1953-1964. 
 
45. Schulze, A., B. Nicke, P. H. Warne, S. Tomlinson, and J. Downward. 2004. The 
transcriptional response to Raf activation is almost completely dependent on Mitogen-
activated Protein Kinase Kinase activity and shows a major autocrine component. Mol. 
Biol. Cell 15: 3450-3463. 
 
46. Yamauchi, T., K. Ueki, K. Tobe, H. Tamemoto, N. Sekine, M. Wada, M. Honjo, M. 
Takahashi, T. Takahashi, H. Hirai, T. Tushima, Y. Akanuma, T. Fujita, I. Komuro, Y. 
Yazaki, and T. Kadowaki. 1997. Tyrosine phosphorylation of the EGF receptor by the 
kinase Jak2 is induced by growth hormone. Nature 390: 91-96. 
 
47. Fu, X. Y. and J. J. Zhang. 1993. Transcription factor p91 interacts with the epidermal 
growth factor receptor and mediates activation of the c-fos gene promoter. Cell 74: 1135-
1145. 
 
48. Zhong, Z., Z. Wen, and J. E. Darnell Jr. 1994. Stat3: a STAT family member activated 
by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. 
Science 264: 95-98. 
 
49. Haura, E. B., Z. Zheng, L. Song, A. Cantor, and G. Bepler. 2005. Activated epidermal 
growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell 
lung cancer. Clin. Cancer Res. 11: 8288-8294. 
 
50. Li, Y., H. Du, Y. Qin, J. Roberts, O. W. Cummings, and C. Yan. 2007. Activation of 
the signal transducers and activators of the transcription 3 pathway in alveolar epithelial 
cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res. 67: 8494-
8503. 
 
51. Yeh, H. H., W. W. Lai, H. H. Chen, H. S. Liu, and W. C. Su. 2006. Autocrine IL-6-
induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and 
malignant pleural effusion. Oncogene 25: 4300-4309. 
 
52. Bromberg, J. F., C. M. Horvath, D. Besser, W. W. Lathem, and J. E. Darnell Jr. 1998. 
Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol. 18: 2553-
2558. 
 
   
 273 
53. Bromberg, J. F., M. H. Wrzeszczynska, G. Devgan, Y. Zhao, R. G. Pestell, C. 
Albanese, and J. E. Darnell Jr. 1999. Stat3 as an oncogene. Cell 98: 295-303. 
 
54. Yu, C. L., D. J. Meyer, G. S. Campbell, A. C. Larner, C. Carter-Su, J. Schwartz, and R. 
Jove. 1995. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed 
by the Src oncoprotein. Science 269: 81-83. 
 
55. Kiuchi, N., K. Nakajima, M. Ichiba, T. Fukada, M. Narimatsu, K. Mizuno, M. Hibi, 
and T. Hirano. 1999. STAT3 is required for the gp130-mediated full activation of the c-
myc gene. J. Exp. Med. 189: 63-73. 
 
56. Masuda, M., M. Suzui, R. Yasumatu, T. Nakashima, Y. Kuratomi, K. Azuma, K. 
Tomita, S. Komiyama, and I. B. Weinstein. 2002. Constitutive activation of signal 
transducers and activators of transcription 3 correlates with cyclin D1 overexpression and 
may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer 
Res. 62: 3351-3355. 
 
57. Puthier, D., R. Bataille, and M. Amiot. 1999. IL-6 up-regulates mcl-1 in human 
myeloma cells through JAK / STAT rather than ras / MAP kinase pathway. Eur. J. 
Immunol. 29: 3945-3950. 
 
58. Aoki, Y., G. M. Feldman, and G. Tosato. 2003. Inhibition of STAT3 signaling induces 
apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101: 
1535-1542. 
 
59. Niu, G., K. L. Wright, M. Huang, L. Song, E. Haura, J. Turkson, S. Zhang, T. Wang, 
D. Sinibaldi, D. Coppola, R. Heller, L. M. Ellis, J. Karras, J. Bromberg, D. Pardoll, R. 
Jove, and H. Yu. 2002. Constitutive Stat3 activity up-regulates VEGF expression and 
tumor angiogenesis. Oncogene 21: 2000-2008. 
 
60. Dechow, T. N., L. Pedranzini, A. Leitch, K. Leslie, W. L. Gerald, I. Linkov, and J. F. 
Bromberg. 2004. Requirement of matrix metalloproteinase-9 for the transformation of 
human mammary epithelial cells by Stat3-C. Proc. Natl. Acad. Sci. U. S. A. 101: 10602-
10607. 
 
61. Colomiere, M., J. Findlay, L. Ackland, and N. Ahmed. 2009. Epidermal growth factor-
induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and 
changes in the abundance and localization of alpha6beta1 integrin. Int. J. Biochem. Cell 
Biol. 41: 1034-1045. 
 
62. Colomiere, M., A. C. Ward, C. Riley, M. K. Trenerry, D. Cameron-Smith, J. Findlay, 
L. Ackland, and N. Ahmed. 2009. Cross talk of signals between EGFR and IL-6R through 
   
 274 
JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br. J. 
Cancer 100: 134-144. 
 
63. Longley, D. B., D. P. Harkin, and P. G. Johnston. 2003. 5-Fluorouracil: Mechanisms of 
Action and Clinical Strategies. Nat. Rev. Cancer. 3: 330-338. 
 
64. Brock, N. 1996. The history of the oxazaphosphorine cytostatics. Cancer 78: 542-547. 
 
65. Shanafelt, T. D., T. Lin, S. M. Geyer, C. S. Zent, N. Leung, B. Kabat, D. Bowen, M. R. 
Grever, J. C. Byrd, and N. E. Kay. 2007. Pentostatin, cyclophosphamide, and rituximab 
regimen in older patients with chronic lymphocytic leukemia. Cancer 109: 2291-2298. 
 
66. Binotto, G., L. Trentin, and G. Semenzato. 2003. Ifosfamide and cyclophosphamide: 
effects on immunosurveillance. Oncology 65 Suppl 2: 17-20. 
 
67. Evans, R., J. A. Fuller, G. Christianson, D. M. Krupke, and A. B. Troutt. 1997. IL-15 
mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and 
enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cell. 
Immunol. 179: 66-73. 
 
68. Wang, D. and S. J. Lippard. 2005. Cellular processing of platinum anticancer drugs. 
Nat. Rev. Drug Discov. 4: 307-320. 
 
69. Bergman, A. M., P. P. Eijk, V. W. Ruiz van Haperen, K. Smid, G. Veerman, I. 
Hubeek, P. van den Ijssel, B. Ylstra, and G. J. Peters. 2005. In vivo induction of resistance 
to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as 
the major determinant. Cancer Res. 65: 9510-9516. 
 
70. Suzuki, E., V. Kapoor, A. S. Jassar, L. R. Kaiser, and S. M. Albelda. 2005. 
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in 
tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11: 
6713-6721. 
 
71. Suzuki, E., J. Sun, V. Kapoor, A. S. Jassar, and S. M. Albelda. 2007. Gemcitabine has 
significant immunomodulatory activity in murine tumor models independent of its 
cytotoxic effects. Cancer. Biol. Ther. 6: 880-885. 
 
72. Calabrich, A., S. Fernandes Gdos, and A. Katz. 2008. Trastuzumab: mechanisms of 
resistance and therapeutic opportunities. Oncology (Williston Park) 22: 1250-8; discussion 
1259, 1263. 
 
   
 275 
73. Sliwkowski, M. X., J. A. Lofgren, G. D. Lewis, T. E. Hotaling, B. M. Fendly, and J. A. 
Fox. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab 
(Herceptin). Semin. Oncol. 26: 60-70. 
 
74. Vogel, C. L., M. A. Cobleigh, D. Tripathy, J. C. Gutheil, L. N. Harris, L. 
Fehrenbacher, D. J. Slamon, M. Murphy, W. F. Novotny, M. Burchmore, S. Shak, S. J. 
Stewart, and M. Press. 2002. Efficacy and safety of trastuzumab as a single agent in first-
line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20: 719-
726. 
 
75. Cobleigh, M. A., C. L. Vogel, D. Tripathy, N. J. Robert, S. Scholl, L. Fehrenbacher, J. 
M. Wolter, V. Paton, S. Shak, G. Lieberman, and D. J. Slamon. 1999. Multinational study 
of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who 
have HER2-overexpressing metastatic breast cancer that has progressed after 
chemotherapy for metastatic disease. J. Clin. Oncol. 17: 2639-2648. 
 
76. Johnson, B. E. and P. A. Janne. 2006. Rationale for a phase II trial of pertuzumab, a 
HER-2 dimerization inhibitor, in patients with non-small cell lung cancer. Clin. Cancer 
Res. 12: 4436s-4440s. 
 
77. Peeters, M., T. Price, and J. L. Van Laethem. 2009. Anti-epidermal growth factor 
receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? 
Oncologist 14: 29-39. 
 
78. Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, 
M. Mueser, A. Harstrick, C. Verslype, I. Chau, and E. Van Cutsem. 2004. Cetuximab 
monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal 
cancer. N. Engl. J. Med. 351: 337-345. 
 
79. Li, S., K. R. Schmitz, P. D. Jeffrey, J. J. Wiltzius, P. Kussie, and K. M. Ferguson. 
2005. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. 
Cancer. Cell. 7: 301-311. 
 
80. Saltz, L. B., N. J. Meropol, S. Loehrer PJ, M. N. Needle, J. Kopit, and R. J. Mayer. 
2004. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses 
the epidermal growth factor receptor. J. Clin. Oncol. 22: 1201-1208. 
 
81. Gibson, T. B., A. Ranganathan, and A. Grothey. 2006. Randomized phase III trial 
results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal 
antibody, in metastatic colorectal cancer. Clin. Colorectal Cancer. 6: 29-31. 
 
   
 276 
82. Socinski, M. A. 2007. Antibodies to the epidermal growth factor receptor in non small 
cell lung cancer: current status of matuzumab and panitumumab. Clin. Cancer Res. 13: 
s4597-601. 
 
83. Schmiedel, J., A. Blaukat, S. Li, T. Knochel, and K. M. Ferguson. 2008. Matuzumab 
binding to EGFR prevents the conformational rearrangement required for dimerization. 
Cancer. Cell. 13: 365-373. 
 
84. Seiden, M. V., H. A. Burris, U. Matulonis, J. B. Hall, D. K. Armstrong, J. Speyer, J. D. 
Weber, and F. Muggia. 2007. A phase II trial of EMD72000 (matuzumab), a humanized 
anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary 
peritoneal malignancies. Gynecol. Oncol. 104: 727-731. 
 
85. Nahta, R. and F. J. Esteva. 2006. HER2 therapy: molecular mechanisms of trastuzumab 
resistance. Breast Cancer Res. 8: 215. 
 
86. Motoyama, A. B., N. E. Hynes, and H. A. Lane. 2002. The efficacy of ErbB receptor-
targeted anticancer therapeutics is influenced by the availability of epidermal growth 
factor-related peptides. Cancer Res. 62: 3151-3158. 
 
87. Knutson, K. L., B. Almand, Y. Dang, and M. L. Disis. 2004. Neu antigen-negative 
variants can be generated after neu-specific antibody therapy in neu transgenic mice. 
Cancer Res. 64: 1146-1151. 
 
88. Adamo, V., T. Franchina, B. Adamo, N. Denaro, P. Gambadauro, G. Chiofalo, A. 
Scimone, N. Caristi, A. Russo, and A. Giordano. 2009. Gefitinib in lung cancer therapy: 
Clinical results, predictive markers of response and future perspectives. Cancer. Biol. 
Ther. 8: 
 
89. Wakeling, A. E., A. J. Barker, D. H. Davies, D. S. Brown, L. R. Green, S. A. Cartlidge, 
and J. R. Woodburn. 1996. Specific inhibition of epidermal growth factor receptor tyrosine 
kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 38: 67-73. 
 
90. Honegger, A. M., T. J. Dull, S. Felder, E. Van Obberghen, F. Bellot, D. Szapary, A. 
Schmidt, A. Ullrich, and J. Schlessinger. 1987. Point mutation at the ATP binding site of 
EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 51: 
199-209. 
 
91. Cohen, E. E., D. W. Davis, T. G. Karrison, T. Y. Seiwert, S. J. Wong, S. Nattam, M. F. 
Kozloff, J. I. Clark, D. H. Yan, W. Liu, C. Pierce, J. E. Dancey, K. Stenson, E. Blair, A. 
Dekker, and E. E. Vokes. 2009. Erlotinib and bevacizumab in patients with recurrent or 
metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet 
Oncol.  
   
 277 
92. Thomas, M. B., J. S. Morris, R. Chadha, M. Iwasaki, H. Kaur, E. Lin, A. Kaseb, K. 
Glover, M. Davila, and J. Abbruzzese. 2009. Phase II Trial of the Combination of 
Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma. J. 
Clin. Oncol. 27: 843-850. 
 
93. van den Bent, M. J., A. A. Brandes, R. Rampling, M. C. Kouwenhoven, J. M. Kros, A. 
F. Carpentier, P. M. Clement, M. Frenay, M. Campone, J. F. Baurain, J. P. Armand, M. J. 
Taphoorn, A. Tosoni, H. Kletzl, B. Klughammer, D. Lacombe, and T. Gorlia. 2009. 
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent 
Glioblastoma: EORTC Brain Tumor Group Study 26034. J. Clin. Oncol.  
 
94. Nimeiri, H. S., A. M. Oza, R. J. Morgan, G. Friberg, K. Kasza, L. Faoro, R. Salgia, W. 
M. Stadler, E. E. Vokes, G. F. Fleming, Chicago Phase II Consortium, PMH Phase II 
Consortium, and California Phase II Consortium. 2008. Efficacy and safety of 
bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and 
fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. 
Gynecol. Oncol. 110: 49-55. 
 
95. Lin, N. U., V. Dieras, D. Paul, D. Lossignol, C. Christodoulou, H. J. Stemmler, H. 
Roche, M. C. Liu, R. Greil, E. Ciruelos, S. Loibl, S. Gori, A. Wardley, D. Yardley, A. 
Brufsky, J. L. Blum, S. D. Rubin, B. Dharan, K. Steplewski, D. Zembryki, C. Oliva, D. 
Roychowdhury, P. Paoletti, and E. P. Winer. 2009. Multicenter Phase II Study of Lapatinib 
in Patients with Brain Metastases from HER2-Positive Breast Cancer. Clin. Cancer Res. 
15: 1452-1459. 
 
96. Blackwell, K. L., M. D. Pegram, E. Tan-Chiu, L. S. Schwartzberg, M. C. Arbushites, J. 
D. Maltzman, J. K. Forster, S. D. Rubin, S. H. Stein, and H. J. Burstein. 2009. Single-agent 
lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on 
first- or second-line trastuzumab-containing regimens. Ann. Oncol.  
 
97. Scaltriti, M., C. Verma, M. Guzman, J. Jimenez, J. L. Parra, K. Pedersen, D. J. Smith, 
S. Landolfi, S. Ramon y Cajal, J. Arribas, and J. Baselga. 2009. Lapatinib, a HER2 
tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates 
trastuzumab-dependent cell cytotoxicity. Oncogene 28: 803-814. 
 
98. Bean, J., G. J. Riely, M. Balak, J. L. Marks, M. Ladanyi, V. A. Miller, and W. Pao. 
2008. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated 
with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. 
Cancer Res. 14: 7519-7525. 
 
99. Yano, S., W. Wang, Q. Li, K. Matsumoto, H. Sakurama, T. Nakamura, H. Ogino, S. 
Kakiuchi, M. Hanibuchi, Y. Nishioka, H. Uehara, T. Mitsudomi, Y. Yatabe, T. Nakamura, 
and S. Sone. 2008. Hepatocyte growth factor induces gefitinib resistance of lung 
   
 278 
adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 
68: 9479-9487. 
 
100. Okabe, T., I. Okamoto, S. Tsukioka, J. Uchida, E. Hatashita, Y. Yamada, T. Yoshida, 
K. Nishio, M. Fukuoka, P. A. Janne, and K. Nakagawa. 2009. Addition of S-1 to the 
epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-
small cell lung cancer cell lines with MET amplification. Clin. Cancer Res. 15: 907-913. 
 
101. Laban, C., S. A. Bustin, and P. J. Jenkins. 2003. The GH-IGF-I axis and breast 
cancer. Trends Endocrinol. Metab. 14: 28-34. 
 
102. Adnane, J., P. Gaudray, C. A. Dionne, G. Crumley, M. Jaye, J. Schlessinger, P. 
Jeanteur, D. Birnbaum, and C. Theillet. 1991. BEK and FLG, two receptors to members of 
the FGF family, are amplified in subsets of human breast cancers. Oncogene 6: 659-663. 
 
103. Kong, A., V. Calleja, P. Leboucher, A. Harris, P. J. Parker, and B. Larijani. 2008. 
HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of 
alternative HER receptors in breast cancer cells. PLoS ONE 3: e2881. 
 
104. Benavente, S., S. Huang, E. A. Armstrong, A. Chi, K. T. Hsu, D. L. Wheeler, and P. 
M. Harari. 2009. Establishment and Characterization of a Model of Acquired Resistance to 
Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells. Clin. 
Cancer Res.  
 
105. Boon, T., P. G. Coulie, and B. Van den Eynde. 1997. Tumor antigens recognized by T 
cells. Immunol. Today 18: 267-268. 
 
106. Ko, B. K., K. Kawano, J. L. Murray, M. L. Disis, C. L. Efferson, H. M. Kuerer, G. E. 
Peoples, and C. G. Ioannides. 2003. Clinical studies of vaccines targeting breast cancer. 
Clin. Cancer Res. 9: 3222-3234. 
 
107. Mittendorf, E. A., J. P. Holmes, S. Ponniah, and G. E. Peoples. 2008. The E75 
HER2/neu peptide vaccine. Cancer Immunol. Immunother. 57: 1511-1521. 
 
108. Manjili, M. H., X. Y. Wang, X. Chen, T. Martin, E. A. Repasky, R. Henderson, and J. 
R. Subjeck. 2003. HSP110-HER2/neu chaperone complex vaccine induces protective 
immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J. 
Immunol. 171: 4054-4061. 
 
109. Czerniecki, B. J., G. K. Koski, U. Koldovsky, S. Xu, P. A. Cohen, R. Mick, H. 
Nisenbaum, T. Pasha, M. Xu, K. R. Fox, S. Weinstein, S. G. Orel, R. Vonderheide, G. 
Coukos, A. DeMichele, L. Araujo, F. R. Spitz, M. Rosen, B. L. Levine, C. June, and P. J. 
   
 279 
Zhang. 2007. Targeting HER-2/neu in early breast cancer development using dendritic 
cells with staged interleukin-12 burst secretion. Cancer Res. 67: 1842-1852. 
 
110. Peoples, G. E., J. P. Holmes, M. T. Hueman, E. A. Mittendorf, A. Amin, S. Khoo, Z. 
A. Dehqanzada, J. M. Gurney, M. M. Woll, G. B. Ryan, C. E. Storrer, D. Craig, C. G. 
Ioannides, and S. Ponniah. 2008. Combined clinical trial results of a HER2/neu (E75) 
vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military 
Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 14: 797-803. 
 
111. Knutson, K. L., K. Schiffman, M. A. Cheever, and M. L. Disis. 2002. Immunization 
of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived 
peptide-specific immunity. Clin. Cancer Res. 8: 1014-1018. 
 
112. Zaks, T. Z. and S. A. Rosenberg. 1998. Immunization with a peptide epitope (p369-
377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to 
recognize HER-2/neu+ tumors. Cancer Res. 58: 4902-4908. 
 
113. Zhou, J. and Y. Zhong. 2004. Breast cancer immunotherapy. Cell. Mol. Immunol. 1: 
247-255. 
 
114. Satthaporn, S., A. Robins, W. Vassanasiri, M. El-Sheemy, J. A. Jibril, D. Clark, D. 
Valerio, and O. Eremin. 2004. Dendritic cells are dysfunctional in patients with operable 
breast cancer. Cancer Immunol. Immunother. 53: 510-518. 
 
115. Brown, R. D., B. Pope, A. Murray, W. Esdale, D. M. Sze, J. Gibson, P. J. Ho, D. 
Hart, and D. Joshua. 2001. Dendritic cells from patients with myeloma are numerically 
normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after 
huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and 
interleukin-10. Blood 98: 2992-2998. 
 
116. Osada, T., T. M. Clay, C. Y. Woo, M. A. Morse, and H. K. Lyerly. 2006. Dendritic 
cell-based immunotherapy. Int. Rev. Immunol. 25: 377-413. 
 
117. Brossart, P., S. Wirths, G. Stuhler, V. L. Reichardt, L. Kanz, and W. Brugger. 2000. 
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-
pulsed dendritic cells. Blood 96: 3102-3108. 
 
118. Kono, K., A. Takahashi, H. Sugai, H. Fujii, A. R. Choudhury, R. Kiessling, and Y. 
Matsumoto. 2002. Dendritic cells pulsed with HER-2/neu-derived peptides can induce 
specific T-cell responses in patients with gastric cancer. Clin. Cancer Res. 8: 3394-3400. 
 
 
 
   
 280 
119. Morse, M. A., T. M. Clay, K. Colling, A. Hobeika, K. Grabstein, M. A. Cheever, and  
H. K. Lyerly. 2003. HER2 dendritic cell vaccines. Clin. Breast Cancer. 3 Suppl 4: S164-
72. 
 
120. Nabekura, T., T. Nagasawa, H. Nakauchi, and M. Onodera. 2008. An immunotherapy 
approach with dendritic cells genetically modified to express the tumor-associated antigen, 
HER2. Cancer Immunol. Immunother. 57: 611-622. 
 
121. Vonderheide, R. H., W. C. Hahn, J. L. Schultze, and L. M. Nadler. 1999. The 
telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by 
cytotoxic T lymphocytes. Immunity 10: 673-679. 
 
122. Nair, S. K., A. Heiser, D. Boczkowski, A. Majumdar, M. Naoe, J. S. Lebkowski, J. 
Vieweg, and E. Gilboa. 2000. Induction of cytotoxic T cell responses and tumor immunity 
against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic 
cells. Nat. Med. 6: 1011-1017. 
 
123. Small, E. J., P. Fratesi, D. M. Reese, G. Strang, R. Laus, M. V. Peshwa, and F. H. 
Valone. 2000. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded 
dendritic cells. J. Clin. Oncol. 18: 3894-3903. 
 
124. Avigan, D., B. Vasir, J. Gong, V. Borges, Z. Wu, L. Uhl, M. Atkins, J. Mier, D. 
McDermott, T. Smith, N. Giallambardo, C. Stone, K. Schadt, J. Dolgoff, J. C. Tetreault, 
M. Villarroel, and D. Kufe. 2004. Fusion cell vaccination of patients with metastatic breast 
and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10: 
4699-4708. 
 
125. Cho, H. I., G. Niu, N. Bradley, and E. Celis. 2008. Optimized DNA vaccines to 
specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. 
Cancer Immunol. Immunother. 57: 1695-1703. 
 
126. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. 
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. 
Cancer. 8: 299-308. 
 
127. Schuetz, F., K. Ehlert, Y. Ge, A. Schneeweiss, J. Rom, N. Inzkirweli, C. Sohn, V. 
Schirrmacher, and P. Beckhove. 2008. Treatment of advanced metastasized breast cancer 
with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Cancer 
Immunol. Immunother.  
 
128. Gattinoni, L., S. E. Finkelstein, C. A. Klebanoff, P. A. Antony, D. C. Palmer, P. J. 
Spiess, L. N. Hwang, Z. Yu, C. Wrzesinski, D. M. Heimann, C. D. Surh, S. A. Rosenberg, 
and N. P. Restifo. 2005. Removal of homeostatic cytokine sinks by lymphodepletion 
   
 281 
enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 
202: 907-912 
. 
129. Gattinoni, L., D. J. Powell Jr, S. A. Rosenberg, and N. P. Restifo. 2006. Adoptive 
immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393. 
 
130. Schluns, K. S., W. C. Kieper, S. C. Jameson, and L. Lefrancois. 2000. Interleukin-7 
mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 1: 426-
432. 
 
131. Tan, J. T., B. Ernst, W. C. Kieper, E. LeRoy, J. Sprent, and C. D. Surh. 2002. 
Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory 
phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. 
Med. 195: 1523-1532. 
 
132. Salem, M. L., C. M. Diaz-Montero, A. A. Al-Khami, S. A. El-Naggar, O. Naga, A. J. 
Montero, A. Khafagy, and D. J. Cole. 2009. Recovery from cyclophosphamide-induced 
lymphopenia results in expansion of immature dendritic cells which can mediate enhanced 
prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 
agonist poly(I:C). J. Immunol. 182: 2030-2040. 
 
133. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. 
Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. 
Robinson, M. Raffeld, P. Duray, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. 
Mavroukakis, D. E. White, and S. A. Rosenberg. 2002. Cancer regression and 
autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 
298: 850-854. 
 
134. Bishop, M. R., D. H. Fowler, D. Marchigiani, K. Castro, C. Kasten-Sportes, S. M. 
Steinberg, J. C. Gea-Banacloche, R. Dean, C. K. Chow, C. Carter, E. J. Read, S. Leitman, 
and R. Gress. 2004. Allogeneic lymphocytes induce tumor regression of advanced 
metastatic breast cancer. J. Clin. Oncol. 22: 3886-3892. 
 
135. Aoki, Y., K. Takakuwa, S. Kodama, K. Tanaka, M. Takahashi, A. Tokunaga, and T. 
Takahashi. 1991. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in 
combination with cisplatin-containing chemotherapy in patients with epithelial ovarian 
cancer. Cancer Res. 51: 1934-1939. 
 
136. Kmieciak, M., K. L. Knutson, C. I. Dumur, and M. H. Manjili. 2007. HER-2/neu 
antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated 
anti-tumor immune responses. Eur. J. Immunol. 37: 675-685. 
   
 282 
137. Chin, C. S., C. H. Miller, L. Graham, M. Parviz, S. Zacur, B. Patel, A. Duong, and H. 
D. Bear. 2004. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-
selectinlow tumor-sensitized lymphocytes. Int. Immunol. 16: 1283-1294. 
 
138. Chin, C. S., L. J. Graham, G. G. Hamad, K. R. George, and H. D. Bear. 2001. 
Bryostatin/ionomycin-activated T cells mediate regression of established tumors. J. Surg. 
Res. 98: 108-115. 
 
139. Tuttle, T. M., T. H. Inge, K. P. Bethke, C. W. McCrady, G. R. Pettit, and H. D. Bear.  
1992. Activation and growth of murine tumor-specific T-cells which have in vivo activity 
with bryostatin 1. Cancer Res. 52: 548-553. 
 
140. Haux, J., A. C. Johnsen, B. Steinkjer, K. Egeberg, A. Sundan, and T. Espevik. 1999. 
The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-
mediated apoptosis. Cancer Immunol. Immunother. 48: 139-146. 
 
141. Refaeli, Y., L. Van Parijs, C. A. London, J. Tschopp, and A. K. Abbas. 1998. 
Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8: 
615-623. 
 
142. Zheng, S. G., J. Wang, P. Wang, J. D. Gray, and D. A. Horwitz. 2007. IL-2 is 
essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T 
cells and for expansion of these cells. J. Immunol. 178: 2018-2027. 
 
143. Zhang, H., K. S. Chua, M. Guimond, V. Kapoor, M. V. Brown, T. A. Fleisher, L. M. 
Long, D. Bernstein, B. J. Hill, D. C. Douek, J. A. Berzofsky, C. S. Carter, E. J. Read, L. J. 
Helman, and C. L. Mackall. 2005. Lymphopenia and interleukin-2 therapy alter 
homeostasis of CD4+CD25+ regulatory T cells. Nat. Med. 11: 1238-1243. 
 
144. Schwartzentruber, D. J., D. Solomon, S. A. Rosenberg, and S. L. Topalian. 1992. 
Characterization of lymphocytes infiltrating human breast cancer: specific immune 
reactivity detected by measuring cytokine secretion. J. Immunother. (1991) 12: 1-12. 
 
145. Buentke, E., A. Mathiot, M. Tolaini, J. Di Santo, R. Zamoyska, and B. Seddon. 2006. 
Do CD8 effector cells need IL-7R expression to become resting memory cells? Blood 108: 
1949-1956. 
 
146. Mueller, Y. M., V. Makar, P. M. Bojczuk, J. Witek, and P. D. Katsikis. 2003. IL-15 
enhances the function and inhibits CD95/Fas-induced apoptosis of human CD4+ and 
CD8+ effector-memory T cells. Int. Immunol. 15: 49-58. 
 
147. Stoklasek, T. A., K. S. Schluns, and L. Lefrancois. 2006. Combined IL-15/IL-
15Ralpha immunotherapy maximizes IL-15 activity in vivo. J. Immunol. 177: 6072-6080. 
   
 283 
148. Weng, N. P., K. Liu, M. Catalfamo, Y. Li, and P. A. Henkart. 2002. IL-15 is a growth 
factor and an activator of CD8 memory T cells. Ann. N. Y. Acad. Sci. 975: 46-56. 
 
149. Cole, D. J., D. P. Weil, J. Shilyansky, M. Custer, Y. Kawakami, S. A. Rosenberg, and 
M. I. Nishimura. 1995. Characterization of the functional specificity of a cloned T-cell 
receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res. 55: 748-
752. 
 
150. Clay, T. M., M. C. Custer, J. Sachs, P. Hwu, S. A. Rosenberg, and M. I. Nishimura. 
1999. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood 
lymphocytes confers anti-tumor reactivity. J. Immunol. 163: 507-513. 
 
151. Morgan, R. A., M. E. Dudley, J. R. Wunderlich, M. S. Hughes, J. C. Yang, R. M. 
Sherry, R. E. Royal, S. L. Topalian, U. S. Kammula, N. P. Restifo, Z. Zheng, A. Nahvi, C. 
R. de Vries, L. J. Rogers-Freezer, S. A. Mavroukakis, and S. A. Rosenberg. 2006. Cancer 
regression in patients after transfer of genetically engineered lymphocytes. Science 314: 
126-129. 
 
152. Li, S., J. Yang, F. A. Urban, J. N. MacGregor, D. P. Hughes, A. E. Chang, K. T. 
McDonagh, and Q. Li. 2008. Genetically engineered T cells expressing a HER2-specific 
chimeric receptor mediate antigen-specific tumor regression. Cancer Gene Ther. 15: 382-
392. 
 
153. Xue, S. A. and H. J. Stauss. 2007. Enhancing immune responses for cancer therapy. 
Cell. Mol. Immunol. 4: 173-184. 
 
154. Xu, L., W. Xu, Z. Jiang, F. Zhang, Y. Chu, and S. Xiong. 2009. Depletion of 
CD4(+)CD25(high) regulatory T cells from tumor infiltrating lymphocytes predominantly 
induces Th1 type immune response in vivo which inhibits tumor growth in adoptive 
immunotherapy. Cancer. Biol. Ther. 8: 
 
155. Chen, L., T. G. Huang, M. Meseck, J. Mandeli, J. Fallon, and S. L. Woo. 2007. 
Rejection of metastatic 4T1 breast cancer by attenuation of Treg cells in combination with 
immune stimulation. Mol. Ther. 15: 2194-2202. 
 
156. Nagai, H., T. Horikawa, I. Hara, A. Fukunaga, S. Oniki, M. Oka, C. Nishigori, and M. 
Ichihashi. 2004. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection 
of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp. Dermatol. 
13: 613-620. 
 
157. Shimizu, J., S. Yamazaki, and S. Sakaguchi. 1999. Induction of tumor immunity by 
removing CD25+CD4+ T cells: a common basis between tumor immunity and 
autoimmunity. J. Immunol. 163: 5211-5218. 
   
 284 
158. Ghebeh, H., E. Barhoush, A. Tulbah, N. Elkum, T. Al-Tweigeri, and S. Dermime. 
2008. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of 
high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer 8: 57. 
 
159. Bohling, S. D. and K. H. Allison. 2008. Immunosuppressive regulatory T cells are 
associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod. 
Pathol. 21: 1527-1532. 
 
160. Ohara, M., Y. Yamaguchi, K. Matsuura, S. Murakami, K. Arihiro, and M. Okada. 
2009. Possible involvement of regulatory T cells in tumor onset and progression in primary 
breast cancer. Cancer Immunol. Immunother. 58: 441-447. 
 
161. Viguier, M., F. Lemaitre, O. Verola, M. S. Cho, G. Gorochov, L. Dubertret, H. 
Bachelez, P. Kourilsky, and L. Ferradini. 2004. Foxp3 expressing CD4+CD25(high) 
regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and 
inhibit the function of infiltrating T cells. J. Immunol. 173: 1444-1453. 
 
162. Woo, E. Y., C. S. Chu, T. J. Goletz, K. Schlienger, H. Yeh, G. Coukos, S. C. Rubin, 
L. R. Kaiser, and C. H. June. 2001. Regulatory CD4(+)CD25(+) T cells in tumors from 
patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer 
Res. 61: 4766-4772. 
 
163. Ahmadzadeh, M. and S. A. Rosenberg. 2006. IL-2 administration increases CD4+ 
CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107: 2409-2414. 
 
164. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. 
Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, L. J. Rogers, G. J. 
Gracia, S. A. Jones, D. P. Mangiameli, M. M. Pelletier, J. Gea-Banacloche, M. R. 
Robinson, D. M. Berman, A. C. Filie, A. Abati, and S. A. Rosenberg. 2005. Adoptive cell 
transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the 
treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357. 
 
165. Powell, D. J.,Jr, L. L. Parker, and S. A. Rosenberg. 2005. Large-scale depletion of 
CD25+ regulatory T cells from patient leukapheresis samples. J. Immunother. 28: 403-411. 
 
166. Gabrilovich, D. I., M. P. Velders, E. M. Sotomayor, and W. M. Kast. 2001.  
Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. 
J. Immunol. 166: 5398-5406. 
 
167. Gallina, G., L. Dolcetti, P. Serafini, C. De Santo, I. Marigo, M. P. Colombo, G. 
Basso, F. Brombacher, I. Borrello, P. Zanovello, S. Bicciato, and V. Bronte. 2006. Tumors 
induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T 
cells. J. Clin. Invest. 116: 2777-2790. 
   
 285 
168. Kusmartsev, S. and D. I. Gabrilovich. 2002. Immature myeloid cells and cancer-
associated immune suppression. Cancer Immunol. Immunother. 51: 293-298. 
 
169. Rodriguez, P. C. and A. C. Ochoa. 2008. Arginine regulation by myeloid derived 
suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. 
Immunol. Rev. 222: 180-191. 
 
170. Kusmartsev, S. A., Y. Li, and S. H. Chen. 2000. Gr-1+ myeloid cells derived from 
tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 
costimulation. J. Immunol. 165: 779-785. 
 
171. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloid-
derived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802. 
 
172. Habibi, M., M. Kmieciak, L. Graham, J. K. Morales, H. D. Bear, and M. H. Manjili. 
2008. Radiofrequency thermal ablation of breast tumors combined with intralesional 
administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits 
tumor development and metastasis. Breast Cancer Res. Treat. 
  
173. Rodriguez, P. C., C. P. Hernandez, D. Quiceno, S. M. Dubinett, J. Zabaleta, J. B. 
Ochoa, J. Gilbert, and A. C. Ochoa. 2005. Arginase I in myeloid suppressor cells is 
induced by COX-2 in lung carcinoma. J. Exp. Med. 202: 931-939. 
 
174. Ochoa, A. C., A. H. Zea, C. Hernandez, and P. C. Rodriguez. 2007. Arginase, 
prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer 
Res. 13: 721s-726s. 
 
175. Zea, A. H., P. C. Rodriguez, M. B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, 
D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, J. Mier, and A. C. Ochoa. 2005. 
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a 
mechanism of tumor evasion. Cancer Res. 65: 3044-3048. 
 
176. Valenti, R., V. Huber, P. Filipazzi, L. Pilla, G. Sovena, A. Villa, A. Corbelli, S. Fais, 
G. Parmiani, and L. Rivoltini. 2006. Human tumor-released microvesicles promote the 
differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive 
activity on T lymphocytes. Cancer Res. 66: 9290-9298. 
 
177. Young, M. R. and D. M. Lathers. 1999. Myeloid progenitor cells mediate immune 
suppression in patients with head and neck cancers. Int. J. Immunopharmacol. 21: 241-
252. 
 
178. Diaz-Montero, C. M., M. L. Salem, M. I. Nishimura, E. Garrett-Mayer, D. J. Cole, 
and A. J. Montero. 2008. Increased circulating myeloid-derived suppressor cells correlate 
   
 286 
with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide 
chemotherapy. Cancer Immunol. Immunother.  
 
179. Salvadori, S., G. Martinelli, and K. Zier. 2000. Resection of solid tumors reverses T 
cell defects and restores protective immunity. J. Immunol. 164: 2214-2220. 
 
180. Sanchez-Ortiz, R. F., N. Tannir, K. Ahrar, and C. G. Wood. 2003. Spontaneous 
regression of pulmonary metastases from renal cell carcinoma after radio frequency 
ablation of primary tumor: an in situ tumor vaccine? J. Urol. 170: 178-179. 
 
181. Melani, C., C. Chiodoni, G. Forni, and M. P. Colombo. 2003. Myeloid cell expansion 
elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic 
BALB/c mice suppresses immune reactivity. Blood 102: 2138-2145. 
 
182. Ezernitchi, A. V., I. Vaknin, L. Cohen-Daniel, O. Levy, E. Manaster, A. Halabi, E. 
Pikarsky, L. Shapira, and M. Baniyash. 2006. TCR zeta down-regulation under chronic 
inflammation is mediated by myeloid suppressor cells differentially distributed between 
various lymphatic organs. J. Immunol. 177: 4763-4772. 
 
183. Nagaraj, S., K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman, L. Kang, D. L. Herber, J. 
Schneck, and D. I. Gabrilovich. 2007. Altered recognition of antigen is a mechanism of 
CD8+ T cell tolerance in cancer. Nat. Med. 13: 828-835. 
 
184. Mazzoni, A., V. Bronte, A. Visintin, J. H. Spitzer, E. Apolloni, P. Serafini, P. 
Zanovello, and D. M. Segal. 2002. Myeloid suppressor lines inhibit T cell responses by an 
NO-dependent mechanism. J. Immunol. 168: 689-695. 
 
185. Bingisser, R. M., P. A. Tilbrook, P. G. Holt, and U. R. Kees. 1998. Macrophage-
derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 
signaling pathway. J. Immunol. 160: 5729-5734. 
 
186. Moffett, J. R. and M. A. Namboodiri. 2003. Tryptophan and the immune response. 
Immunol. Cell Biol. 81: 247-265. 
 
187. Hou, D. Y., A. J. Muller, M. D. Sharma, J. DuHadaway, T. Banerjee, M. Johnson, A. 
L. Mellor, G. C. Prendergast, and D. H. Munn. 2007. Inhibition of indoleamine 2,3-
dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with 
antitumor responses. Cancer Res. 67: 792-801. 
 
188. Rodriguez, P. C., D. G. Quiceno, J. Zabaleta, B. Ortiz, A. H. Zea, M. B. Piazuelo, A. 
Delgado, P. Correa, J. Brayer, E. M. Sotomayor, S. Antonia, J. B. Ochoa, and A. C. Ochoa. 
2004. Arginase I production in the tumor microenvironment by mature myeloid cells 
   
 287 
inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64: 
5839-5849. 
 
189. Gruber, I. V., S. El Yousfi, S. Durr-Storzer, D. Wallwiener, E. F. Solomayer, and T. 
Fehm. 2008. Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in 
peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res. 28: 779-
784. 
 
190. Dworacki, G., N. Meidenbauer, I. Kuss, T. K. Hoffmann, W. Gooding, M. Lotze, and 
T. L. Whiteside. 2001. Decreased zeta chain expression and apoptosis in CD3+ peripheral 
blood T lymphocytes of patients with melanoma. Clin. Cancer Res. 7: 947s-957s. 
 
191. Takahashi, A., K. Kono, H. Amemiya, H. Iizuka, H. Fujii, and Y. Matsumoto. 2001. 
Elevated caspase-3 activity in peripheral blood T cells coexists with increased degree of T-
cell apoptosis and down-regulation of TCR zeta molecules in patients with gastric cancer. 
Clin. Cancer Res. 7: 74-80. 
 
192. Angus G. Dalgleish, Burkhard Haefner. The link between inflammation and cancer : 
wounds that do not heal. Vol. 130. Springer, New York. 
 
193. Ma, X., Q. Yang, K. T. Wilson, N. Kundu, S. J. Meltzer, and A. M. Fulton. 2004. 
Promoter methylation regulates cyclooxygenase expression in breast cancer. Breast Cancer 
Res. 6: R316-21. 
 
194. Thun, M. J., M. M. Namboodiri, and C. W. Heath Jr. 1991. Aspirin use and reduced 
risk of fatal colon cancer. N. Engl. J. Med. 325: 1593-1596. 
 
195. Giovannucci, E., K. M. Egan, D. J. Hunter, M. J. Stampfer, G. A. Colditz, W. C. 
Willett, and F. E. Speizer. 1995. Aspirin and the risk of colorectal cancer in women. N. 
Engl. J. Med. 333: 609-614. 
 
196. Rozic, J. G., C. Chakraborty, and P. K. Lala. 2001. Cyclooxygenase inhibitors retard 
murine mammary tumor progression by reducing tumor cell migration, invasiveness and 
angiogenesis. Int. J. Cancer 93: 497-506. 
 
197. Kundu, N. and A. M. Fulton. 2002. Selective cyclooxygenase (COX)-1 or COX-2 
inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res. 62: 
2343-2346. 
 
198. Talmadge, J. E., K. C. Hood, L. C. Zobel, L. R. Shafer, M. Coles, and B. Toth. 2007. 
Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor 
cell expansion. Int. Immunopharmacol. 7: 140-151. 
   
 288 
199. Wang, T., G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, 
D. Gabrilovich, R. Heller, D. Coppola, W. Dalton, R. Jove, D. Pardoll, and H. Yu. 2004. 
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. 
Nat. Med. 10: 48-54. 
 
200. Yu, H., M. Kortylewski, and D. Pardoll. 2007. Crosstalk between cancer and immune 
cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 7: 41-51. 
 
201. Nefedova, Y., M. Huang, S. Kusmartsev, R. Bhattacharya, P. Cheng, R. Salup, R. 
Jove, and D. Gabrilovich. 2004. Hyperactivation of STAT3 is involved in abnormal 
differentiation of dendritic cells in cancer. J. Immunol. 172: 464-474. 
 
202. Park, S. J., T. Nakagawa, H. Kitamura, T. Atsumi, H. Kamon, S. Sawa, D. Kamimura, 
N. Ueda, Y. Iwakura, K. Ishihara, M. Murakami, and T. Hirano. 2004. IL-6 regulates in 
vivo dendritic cell differentiation through STAT3 activation. J. Immunol. 173: 3844-3854. 
 
203. Dalwadi, H., K. Krysan, N. Heuze-Vourc'h, M. Dohadwala, D. Elashoff, S. Sharma, 
N. Cacalano, A. Lichtenstein, and S. Dubinett. 2005. Cyclooxygenase-2-dependent 
activation of signal transducer and activator of transcription 3 by interleukin-6 in non-
small cell lung cancer. Clin. Cancer Res. 11: 7674-7682. 
 
204. Bromberg, J. and J. E. Darnell Jr. 2000. The role of STATs in transcriptional control 
and their impact on cellular function. Oncogene 19: 2468-2473. 
 
205. Battle, T. E. and D. A. Frank. 2002. The role of STATs in apoptosis. Curr. Mol. Med. 
2: 381-392. 
 
206. Stephanou, A. and D. S. Latchman. 2005. Opposing actions of STAT-1 and STAT-3. 
Growth Factors 23: 177-182. 
 
207. Pan, P. Y., G. X. Wang, B. Yin, J. Ozao, T. Ku, C. M. Divino, and S. H. Chen. 2008. 
Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived 
suppressor cell development by blockade of stem-cell factor function. Blood 111: 219-228. 
 
208. Gabrilovich, D., T. Ishida, T. Oyama, S. Ran, V. Kravtsov, S. Nadaf, and D. P.  
Carbone. 1998. Vascular endothelial growth factor inhibits the development of dendritic 
cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. 
Blood 92: 4150-4166. 
 
209. Almand, B., J. R. Resser, B. Lindman, S. Nadaf, J. I. Clark, E. D. Kwon, D. P. 
Carbone, and D. I. Gabrilovich. 2000. Clinical significance of defective dendritic cell 
differentiation in cancer. Clin. Cancer Res. 6: 1755-1766. 
 
   
 289 
210. Garrity, T., R. Pandit, M. A. Wright, J. Benefield, S. Keni, and M. R. Young. 1997. 
Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients 
and their differentiation into dendritic cells. Int. J. Cancer 73: 663-669. 
 
211. Parmiani, G., C. Castelli, L. Pilla, M. Santinami, M. P. Colombo, and L. Rivoltini. 
2007. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer 
patients. Ann. Oncol. 18: 226-232. 
 
212. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. 
Topalian, N. P. Restifo, M. Sznol, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, C. A. 
Seipp, J. H. Einhorn, L. Rogers-Freezer, and D. E. White. 1999. Impact of cytokine 
administration on the generation of antitumor reactivity in patients with metastatic 
melanoma receiving a peptide vaccine. J. Immunol. 163: 1690-1695. 
 
213. Filipazzi, P., R. Valenti, V. Huber, L. Pilla, P. Canese, M. Iero, C. Castelli, L. 
Mariani, G. Parmiani, and L. Rivoltini. 2007. Identification of a new subset of myeloid 
suppressor cells in peripheral blood of melanoma patients with modulation by a 
granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. 
Oncol. 25: 2546-2553. 
 
214. Serafini, P., R. Carbley, K. A. Noonan, G. Tan, V. Bronte, and I. Borrello. 2004. 
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair 
the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64: 
6337-6343. 
 
215. Movahedi, K., M. Guilliams, J. Van den Bossche, R. Van den Bergh, C. Gysemans, 
A. Beschin, P. De Baetselier, and J. A. Van Ginderachter. 2008. Identification of discrete 
tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-
suppressive activity. Blood 111: 4233-4244. 
 
216. Sawanobori, Y., S. Ueha, M. Kurachi, T. Shimaoka, J. E. Talmadge, J. Abe, Y. 
Shono, M. Kitabatake, K. Kakimi, N. Mukaida, and K. Matsushima. 2008. Chemokine-
mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 
111: 5457-5466. 
 
217. Kusmartsev, S., Z. Su, A. Heiser, J. Dannull, E. Eruslanov, H. Kubler, D. Yancey, P. 
Dahm, and J. Vieweg. 2008. Reversal of myeloid cell-mediated immunosuppression in 
patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14: 8270-8278. 
 
218. Ko, J. S., A. H. Zea, B. I. Rini, J. L. Ireland, P. Elson, P. Cohen, A. Golshayan, P. A. 
Rayman, L. Wood, J. Garcia, R. Dreicer, R. Bukowski, and J. H. Finke. 2009. Sunitinib 
mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma 
patients. Clin. Cancer Res. 15: 2148-2157. 
   
 290 
219. Hoechst, B., L. A. Ormandy, M. Ballmaier, F. Lehner, C. Kruger, M. P. Manns, T. F. 
Greten, and F. Korangy. 2008. A new population of myeloid-derived suppressor cells in 
hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. 
Gastroenterology 135: 234-243. 
 
220. Rodriguez, P. C., M. S. Ernstoff, C. Hernandez, M. Atkins, J. Zabaleta, R. Sierra, and 
A. C. Ochoa. 2009. Arginase I-producing myeloid-derived suppressor cells in renal cell 
carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69: 1553-1560. 
 
221. Kmieciak, M., J. K. Morales, J. Morales, E. Bolesta, M. Grimes, and M. H. Manjili. 
2008. Danger signals and nonself entity of tumor antigen are both required for eliciting 
effective immune responses against HER-2/neu positive mammary carcinoma: 
implications for vaccine design. Cancer Immunol. Immunother.  
 
222. Worschech, A., M. Kmieciak, K. L. Knutson, H. D. Bear, A. A. Szalay, E. Wang, F. 
M. Marincola, and M. H. Manjili. 2008. Signatures associated with rejection or recurrence 
in HER-2/neu-positive mammary tumors. Cancer Res. 68: 2436-2446. 
 
223. Dooms, H., K. Wolslegel, P. Lin, and A. K. Abbas. 2007. Interleukin-2 enhances 
CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. J. Exp. 
Med. 204: 547-557. 
 
224. Klebanoff, C. A., L. Gattinoni, and N. P. Restifo. 2006. CD8+ T-cell memory in 
tumor immunology and immunotherapy. Immunol. Rev. 211: 214-224. 
 
225. Kim, H. R., K. A. Hwang, and I. Kang. 2007. Dual roles of IL-15 in maintaining IL-
7RalphalowCCR7- memory CD8+ T cells in humans via recovering the 
phosphatidylinositol 3-kinase/AKT pathway. J. Immunol. 179: 6734-6740. 
 
226. Surh, C. D. and J. Sprent. 2008. Homeostasis of naive and memory T cells. Immunity 
29: 848-862. 
 
227. Dela Cruz, J. S., S. Y. Lau, E. M. Ramirez, C. De Giovanni, G. Forni, S. L. Morrison, 
and M. L. Penichet. 2003. Protein vaccination with the HER2/neu extracellular domain 
plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu 
immune response in mice. Vaccine 21: 1317-1326. 
 
228. Emens, L. A., R. T. Reilly, and E. M. Jaffee. 2005. Breast cancer vaccines: 
maximizing cancer treatment by tapping into host immunity. Endocr. Relat. Cancer 12: 1-
17. 
 
229. Kim, P. S., T. D. Armstrong, H. Song, M. E. Wolpoe, V. Weiss, E. A. Manning, L. Q. 
Huang, S. Murata, G. Sgouros, L. A. Emens, R. T. Reilly, and E. M. Jaffee. 2008. 
   
 291 
Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in 
mice through Fc-mediated activation of DCs. J. Clin. Invest. 118: 1700-1711. 
 
230. Bernhard, H., J. Neudorfer, K. Gebhard, H. Conrad, C. Hermann, J. Nahrig, F. Fend, 
W. Weber, D. H. Busch, and C. Peschel. 2008. Adoptive transfer of autologous, HER2-
specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. 
Cancer Immunol. Immunother. 57: 271-280. 
 
231. Kan, N. 2003. Analysis of 5-year survival among breast cancer patients with 
malignant pleural effusion receiving intrapleural OK-432 followed by adoptive transfer 
with cultured effusion lymphocytes. Gan to Kagaku Ryoho 30: 1559-1561. 
 
232. Angulo, I., F. G. de las Heras, J. F. Garcia-Bustos, D. Gargallo, M. A. Munoz-
Fernandez, and M. Fresno. 2000. Nitric oxide-producing CD11b(+)Ly-6G(Gr-
1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: 
implications for T-cell responses in immunosuppressed mice. Blood 95: 212-220. 
 
233. Kusmartsev, S., Y. Nefedova, D. Yoder, and D. I. Gabrilovich. 2004. Antigen-
specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is 
mediated by reactive oxygen species. J. Immunol. 172: 989-999. 
 
234. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. 
Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765. 
 
235. Li, M. O. and R. A. Flavell. 2008. Contextual regulation of inflammation: a duet by 
transforming growth factor-beta and interleukin-10. Immunity 28: 468-476. 
 
236. Boivin, G. P., I. Ormsby, J. Jones-Carson, B. A. O'Toole, and T. Doetschman. 1997. 
Germ-free and barrier-raised TGF beta 1-deficient mice have similar inflammatory lesions. 
Transgenic Res. 6: 197-202. 
 
237. Kulkarni, A. B., C. G. Huh, D. Becker, A. Geiser, M. Lyght, K. C. Flanders, A. B. 
Roberts, M. B. Sporn, J. M. Ward, and S. Karlsson. 1993. Transforming growth factor beta 
1 null mutation in mice causes excessive inflammatory response and early death. Proc. 
Natl. Acad. Sci. U. S. A. 90: 770-774. 
 
238. Li, M. O. and R. A. Flavell. 2008. TGF-beta: a master of all T cell trades. Cell 134: 
392-404. 
 
239. Shull, M. M., I. Ormsby, A. B. Kier, S. Pawlowski, R. J. Diebold, M. Yin, R. Allen, 
C. Sidman, G. Proetzel, and D. Calvin. 1992. Targeted disruption of the mouse 
transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 
359: 693-699. 
   
 292 
240. Anderson, M. E. and T. J. Siahaan. 2003. Targeting ICAM-1/LFA-1 interaction for 
controlling autoimmune diseases: designing peptide and small molecule inhibitors. 
Peptides 24: 487-501. 
 
241. Gao, Q., X. Y. Wang, S. J. Qiu, I. Yamato, M. Sho, Y. Nakajima, J. Zhou, B. Z. Li, 
Y. H. Shi, Y. S. Xiao, Y. Xu, and J. Fan. 2009. Overexpression of PD-L1 Significantly 
Associates with Tumor Aggressiveness and Postoperative Recurrence in Human 
Hepatocellular Carcinoma. Clin. Cancer Res. 15: 971-979. 
 
242. Keir, M. E., G. J. Freeman, and A. H. Sharpe. 2007. PD-1 regulates self-reactive 
CD8+ T cell responses to antigen in lymph nodes and tissues. J. Immunol. 179: 5064-5070. 
 
243. Latchman, Y., C. R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. 
Iwai, A. J. Long, J. A. Brown, R. Nunes, E. A. Greenfield, K. Bourque, V. A. Boussiotis, 
L. L. Carter, B. M. Carreno, N. Malenkovich, H. Nishimura, T. Okazaki, T. Honjo, A. H. 
Sharpe, and G. J. Freeman. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell 
activation. Nat. Immunol. 2: 261-268. 
 
244. Perales, M. A., J. Yuan, S. Powel, H. F. Gallardo, T. S. Rasalan, C. Gonzalez, G. 
Manukian, J. Wang, Y. Zhang, P. B. Chapman, S. E. Krown, P. O. Livingston, S. Ejadi, K. 
S. Panageas, M. E. Engelhorn, S. L. Terzulli, A. N. Houghton, and J. D. Wolchok. 2008. 
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in 
patients with advanced melanoma. Mol. Ther. 16: 2022-2029. 
 
245. Urba, W. J., J. Nemunaitis, F. Marshall, D. C. Smith, K. M. Hege, J. Ma, M. Nguyen, 
and E. J. Small. 2008. Treatment of biochemical recurrence of prostate cancer with 
granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular 
immunotherapy. J. Urol. 180: 2011-7; discussion 2017-8. 
 
246. Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, and M. 
Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional 
microenvironments in secondary lymphoid organs. Cell 99: 23-33. 
 
247. Nakano, H., S. Mori, H. Yonekawa, H. Nariuchi, A. Matsuzawa, and T. Kakiuchi. 
1998. A novel mutant gene involved in T-lymphocyte-specific homing into peripheral 
lymphoid organs on mouse chromosome 4. Blood 91: 2886-2895. 
 
248. Yanagihara, S., E. Komura, J. Nagafune, H. Watarai, and Y. Yamaguchi. 1998. 
EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated 
upon maturation. J. Immunol. 161: 3096-3102. 
 
249. Dranoff, G. 2002. GM-CSF-based cancer vaccines. Immunol. Rev. 188: 147-154. 
   
 293 
250. Kondrack, R. M., J. Harbertson, J. T. Tan, M. E. McBreen, C. D. Surh, and L. M. 
Bradley. 2003. Interleukin 7 regulates the survival and generation of memory CD4 cells. J. 
Exp. Med. 198: 1797-1806. 
 
251. Schluns, K. S. and L. Lefrancois. 2003. Cytokine control of memory T-cell 
development and survival. Nat. Rev. Immunol. 3: 269-279. 
 
252. Klebanoff, C. A., S. E. Finkelstein, D. R. Surman, M. K. Lichtman, L. Gattinoni, M. 
R. Theoret, N. Grewal, P. J. Spiess, P. A. Antony, D. C. Palmer, Y. Tagaya, S. A. 
Rosenberg, T. A. Waldmann, and N. P. Restifo. 2004. IL-15 enhances the in vivo 
antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl. Acad. Sci. U. S. A. 101: 
1969-1974. 
 
253. Olejniczak, K. and A. Kasprzak. 2008. Biological properties of interleukin 2 and its 
role in pathogenesis of selected diseases--a review. Med. Sci. Monit. 14: RA179-89. 
 
254. Park, J. H., Q. Yu, B. Erman, J. S. Appelbaum, D. Montoya-Durango, H. L. Grimes, 
and A. Singer. 2004. Suppression of IL7Ralpha transcription by IL-7 and other prosurvival 
cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity 
21: 289-302. 
 
255. Bronte, V. and P. Zanovello. 2005. Regulation of immune responses by L-arginine 
metabolism. Nat. Rev. Immunol. 5: 641-654. 
 
256. Sakai, K., H. Yokote, K. Murakami-Murofushi, T. Tamura, N. Saijo, and K. Nishio. 
2007. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung 
cancer cells mediated by the HER3 signaling pathway. Cancer. Sci. 98: 1498-1503. 
 
257. Goni, O., P. Alcaide, and M. Fresno. 2002. Immunosuppression during acute 
Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+ )immature myeloid 
suppressor cells. Int. Immunol. 14: 1125-1134. 
 
258. Delano, M. J., P. O. Scumpia, J. S. Weinstein, D. Coco, S. Nagaraj, K. M. Kelly-
Scumpia, K. A. O'Malley, J. L. Wynn, S. Antonenko, S. Z. Al-Quran, R. Swan, C. S. 
Chung, M. A. Atkinson, R. Ramphal, D. I. Gabrilovich, W. H. Reeves, A. Ayala, J. 
Phillips, D. Laface, P. G. Heyworth, M. Clare-Salzler, and L. L. Moldawer. 2007. MyD88-
dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell 
suppression and Th2 polarization in sepsis. J. Exp. Med. 204: 1463-1474. 
 
259. Ko, H. J., Y. J. Kim, Y. S. Kim, W. S. Chang, S. Y. Ko, S. Y. Chang, S. Sakaguchi, 
and C. Y. Kang. 2007. A combination of chemoimmunotherapies can efficiently break 
self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. 
Cancer Res. 67: 7477-7486. 
   
 294 
260. Le, H. K., L. Graham, E. Cha, J. K. Morales, M. H. Manjili, and H. D. Bear. 2009. 
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 
4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. 
Int. Immunopharmacol.  
 
261. Serafini, P., I. Borrello, and V. Bronte. 2006. Myeloid suppressor cells in cancer: 
recruitment, phenotype, properties, and mechanisms of immune suppression. Semin. 
Cancer Biol. 16: 53-65. 
 
262. Liu, Z., H. Dai, N. Wan, T. Wang, S. Bertera, M. Trucco, and Z. Dai. 2007. 
Suppression of memory CD8 T cell generation and function by tryptophan catabolism. J. 
Immunol. 178: 4260-4266. 
 
263. Linsley, P. S., J. Bradshaw, J. Greene, R. Peach, K. L. Bennett, and R. S. Mittler. 
1996. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR 
engagement. Immunity 4: 535-543. 
 
264. Linsley, P. S., J. L. Greene, P. Tan, J. Bradshaw, J. A. Ledbetter, C. Anasetti, and N. 
K. Damle. 1992. Coexpression and functional cooperation of CTLA-4 and CD28 on 
activated T lymphocytes. J. Exp. Med. 176: 1595-1604. 
 
265. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. 
Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. 
Exp. Med. 180: 631-640. 
 
266. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo Jr, L. A. 
Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-
receptor that costimulates human T cell proliferation. Science 262: 909-911. 
 
267. Morales, J. K., M. Kmieciak, L. Graham, M. Feldmesser, H. D. Bear, and M. H. 
Manjili. 2008. Adoptive transfer of HER2/neu-specific T cells expanded with alternating 
gamma chain cytokines mediate tumor regression when combined with the depletion of 
myeloid-derived suppressor cells. Cancer Immunol. Immunother.  
 
268. Chen, X. and P. E. Jensen. 2008. MHC class II antigen presentation and 
immunological abnormalities due to deficiency of MHC class II and its associated genes. 
Exp. Mol. Pathol. 85: 40-44. 
 
269. Bunt, S. K., P. Sinha, V. K. Clements, J. Leips, and S. Ostrand-Rosenberg. 2006. 
Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. 
Immunol. 176: 284-290. 
 
   
 295 
270. Huang, B., P. Y. Pan, Q. Li, A. I. Sato, D. E. Levy, J. Bromberg, C. M. Divino, and S. 
H. Chen. 2006. Gr-1+CD115+ immature myeloid suppressor cells mediate the 
development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. 
Cancer Res. 66: 1123-1131. 
 
271. Serafini, P., R. Carbley, K. A. Noonan, G. Tan, V. Bronte, and I. Borrello. 2004. 
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair 
the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64: 
6337-6343. 
 
272. Ohm, J. E., M. R. Shurin, C. Esche, M. T. Lotze, D. P. Carbone, and D. I. 
Gabrilovich. 1999. Effect of vascular endothelial growth factor and FLT3 ligand on 
dendritic cell generation in vivo. J. Immunol. 163: 3260-3268. 
 
273. Driessens, G., P. Hoffmann, M. Pouwels, A. Zlotta, C. Schulman, T. Velu, and C. A. 
Bruyns. 2009. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the 
treatment of a murine renal cell carcinoma. J. Immunother. 32: 140-144. 
 
274. Conti, L. and S. Gessani. 2008. GM-CSF in the generation of dendritic cells from 
human blood monocyte precursors: recent advances. Immunobiology 213: 859-870. 
 
275. Waller, E. K. and M. S. Ernstoff. 2003. Modulation of antitumor immune responses 
by hematopoietic cytokines. Cancer 97: 1797-1809. 
 
276. Barreda, D. R., P. C. Hanington, and M. Belosevic. 2004. Regulation of myeloid 
development and function by colony stimulating factors. Dev. Comp. Immunol. 28: 509-
554. 
 
277. Kirkwood, J. M., S. Lee, S. J. Moschos, M. R. Albertini, J. C. Michalak, C. Sander, T. 
Whiteside, L. H. Butterfield, and L. Weiner. 2009. Immunogenicity and antitumor effects 
of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor 
and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology 
Group Phase II Trial E1696. Clin. Cancer Res. 15: 1443-1451. 
 
278. Soiffer, R., T. Lynch, M. Mihm, K. Jung, C. Rhuda, J. C. Schmollinger, F. S. Hodi, L. 
Liebster, P. Lam, S. Mentzer, S. Singer, K. K. Tanabe, A. B. Cosimi, R. Duda, A. Sober, 
A. Bhan, J. Daley, D. Neuberg, G. Parry, J. Rokovich, L. Richards, J. Drayer, A. Berns, S. 
Clift, L. K. Cohen, R. C. Mulligan, and G. Dranoff. 1998. Vaccination with irradiated 
autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-
stimulating factor generates potent antitumor immunity in patients with metastatic 
melanoma. Proc. Natl. Acad. Sci. U. S. A. 95: 13141-13146. 
 
   
 296 
279. Forster, R., A. C. Davalos-Misslitz, and A. Rot. 2008. CCR7 and its ligands: 
balancing immunity and tolerance. Nat. Rev. Immunol. 8: 362-371. 
 
280. Marsland, B. J., P. Battig, M. Bauer, C. Ruedl, U. Lassing, R. R. Beerli, K. Dietmeier, 
L. Ivanova, T. Pfister, L. Vogt, H. Nakano, C. Nembrini, P. Saudan, M. Kopf, and M. F. 
Bachmann. 2005. CCL19 and CCL21 induce a potent proinflammatory differentiation 
program in licensed dendritic cells. Immunity 22: 493-505. 
 
281. Yanagawa, Y. and K. Onoe. 2003. CCR7 ligands induce rapid endocytosis in mature 
dendritic cells with concomitant up-regulation of Cdc42 and Rac activities. Blood 101: 
4923-4929. 
 
282. Bronte, V., D. B. Chappell, E. Apolloni, A. Cabrelle, M. Wang, P. Hwu, and N. P. 
Restifo. 1999. Unopposed production of granulocyte-macrophage colony-stimulating 
factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell 
maturation. J. Immunol. 162: 5728-5737. 
 
283. Daud, A. I., N. Mirza, B. Lenox, S. Andrews, P. Urbas, G. X. Gao, J. H. Lee, V. K. 
Sondak, A. I. Riker, R. C. Deconti, and D. Gabrilovich. 2008. Phenotypic and functional 
analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated 
with adjuvant granulocyte macrophage colony-stimulating factor. J. Clin. Oncol. 26: 3235-
3241. 
 
284. Soria, G. and A. Ben-Baruch. 2008. The inflammatory chemokines CCL2 and CCL5 
in breast cancer. Cancer Lett. 267: 271-285. 
 
285. Yamashiro, S., M. Takeya, T. Nishi, J. Kuratsu, T. Yoshimura, Y. Ushio, and K. 
Takahashi. 1994. Tumor-derived monocyte chemoattractant protein-1 induces intratumoral 
infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors. Am. 
J. Pathol. 145: 856-867. 
 
286. Takeuchi, N., S. Hiraoka, X. Y. Zhou, M. Nagafuku, S. Ono, T. Tsujimura, M. 
Nakazawa, Y. Yura, T. Hamaoka, and H. Fujiwara. 2004. Anti-HER-2/neu immune 
responses are induced before the development of clinical tumors but declined following 
tumorigenesis in HER-2/neu transgenic mice. Cancer Res. 64: 7588-7595. 
 
 
 
 
   
 297 
 
 
VITA 
 
 
 
Personal Summary:  
Johanna Keeler Morales was born Johanna Michelle Keeler on the 24
th
 of  
November, 1982 in the state of Virginia. She graduated with an advanced studies  
degree from Great Bridge High School in 2001 and went on to attend James Madison 
University from 2001-2005 where she received a bachelor’s of science degree in biology 
and discovered a love of research while working in the laboratory of Dr. Chris Lantz. 
Johanna entered the Ph.D. program in the fall of 2005 and subsequently entered the 
laboratory of Dr. Masoud Manjili in the fall of 2006.  
 
Education: 
April 2009 Ph.D. defense, Virginia Commonwealth University, Richmond, VA 
Dissertation title: “The Role of Myeloid-Derived Suppressor Cells in the 
Immunotherapy of Breast Carcinoma” 
  GPA: 3.815 
  Advisor: Masoud H. Manjili 
May 2005 B.S. in biology, James Madison University 
  GPA: 3.376 
   
Awards: 
o Pre-doctoral Traineeship Award Recipient from the Department of Defense Breast 
Cancer Research Program: BC083048, “The Role of Myeloid-Derived Suppressor 
Cells in the Immunotherapy of HER2/neu Positive Breast Carcinomas” (2008-
2009). 
o Recipient of “The Mary P. Coleman Microbiology and Immunology Award” 
(2009). 
 
Societies: 
o 2007-2008: Member of American Association for Cancer Research 
 
Teaching Experience: 
o Adjunct Professor at John Tyler Community College in the fall of 2006 teaching an 
introductory biology course.  
o Teaching associate for Saturday Questers, a scientific enrichment course for gifted 
high school students, during the spring of 2007.  
   
 298 
 
Community Service: 
o Volunteer at Rockingham Memorial Hospital, 2002-2005. 
o Volunteered during the summer of 2003 at Chesapeake General Hospital. 
o Volunteer with the Adopt-A-Grandparent organization at Sunnyside Retirement 
Home, 2004-2005. 
o Committee member and team captain for the Relay for Life event of the American 
Cancer Society in 2005.    
o Member of ElderFriends of Richmond, 2006-present. 
o Member of the Geriatrics club of the Medical College of Virginia, currently 
participating in volunteer activities at local nursing homes. 
 
Publications: 
o Hanh K. Le, Laura Graham, Esther Cha, Johanna K. Morales, Masoud H. 
Manjili, and Harry D. Bear, MD, PhD, FACS (2009). Gemcitabine Directly 
Inhibits Myeloid Derived Suppressor Cells in BALB/c Mice Bearing 4T1 
Mammary Carcinoma and Augments Expansion of T cells from Tumor Bearing 
Mice. International Immunopharmacology. 
o Morales, J. K., Kmieciak, M., Graham, L., Feldmesser, M., Bear, H. D., & 
Manjili, M. H. (2008). Adoptive transfer of HER2/neu-specific T cells expanded 
with alternating gamma chain cytokines mediate tumor regression when combined 
with the depletion of myeloid-derived suppressor cells. Cancer Immunology & 
Immunotherapy [Epub ahead of print]. 
o Habibi, M., Kmieciak, M., Graham, L., Morales, J. K., Bear, H. D., & Manjili, M. 
H. (2008). Radiofrequency thermal ablation of breast tumors combined with 
intralesional administration of IL-7 and IL-15 augments anti-tumor immune 
responses and inhibits tumor development and metastasis. Breast Cancer Research 
and Treatment [Epub ahead of print]. 
o Kmieciak, M., Morales, J. K., Morales, J., Bolesta, E., Grimes, M., & Manjili, M. 
H. (2008). Danger signals and nonself entity of tumor antigen are both required for 
eliciting effective immune responses against HER-2/neu positive mammary 
carcinoma: Implications for vaccine design. Cancer Immunology & Immunotherapy 
57(9), 1391-8. 
o Manjili, M. H., Kmieciak, M., & Keeler, J. (2006). Comment on "tumor 
progression can occur despite the induction of very high levels of self/tumor 
antigen-specific CD8+ T cells in patients with melanoma". Journal of immunology  
176(8), 4511 
 
Poster Presentations: 
o Morales, J.K., Kmieciak, M., Graham, L. Feldmesser, M., Bear, H.D. Manjili, 
M.H. Adoptive Transfer of HER2/neu Specific T Cells Expanded with Alternating 
Gamma Chain Cytokines Mediates Tumor Regression when Combined with the 
   
 299 
Depletion of Myeloid-Derived Suppressor Cells. Cancer Immunotherapy: Realizing 
the Promise, National Institutes of Health 2008. 
o Morales, J.K., Kmieciak, M., Manjili, M.H. Adoptive Immunotherapy Targeting 
HER2/neu Positive Breast Carcinomas Requires the Depletion of Myeloid-Derived 
Suppressor Cells. Massey Cancer Center Retreat, Virginia Commonwealth 
University 2008. 
o Morales, J.K., Kmieciak, M., Manjili, M.H. Tumor-Derived Soluble Factors Cause 
the Differentiation and Maintenance of Myeloid-Derived Suppressor Cells. Watt’s 
Day, Virginia Commonwealth University 2008. 
o Keeler, J.M., Kmieciak, M., Manjili, M.H. Myeloid-Derived Suppressor Cells Are 
Key Inhibitors of Adoptive Immunotherapy Targeting HER-2/neu Positive Breast 
Carcinomas. Watt’s Day, Virginia Commonwealth University 2007. 
o Morales, J.A., Keeler, J.M., Ryan, J.J. and Lantz, C.S. Basophil Development and 
Anaphylaxis in Mice with a Simultaneous Disruption of IL-3 and IL-4.  Virginia 
Academy of Sciences 2005. 
o Morales, J.A., Keeler, J.M., Ryan, J.J. and Lantz, C.S. Basophil Development and 
Anaphylaxis in Mice with a Simultaneous Disruption of IL-3 and IL-4. 
Biosymposium, James Madison University 2005. 
 
